{
  "publisher": "HeartPep",
  "reviewedAt": "2026-11-20",
  "scope": "Selected narrative reviews, identity notes and specification guides. Not a systematic review or clinical guidance.",
  "entries": [
    {
      "slug": "5-amino-1",
      "names": [
        "5 Amino 1"
      ],
      "title": "5 Amino 1",
      "kind": "identity-pending",
      "summary": "The US supplier label does not establish that this is the same substance as 5-Amino-1MQ in the UK/EU catalogue. Its research identity remains unresolved.",
      "identity": "The catalogue name is a supplier label, not an authenticated molecular specification. This note preserves the exact published names without assigning an unverified identity.",
      "evidenceOverview": "Identity unresolved. No biological evidence is attributed to this product here. This is an evidence-matching gap, not a statement that no research exists.",
      "whatResearchShows": [
        "A meaningful literature review needs an identified substance or a defined mixture. Studies of an assumed ingredient would answer a different question."
      ],
      "limitations": [
        "No confirmed sequence, complete composition or matched chemical specification is available in the catalogue record used for this note.",
        "A general research paper or another seller’s blend formula cannot establish the contents, stability or effects of this listing."
      ],
      "openQuestions": [
        "Confirm the full chemical name, structure and counterion before using the separate 5-Amino-1MQ review.",
        "Once the identity is confirmed, which primary studies match that exact compound, route and formulation?"
      ],
      "studies": [],
      "search": {
        "date": "2026-11-08",
        "method": "Identity-gated catalogue review",
        "queries": [],
        "scope": "Exact supplier labels and published catalogue specifications were checked. Biological literature was not attributed while the identity remained unresolved.",
        "limitations": "This is an identity note, not a negative literature search. It cannot show that relevant studies do not exist."
      }
    },
    {
      "slug": "5-amino-1mq",
      "names": [
        "5-Amino-1MQ",
        "5-Amino-1MQ Capsules"
      ],
      "title": "5-Amino-1MQ",
      "kind": "compound",
      "summary": "The selected evidence concerns NNMT inhibition in cells and mice. It supports a metabolic research hypothesis, not an established human weight-loss effect.",
      "identity": "5-amino-1-methylquinolinium is a small molecule, not a peptide. The exact counterion and formulation of a supplied product remain separate specification questions. The catalogue label 5 Amino 1 is not automatically treated as the same compound.",
      "evidenceOverview": "Three preclinical papers examine the named inhibitor, including a diet-controlled mouse experiment. None is a human trial or a validation of the listed capsule or vial.",
      "whatResearchShows": [
        "The earlier experiments connect NNMT inhibition to changes in cultured adipocytes and reduced adiposity in diet-induced-obese mice [1].",
        "A later mouse experiment reports changes in fat accumulation, glucose handling and liver pathology over 28 days [2]."
      ],
      "limitations": [
        "Animal metabolic responses do not establish human efficacy, exposure, long-term safety or a clinical formulation.",
        "Independent replication and translation to humans remain important gaps. This selected review did not identify a human efficacy trial."
      ],
      "openQuestions": [
        "Do independently replicated human studies confirm the preclinical metabolic findings?",
        "How do chemical form, exposure and off-target activity affect the interpretation of NNMT inhibition?"
      ],
      "studies": [
        {
          "id": "pmid-29155147",
          "title": "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice",
          "authors": "Neelakantan H, Vance V, Wetzel MD, et al.",
          "year": 2018,
          "journal": "Biochemical Pharmacology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/29155147/",
          "doi": "10.1016/j.bcp.2017.11.007",
          "pmid": "29155147",
          "evidenceType": "animal",
          "design": "Cell-based inhibitor characterization followed by experiments in diet-induced-obese mice.",
          "findings": "The researchers reported less lipid accumulation in cultured adipocytes and reduced body weight and adipose mass in treated mice.",
          "limitations": "Short preclinical experiments cannot establish human weight loss or long-term safety. Target-level observations should not be assigned to every NNMT inhibitor.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5826726/"
        },
        {
          "id": "pmid-39161060",
          "title": "Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction",
          "authors": "Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H",
          "year": 2024,
          "journal": "Diabetes, Obesity and Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39161060/",
          "doi": "10.1111/dom.15879",
          "pmid": "39161060",
          "evidenceType": "animal",
          "design": "28-day vehicle-controlled study in diet-induced-obese mice, with pharmacokinetic and tissue-distribution experiments.",
          "findings": "Treatment limited fat and weight gain and improved several glucose, insulin and liver measurements in this model.",
          "limitations": "Mouse findings, not human outcomes. Several authors disclosed employment or founder relationships with the developer.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11622326/"
        },
        {
          "id": "pmid-33707534",
          "title": "Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice",
          "authors": "Sampson CM, Dimet AL, Neelakantan H, et al.",
          "year": 2021,
          "journal": "Scientific Reports",
          "url": "https://pubmed.ncbi.nlm.nih.gov/33707534/",
          "evidenceType": "animal",
          "design": "Diet-induced-obese mice underwent a diet switch, with or without the named NNMT inhibitor; body composition and liver measurements were followed.",
          "findings": "The combination produced larger fat and weight changes than the diet switch alone. Some liver histology comparisons were sensitive to multiple-testing correction.",
          "limitations": "Small mouse groups, dietary co-intervention and developer-linked authorship. A lean-mass ratio is not evidence of muscle growth, and the model did not reproduce advanced fibrotic human liver disease.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "doi": "10.1038/s41598-021-85051-6",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7952898/",
          "pmid": "33707534"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record search and verification of existing references.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov 39161060 5 Amino 1MQ",
          "site.pubmed.ncbi.nlm.nih.gov 5 amino 1MQ 29155147",
          "site.pubmed.ncbi.nlm.nih.gov 39161060 retraction",
          "site.pubmed.ncbi.nlm.nih.gov 33707534",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC11622326/",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC7952898/"
        ],
        "scope": "Selected cell and mouse metabolic studies of the named compound.",
        "limitations": "Narrative selection, not a systematic database search or formal risk-of-bias assessment. Selected methods, results, discussion and disclosure sections of the 2021 and 2024 full texts were checked; supplements were not comprehensively appraised."
      },
      "discussion": [
        {
          "heading": "Less weight gain is a different outcome from weight loss",
          "body": "The 2024 study continued an obesogenic diet. Its principal weight finding was attenuation of further gain, which should not be retold as demonstrated weight loss. The diet-switch experiment asked a different question, whether adding inhibition improved an already changed dietary environment. Those designs help explain why seemingly similar headlines describe different biological comparisons. The latter also measured lean mass relative to body weight: losing fat can improve that ratio without creating new muscle. Neither model establishes a treatment effect in people.",
          "citations": [
            "pmid-39161060",
            "pmid-33707534"
          ]
        },
        {
          "heading": "A probe compound and a clinical candidate are different evidence stages",
          "body": "The full-text discussion of the 2024 paper acknowledges ongoing optimisation addressing mouse-specific clearance and activity against MAO-A. That makes an unqualified claim of complete selectivity inappropriate. The earlier cell work is useful target-characterisation evidence, but it cannot resolve exposure and off-target behaviour throughout an organism. Across this selected set, investigators and developer relationships overlap, so several publications should not automatically be counted as independent replication. The next translational questions concern reproducibility, pharmacology and safety before any human-outcome claim.",
          "citations": [
            "pmid-39161060",
            "pmid-29155147",
            "pmid-33707534"
          ]
        }
      ]
    },
    {
      "slug": "adamax",
      "names": [
        "Adamax"
      ],
      "title": "Adamax",
      "kind": "identity-pending",
      "summary": "The exact molecular identity behind this supplier label is not established in the catalogue documents reviewed. Research on a similarly named peptide cannot safely be assigned to it.",
      "identity": "The catalogue name is a supplier label, not an authenticated molecular specification. This note preserves the exact published names without assigning an unverified identity.",
      "evidenceOverview": "Identity unresolved. No biological evidence is attributed to this product here. This is an evidence-matching gap, not a statement that no research exists.",
      "whatResearchShows": [
        "A meaningful literature review needs an identified substance or a defined mixture. Studies of an assumed ingredient would answer a different question."
      ],
      "limitations": [
        "No confirmed sequence, complete composition or matched chemical specification is available in the catalogue record used for this note.",
        "A general research paper or another seller’s blend formula cannot establish the contents, stability or effects of this listing."
      ],
      "openQuestions": [
        "Confirm the peptide sequence, modification, salt and analytical identity before selecting compound-specific literature.",
        "Once the identity is confirmed, which primary studies match that exact compound, route and formulation?"
      ],
      "studies": [],
      "search": {
        "date": "2026-11-08",
        "method": "Identity-gated catalogue review",
        "queries": [],
        "scope": "Exact supplier labels and published catalogue specifications were checked. Biological literature was not attributed while the identity remained unresolved.",
        "limitations": "This is an identity note, not a negative literature search. It cannot show that relevant studies do not exist."
      }
    },
    {
      "slug": "ahk-cu",
      "names": [
        "AHK-Cu"
      ],
      "title": "AHK-Cu",
      "kind": "compound",
      "summary": "The directly checked hair-growth evidence is an experiment with isolated human follicles and cultured cells. Human tissue in a laboratory is not a clinical hair-restoration trial.",
      "identity": "The cited paper examines the copper complex of alanyl-histidyl-lysine. AHK-Cu and GHK-Cu are distinct sequences; their findings should not be substituted.",
      "evidenceOverview": "One directly relevant hair-follicle study is included, alongside an identity cross-check explaining why a superficially similar Tripeptide-3 paper is not AHK-Cu evidence.",
      "whatResearchShows": [
        "Follicle elongation and dermal-papilla-cell proliferation increased under the experimental conditions; the measured reduction in apoptotic cells was not statistically significant."
      ],
      "limitations": [
        "Isolated follicles do not reproduce long-term scalp exposure, formulation delivery or clinical hair counts."
      ],
      "openQuestions": [
        "Would a characterised formulation produce a durable, independently replicated benefit in a controlled human trial?"
      ],
      "studies": [
        {
          "id": "pmid-17703734",
          "title": "The effect of tripeptide-copper complex on human hair growth in vitro",
          "authors": "Pyo HK, Yoo HG, Won CH, et al.",
          "year": 2007,
          "journal": "Archives of Pharmacal Research",
          "url": "https://pubmed.ncbi.nlm.nih.gov/17703734/",
          "doi": "10.1007/BF02978833",
          "pmid": "17703734",
          "evidenceType": "laboratory",
          "design": "Isolated human follicles and cultured dermal papilla cells.",
          "findings": "Elongation and proliferation signals increased; apoptosis findings were mixed.",
          "limitations": "No clinical hair-restoration endpoint.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-38675215",
          "title": "Microemulsions and Nanoemulsions for Topical Delivery of Tripeptide-3: From Design of Experiment to Anti-Sebum Efficacy on Facial Skin",
          "authors": "Magrode N, Poomanee W, Kiattisin K, Ampasavate C",
          "year": 2024,
          "journal": "Pharmaceutics",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38675215/",
          "doi": "10.3390/pharmaceutics16040554",
          "pmid": "38675215",
          "evidenceType": "reference",
          "design": "Identity cross-check of a formulation paper that uses the name Tripeptide-3; this is not an AHK-Cu study.",
          "findings": "Materials identify dipeptide diaminobutyroyl benzylamide diacetate, CAS823202-99-9, rather than alanyl-histidyl-lysine copper.",
          "limitations": "Included to prevent misattribution. Its formulation and sebum results are not AHK-Cu efficacy evidence.",
          "appliesTo": "identity-only",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11053593/"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record search.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov AHK Cu human clinical hair trial",
          "The effect of tripeptide-copper complex on human hair growth in vitro retracted",
          "AHK Cu tripeptide-3 microemulsion nanoemulsion Magrode 2024 PubMed",
          "Microemulsions and Nanoemulsions Dipeptide 823202"
        ],
        "scope": "One direct AHK-Cu follicle study plus a full-text materials identity cross-check of the 2024 Tripeptide-3 paper.",
        "limitations": "Not an exhaustive review or proof that no additional AHK-Cu research exists. The identity-only reference is excluded from AHK-Cu human efficacy evidence."
      },
      "discussion": [
        {
          "heading": "Human tissue does not make this a treatment trial",
          "body": "The follicle experiment supports a local biological hypothesis. It cannot show that a product crosses a scalp or nasal barrier, reaches a comparable exposure or changes a person's hair growth over time. A follow-up clinical study would need a characterised formulation, an appropriate vehicle comparison and objective hair outcomes, rather than counting a cultured follicle as a treated participant.",
          "citations": [
            "pmid-17703734"
          ]
        },
        {
          "heading": "A naming collision can create false clinical evidence",
          "body": "Tripeptide-3 is not a sufficient identity match. The 2024 emulsion paper specifies dipeptide diaminobutyroyl benzylamide diacetate in its materials section. That chemical identity differs from the copper-bound alanyl-histidyl-lysine in the follicle study. The paper is retained here as a cross-check, not as evidence that AHK-Cu controls facial oil or has been clinically validated. This distinction demonstrates why sequence, chemical identifiers and metal binding matter more than a shared marketing shorthand when selecting references.",
          "citations": [
            "pmid-17703734",
            "pmid-38675215"
          ]
        },
        {
          "heading": "Keep excluded material visible",
          "body": "Recording the identity mismatch is useful even though the paper is not support for AHK-Cu. It lets another reader reproduce the exclusion and prevents an appealing clinical result from entering a bibliography through a name match alone. More references would not improve this review if they tested another chemical.",
          "citations": [
            "pmid-38675215"
          ]
        }
      ]
    },
    {
      "slug": "aod-9604",
      "names": [
        "AOD-9604"
      ],
      "title": "AOD-9604",
      "kind": "compound",
      "summary": "Mouse lipid-metabolism findings should be read alongside the unsuccessful human obesity development programme. A safety-focused publication is not proof of weight-loss efficacy.",
      "identity": "AOD-9604 is a modified growth-hormone C-terminal fragment. It is distinct from full-length growth hormone and should not be equated with an unspecified supplier label such as H Frag.",
      "evidenceOverview": "The sources span mouse experiments, a sponsor-associated human safety summary and an FDA assessment of the reported clinical programme.",
      "whatResearchShows": [
        "Mouse experiments implicated beta-adrenergic signalling in effects on fat metabolism [1].",
        "A six-trial safety summary reported several reassuring monitored outcomes but did not establish clinical efficacy [2].",
        "FDA's assessment describes a larger obesity trial that did not show a significant advantage over placebo for its principal weight-loss comparison [3]."
      ],
      "limitations": [
        "The major negative trial was not available as a full peer-reviewed efficacy report in the agency assessment.",
        "Historical investigational oral or intravenous preparations do not validate a catalogue vial, nasal preparation or proposed clinical use."
      ],
      "openQuestions": [
        "Can complete participant-level and adverse-event reporting from the historical programme be independently examined?",
        "What additional evidence would be needed for any specific formulation or proposed indication?"
      ],
      "studies": [
        {
          "id": "pmid-11713213",
          "title": "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice",
          "authors": "Heffernan M, Summers RJ, Thorburn A, et al.",
          "year": 2001,
          "journal": "Endocrinology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/11713213/",
          "doi": "10.1210/endo.142.12.8522",
          "pmid": "11713213",
          "evidenceType": "animal",
          "design": "14-day experiments in obese mice and beta-3-adrenoceptor knockout mice.",
          "findings": "Weight and fat effects in the obese mice differed from knockout animals, supporting a role for beta-adrenergic signalling in the model.",
          "limitations": "Species-specific experimental findings do not establish a human weight-loss effect.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "doi-10.4021-jem157w",
          "title": "Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans",
          "authors": "Stier H, Vos E, Kenley D",
          "year": 2013,
          "journal": "Journal of Endocrinology and Metabolism",
          "url": "https://www.jofem.org/index.php/jofem/article/view/157/194",
          "doi": "10.4021/jem157w",
          "evidenceType": "human",
          "design": "Summary of six placebo-controlled clinical studies, with different exposure durations and study preparations.",
          "findings": "The authors reported no detected anti-AOD9604 antibodies in tested participants and no adverse changes in selected IGF-1 and glucose measures.",
          "limitations": "Safety-focused, sponsor-associated reporting with limited detail. It does not demonstrate weight-loss efficacy or exclude uncommon, delayed or formulation-specific harm.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://www.jofem.org/index.php/jofem/article/view/157/194"
        },
        {
          "id": "fda-aod-9604-2024",
          "title": "FDA evaluation of AOD-9604-related bulk drug substances",
          "authors": "U.S. Food and Drug Administration",
          "year": 2024,
          "journal": "Pharmacy Compounding Advisory Committee briefing document",
          "url": "https://www.fda.gov/media/183584/download",
          "evidenceType": "reference",
          "design": "Agency evidence assessment, including the developer's report of the 24-week OPTIONS obesity study.",
          "findings": "FDA found that the reported primary weight-loss comparison did not significantly favour AOD-9604 over placebo and identified substantial evidence limitations.",
          "limitations": "This is an agency assessment, not the original trial report or a final marketing-authorisation decision. The underlying efficacy report was not located as a full medical-journal publication.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://www.fda.gov/media/183584/download"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary literature and agency-document review, retaining the negative clinical finding.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov AOD9604 obesity randomized trial negative",
          "AOD9604 Stier Vos Kenley 2013 10.4021/jem157w safety tolerability human",
          "site.fda.gov AOD-9604 2024 502 weight loss"
        ],
        "scope": "Mouse metabolic experiment, human safety publication and agency assessment of the historical obesity programme.",
        "limitations": "Not a systematic review. The original major efficacy trial was not reviewed in full; its result is attributed to FDA's assessment of the developer's report."
      },
      "discussion": [
        {
          "heading": "Why the clinical comparison outweighs the animal headline",
          "body": "The mouse paper investigated a biological pathway; the obesity programme asked whether that pathway produced an advantage over placebo in people. FDA describes an unsuccessful primary comparison in the larger study. Weight lost inside an active group is not the same as weight loss caused by the intervention, because the comparison group also received a structured programme. A favourable animal finding or subgroup cannot replace that principal clinical comparison. Incomplete publication of the original efficacy data limits further independent checking, rather than converting a negative result into positive evidence.",
          "citations": [
            "pmid-11713213",
            "fda-aod-9604-2024"
          ]
        },
        {
          "heading": "Safety summaries and agency assessments have different roles",
          "body": "The 2013 publication concentrates on selected safety measurements across heterogeneous trials, including very short exposures. Its reassuring interpretation does not establish that every formulation is harmless or that uncommon events were excluded. The FDA briefing is a regulatory evidence assessment, not a new randomized trial or a final approval decision. It raises questions about the adequacy of the available evidence and certain preclinical methods. Readers should keep the study preparation, observation period and outcome question attached to each claim, rather than treating the phrase growth-hormone fragment as a transferable safety assurance.",
          "citations": [
            "doi-10.4021-jem157w",
            "fda-aod-9604-2024"
          ]
        }
      ]
    },
    {
      "slug": "ara-290",
      "names": [
        "ARA-290"
      ],
      "title": "ARA-290",
      "kind": "compound",
      "summary": "ARA-290 has small exploratory human studies in sarcoidosis-associated small-fibre neuropathy. Some symptom and nerve measurements improved, but these results are not broad evidence of tissue repair or immune benefits.",
      "identity": "ARA-290 is the experimental peptide code used in the cited clinical studies. Research on a defined study drug does not verify that a supplier product with the same code is analytically or pharmacologically equivalent.",
      "evidenceOverview": "Selected small human studies concern sarcoidosis-associated and diabetic neuropathy. Positive symptom and nerve-related measurements remain exploratory, with developer involvement, multiple outcomes and short observation windows. The 2013 corneal nerve-area measurements have a linked arithmetic correction.",
      "whatResearchShows": [
        "The 2012 pilot improved a small-fibre symptom score, while pain and fatigue improved similarly in both groups.",
        "The 2013 study reported symptom, corneal-nerve and selected functional changes in patients with documented nerve-fibre loss."
      ],
      "limitations": [
        "Small exploratory trials with several endpoints can overestimate or incompletely characterise effects.",
        "Results from sarcoidosis-associated neuropathy cannot establish general nerve regeneration or recovery from unrelated injuries.",
        "Study duration and sample size leave important safety and durability questions; catalogue nasal and vial formulations were not validated."
      ],
      "openQuestions": [
        "Do larger independently replicated trials confirm prespecified benefits?",
        "How durable are effects on function, symptoms and objective nerve measures?"
      ],
      "studies": [
        {
          "id": "pmid-23168581",
          "title": "Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study",
          "authors": "Heij L, Niesters M, Swartjes M, et al.",
          "year": 2012,
          "journal": "Molecular Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/23168581/",
          "doi": "10.2119/molmed.2012.00332",
          "pmid": "23168581",
          "evidenceType": "human",
          "design": "Exploratory four-week double-blind placebo-controlled study in 22 sarcoidosis patients with neuropathy symptoms.",
          "findings": "Small-fibre symptom scores improved more with ARA-290; pain and fatigue scores improved similarly in both groups.",
          "limitations": "Pilot scale, multiple symptom outcomes and limited duration. The safety observations cannot establish long-term safety.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3563705/"
        },
        {
          "id": "pmid-24136731",
          "title": "ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density",
          "authors": "Dahan A, Dunne A, Swartjes M, et al.",
          "year": 2013,
          "journal": "Molecular Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/24136731/",
          "doi": "10.2119/molmed.2013.00122",
          "pmid": "24136731",
          "evidenceType": "human",
          "design": "Blinded placebo-controlled study in sarcoidosis-associated small-nerve-fibre loss with short treatment and subsequent follow-up.",
          "findings": "Reported improved neuropathic symptoms, corneal nerve-fibre density and selected sensory and exercise measurements.",
          "limitations": "Small disease-specific study with several measures. Nerve-marker changes do not prove general tissue recovery. The corneal nerve-fibre area algorithm was corrected in a 2016 erratum; use corrected values if extracting that endpoint.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3883966/"
        },
        {
          "id": "pmid-25387363",
          "title": "ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes",
          "authors": "Brines M, Dunne AN, van Velzen M, et al.",
          "year": 2015,
          "journal": "Molecular Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/25387363/",
          "doi": "10.2119/molmed.2014.00215",
          "pmid": "25387363",
          "evidenceType": "human",
          "design": "Short phase 2 double-blind placebo-controlled study in type 2 diabetes with painful neuropathy; 49 enrolled, 48 analysed. Published online in 2014, PubMed issue record dated 2015.",
          "findings": "Reported changes in selected glycaemic and neuropathic measures. A corneal-nerve subgroup analysis was post hoc.",
          "limitations": "Small, short, multiple-outcome study with developer involvement. Serious adverse events occurred, including a withdrawal for renal deterioration; causal attribution was not established.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/"
        },
        {
          "id": "pmid-28059429",
          "title": "Erratum to: ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density",
          "authors": "Dahan A, Dunne A, Swartjes M, et al.",
          "year": 2016,
          "journal": "Molecular Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/28059429/",
          "doi": "10.2119/molmed.2013.00122.erratum",
          "pmid": "28059429",
          "evidenceType": "reference",
          "design": "Publisher erratum correcting the 2013 corneal nerve-fibre area algorithm, not another participant study.",
          "findings": "States that the original area values were too small and provides correction and area-normalisation factors.",
          "limitations": "Do not extract uncorrected absolute nerve-area values from the original paper. Area and nerve-fibre density are distinct measurements.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://link.springer.com/article/10.2119/molmed.2013.00122.erratum"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.",
        "queries": [
          "24136731 ARA-290 sarcoidosis small fiber neuropathy",
          "\"ARA 290 improves symptoms\" 2013 Dahan 00122",
          "\"23168581\" ARA \"10.\" Heij",
          "ARA 290 type 2 diabetes neuropathy placebo Brines 2015 trial",
          "\"10.2119/molmed.2013.00122\" correction retraction",
          "\"10.2119/molmed.2014.00215\" erratum correction"
        ],
        "scope": "Two early sarcoidosis trials, a short diabetes-neuropathy trial and the corneal nerve-area erratum. Selected full-text methods, endpoints and safety sections consulted where accessible; no comprehensive neuropathy evidence synthesis.",
        "limitations": "Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates."
      },
      "discussion": [
        {
          "heading": "Symptoms and nerve images answer different questions",
          "body": "A symptom scale is directly relevant to experience, while corneal imaging can test a proposed biological effect. Concordance would strengthen a hypothesis, but neither measure should be assumed to validate the other. Our interpretation is that selecting a favourable nerve subgroup after seeing the data is less conclusive than prospectively defining that population and reproducing the finding with a prespecified analysis.",
          "citations": [
            "pmid-24136731",
            "pmid-25387363"
          ]
        },
        {
          "heading": "Inspect the corrected measurement before pooling",
          "body": "The nerve-area erratum is material to any quantitative synthesis even if a summary does not quote the old numbers. Area, fibre count and fibre density should remain separate variables with their units and algorithms. Before combining studies, a researcher should determine which measurement was corrected and whether the extracted data reflect it, rather than treating every corneal endpoint as interchangeable.",
          "citations": [
            "pmid-28059429",
            "pmid-24136731"
          ]
        },
        {
          "heading": "Small studies cannot settle safety",
          "body": "Short trials may suggest feasibility without estimating uncommon or delayed harms. The diabetes report illustrates why abstract-level reassurance should be checked against the full safety section and participant flow. An event judged unrelated does not prove a cause, while an uncertain attribution does not justify ignoring it. Larger independent trials and longer follow-up are needed for a robust benefit-risk assessment.",
          "citations": [
            "pmid-23168581",
            "pmid-25387363"
          ]
        }
      ]
    },
    {
      "slug": "bacteriostatic-water",
      "names": [
        "Bacteriostatic Water",
        "BAC Water"
      ],
      "title": "Bacteriostatic water / BAC Water",
      "kind": "supply",
      "summary": "Water supplies appear in the regional catalogues with different labelled volumes. The name and volume alone do not establish composition, preservative concentration or quality.",
      "identity": "The UK/EU label is Bacteriostatic Water; the US label is BAC Water. They are grouped here for specification review, not asserted to be identical formulations.",
      "evidenceOverview": "Specification review, with a technical laboratory-quality reference. No biological benefit is assigned to this supply.",
      "whatResearchShows": [
        "Volume describes the amount of liquid in the listing, not its chemical composition or microbiological properties.",
        "The appropriate water specification depends on the analytical method."
      ],
      "limitations": [
        "Published quality guidance is not an assay or certification of a HeartPep product.",
        "The listing is not a substitute for the manufacturer’s complete specification or lot documentation."
      ],
      "openQuestions": [
        "Confirm the composition, preservative identity and concentration, grade and manufacturer.",
        "Obtain a matching lot report and any required microbial or endotoxin results."
      ],
      "studies": [
        {
          "id": "who-trs-1052-annex-4",
          "title": "WHO good practices for pharmaceutical quality control laboratories",
          "authors": "World Health Organization",
          "year": 2024,
          "journal": "WHO Technical Report Series 1052, Annex 4",
          "url": "https://www.who.int/publications/m/item/who-good-practices-for-pharmaceutical-quality-control-laboratories",
          "evidenceType": "reference",
          "design": "Technical guidance, sections 4.1, 5.3 and 5.4 consulted.",
          "findings": "Laboratory supplies require appropriate specifications and documented suitability checks.",
          "limitations": "General guidance does not test or certify these catalogue items.",
          "appliesTo": "identity-only",
          "verification": "full-text",
          "fullTextUrl": "https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/trs1052_annex4.pdf"
        }
      ],
      "search": {
        "date": "2026-11-08",
        "method": "Catalogue specification review and official technical-reference check",
        "queries": [
          "site.who.int \"TRS 1052\" \"Annex 4\" \"quality control laboratories\""
        ],
        "scope": "Regional catalogue labels and WHO 2024 guidance on laboratory supplies, equipment and reagents.",
        "limitations": "No independent performance testing of the supplied items was undertaken. This is a specification guide, not a biological literature review."
      }
    },
    {
      "slug": "bpc-157",
      "names": [
        "BPC-157",
        "BPC-157 Arginine Salt"
      ],
      "title": "BPC-157",
      "kind": "compound",
      "summary": "Tendon-cell findings and small uncontrolled human reports make BPC-157 a research subject, but do not establish reliable clinical recovery or validate the catalogue formats.",
      "identity": "The literature describes a synthetic 15-amino-acid peptide. The arginine-salt capsule label is retained as a separate product specification; the selected studies do not validate that salt or capsule formulation.",
      "evidenceOverview": "The selected record includes rat-derived tendon experiments and three small uncontrolled human reports covering knee pain, bladder symptoms and brief safety observation. Their endpoints and routes differ and should not be pooled into a treatment success rate.",
      "whatResearchShows": [
        "Chang and colleagues observed migration and stress-survival effects in rat tendon cultures, without a direct proliferation effect in the 2011 experiment.",
        "The 2021 knee report records perceived pain improvement, not controlled proof of tendon, ligament or cartilage repair."
      ],
      "limitations": [
        "The human chart review had no placebo or untreated comparison, variable follow-up and no validated functional assessment.",
        "Evidence for a peptide does not establish absorption, stability, efficacy or safety of a nasal preparation, capsule, pen or supplied vial."
      ],
      "openQuestions": [
        "Would adequately blinded, controlled human studies demonstrate a clinically meaningful benefit with a fully characterised formulation?"
      ],
      "studies": [
        {
          "id": "pmid-21030672",
          "title": "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration",
          "authors": "Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH",
          "year": 2011,
          "journal": "Journal of Applied Physiology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/21030672/",
          "doi": "10.1152/japplphysiol.00945.2010",
          "pmid": "21030672",
          "evidenceType": "laboratory",
          "design": "Rat Achilles-tendon explants and cultured tendon fibroblasts.",
          "findings": "Outgrowth, migration and survival under oxidative stress increased; direct proliferation did not. FAK/paxillin phosphorylation changed.",
          "limitations": "Cell and explant endpoints do not measure recovery in people.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-25415472",
          "title": "Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts",
          "authors": "Chang CH, Tsai WC, Hsu YH, Pang JH",
          "year": 2014,
          "journal": "Molecules",
          "url": "https://pubmed.ncbi.nlm.nih.gov/25415472/",
          "doi": "10.3390/molecules191119066",
          "pmid": "25415472",
          "evidenceType": "laboratory",
          "design": "Cultured tendon fibroblasts isolated from male rats.",
          "findings": "Growth-hormone-receptor expression increased, and added growth hormone increased proliferation-related measures after BPC-157 pretreatment.",
          "limitations": "A cellular interaction does not establish increased circulating growth hormone or human tissue repair.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/"
        },
        {
          "id": "pmid-34324435",
          "title": "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain",
          "authors": "Lee E, Padgett B",
          "year": 2021,
          "journal": "Alternative Therapies in Health and Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/34324435/",
          "pmid": "34324435",
          "evidenceType": "human",
          "design": "Retrospective chart review with telephone follow-up of 16 patients, including 12 receiving BPC-157 alone.",
          "findings": "Eleven of the 12 BPC-157-only recipients reported improvement; one did not.",
          "limitations": "Uncontrolled, unblinded and reliant on recollection. No validated function scale or imaging evidence of structural repair.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://instituteofhormonalbalance.com/wp-content/uploads/2022/02/Intra-Articular-Injection-of-BPC-157-for-Multiple-Types-of-Knee-Pain.pdf"
        },
        {
          "id": "pmid-39325560",
          "title": "Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study",
          "authors": "Lee E, Walker C, Ayadi B",
          "year": 2024,
          "journal": "Alternative Therapies in Health and Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39325560/",
          "pmid": "39325560",
          "evidenceType": "human",
          "design": "Retrospective clinical-record review of 12 women with bladder pain syndrome after an experimental local procedure.",
          "findings": "Ten reported complete symptom resolution and two reported substantial improvement; no adverse events were reported.",
          "limitations": "No control group or blinded assessment, selected clinic population and a local procedure. These findings cannot establish a causal effect or general safety.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://innovisionhm.com/journalslibrary/athm/pdfarticles/11423.pdf"
        },
        {
          "id": "pmid-40131143",
          "title": "Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study",
          "authors": "Lee E, Burgess K",
          "year": 2025,
          "journal": "Alternative Therapies in Health and Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40131143/",
          "pmid": "40131143",
          "evidenceType": "human",
          "design": "Uncontrolled three-day observation of two adults who had previously received intravenous BPC-157.",
          "findings": "No reported adverse symptoms or clinically important changes in the selected routine measurements during observation.",
          "limitations": "Two previously exposed volunteers and very brief follow-up cannot establish population safety, rare harms or pharmacokinetics. This is not a human half-life study.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://innovisionhm.com/journalslibrary/athm/pdfarticles/11513.pdf"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web discovery of primary PubMed and journal records, following the existing tendon reference and looking for human reports.",
        "queries": [
          "BPC-157 21030672 Chang growth hormone tendon cells",
          "site.pubmed.ncbi.nlm.nih.gov BPC 157 human knee pain 2021 Lee Burgess",
          "BPC 157 retraction 21030672",
          "Safety of Intravenous Infusion of BPC157 in Humans pdf",
          "Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis pdf",
          "Safety of Intravenous Infusion of BPC157 retracted OR erratum OR correction",
          "Intra-Articular Injection of BPC 157 retracted OR erratum OR correction",
          "Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis retracted OR erratum OR correction"
        ],
        "scope": "Selected tendon mechanisms plus the knee, bladder and intravenous human reports. Publisher or author-hosted full text was consulted for all three human reports.",
        "limitations": "Not an exhaustive database review or pooled estimate. Targeted exact-title/PMID notice searches did not retrieve a formal correction or retraction for these three human reports; intermittent PubMed retrieval and search-index coverage prevent a comprehensive status clearance."
      },
      "discussion": [
        {
          "heading": "Mechanism is a question, not a clinical conclusion",
          "body": "Migration, cell survival and receptor expression can help explain why a molecule merits investigation. They do not by themselves show that an injured human tendon becomes stronger or that recovery is faster. The two tendon papers ask different experimental questions: absence of a direct proliferation signal in one assay is compatible with altered responsiveness to added growth hormone in another. It would be misleading to compress both into a claim that BPC-157 broadly increases growth hormone or heals injuries.",
          "citations": [
            "pmid-21030672",
            "pmid-25415472"
          ]
        },
        {
          "heading": "The human reports need controls and replication",
          "body": "The knee and bladder reports are useful observations, but symptom change after a procedure cannot separate the compound from expectation, natural fluctuation, selection or other care. The tiny intravenous study adds short-term observations in two prior users. Its normal selected measurements are not evidence that uncommon or delayed problems cannot occur. These studies support better trial design, not a general safety declaration. A research programme would need prospective controls, prespecified outcomes, transparent formulation testing and follow-up matched to the harms being investigated.",
          "citations": [
            "pmid-34324435",
            "pmid-39325560",
            "pmid-40131143"
          ]
        },
        {
          "heading": "Separate the compound from the delivery claim",
          "body": "None of these studies is a comparison of the listed arginine-salt capsules with a vial, spray or pen. A format-specific conclusion would require its own composition, stability and exposure evidence. The literature can justify a research question while leaving that commercial specification unvalidated.",
          "citations": [
            "pmid-21030672",
            "pmid-39325560",
            "pmid-40131143"
          ]
        }
      ]
    },
    {
      "slug": "bpc-tb-500",
      "names": [
        "BPC/TB-500"
      ],
      "title": "BPC/TB-500",
      "kind": "blend",
      "summary": "There is limited combination research, including a small rat study reporting no additive benefit. Neither that experiment nor component studies validate this catalogue blend.",
      "identity": "The catalogue name identifies a proposed combination, not an independently verified composition. The precise TB-500 sequence, component amounts, formulation and lot identity remain separate questions.",
      "evidenceOverview": "A 2026 rat experiment and a small earlier human report provide combination context. Their preparations and methods differ from the catalogue product and cannot establish equivalence.",
      "whatResearchShows": [
        "In the rat experiment, combining the agents did not outperform either alone.",
        "A four-person combination subgroup in an uncontrolled knee report is insufficient to distinguish synergy, component effects or placebo response."
      ],
      "limitations": [
        "Clinical benefit of the exact supplied blend is not established.",
        "Results for BPC-157, full-length thymosin beta-4 or one fragment cannot be assigned to an unspecified combination."
      ],
      "openQuestions": [
        "Can an independently characterised blend demonstrate an advantage over its individual components in adequately powered comparative research?"
      ],
      "studies": [
        {
          "id": "pmid-42542926",
          "title": "Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study",
          "authors": "Biçer O, Adanir O, Güleryüz Y, et al.",
          "year": 2026,
          "journal": "Joint Diseases and Related Surgery",
          "url": "https://pubmed.ncbi.nlm.nih.gov/42542926/",
          "doi": "10.52312/jdrs.2026.2951",
          "pmid": "42542926",
          "evidenceType": "animal",
          "design": "Thirty-two male rats randomised to control, BPC-157, TB-500 or combination following tendon repair; four weeks of observation.",
          "findings": "TB-500 improved load to failure versus control. The combination offered no additional benefit over individual agents.",
          "limitations": "Four tendons per group per endpoint, one time point and no functional recovery test. The paper's TB-500 terminology does not verify the catalogue sequence.",
          "appliesTo": "related-compound",
          "verification": "full-text",
          "fullTextUrl": "https://jointdrs.org/full-text/1851"
        },
        {
          "id": "pmid-34324435",
          "title": "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain",
          "authors": "Lee E, Padgett B",
          "year": 2021,
          "journal": "Alternative Therapies in Health and Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/34324435/",
          "pmid": "34324435",
          "evidenceType": "human",
          "design": "Retrospective knee-pain report; four patients received BPC-157 with TB4.",
          "findings": "Three combination recipients reported improvement and one did not.",
          "limitations": "Tiny nonrandomised subgroup, no comparison capable of testing synergy, and TB4 is not proof of the catalogue TB-500 identity.",
          "appliesTo": "related-compound",
          "verification": "full-text",
          "fullTextUrl": "https://instituteofhormonalbalance.com/wp-content/uploads/2022/02/Intra-Articular-Injection-of-BPC-157-for-Multiple-Types-of-Knee-Pain.pdf"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted discovery of primary combination studies and inspection of the 2026 journal methods and results.",
        "queries": [
          "Effects of BPC-157 and TB-500 on Achilles tendon healing in rats",
          "42542926 BPC TB500",
          "Intra-Articular Injection of BPC 157 Results"
        ],
        "scope": "Selected rat combination evidence and the small human TB4 combination subgroup.",
        "limitations": "No exhaustive trial-registry review or proof that the studied preparations match the supplier blend. Full-text methods and results were checked for both reports; a comprehensive correction/retraction audit was not performed."
      },
      "discussion": [
        {
          "heading": "What the combination experiment can resolve",
          "body": "A combination arm is more informative about an interaction than two separate positive papers. In the rat study, however, only four tendons per group contributed to each endpoint and assessment occurred at one early stage. Failure to demonstrate an added effect therefore does not prove equivalence under every circumstance. It does mean this experiment cannot substantiate a synergy claim. The relevant result is comparative performance, not whether any treated tissue looked better than control.",
          "citations": [
            "pmid-42542926"
          ]
        },
        {
          "heading": "Keep the tested preparations distinct",
          "body": "The human report used TB4 alongside BPC-157 in four patients, with no randomised comparison between components and combination. That cannot identify which agent, if either, caused symptom change. Nor does the label establish the sequence of the catalogue blend. Translational reasoning requires matching composition and then testing the combination itself, rather than adding together proposed component benefits.",
          "citations": [
            "pmid-34324435"
          ]
        },
        {
          "heading": "Composition must be explicit",
          "body": "Even a carefully controlled combination experiment supports only the tested materials and exposure relationship. A blend review should therefore preserve component identity and relative amounts as unresolved until documented. It should not import a recipe from another seller or infer a standard combination from the short catalogue label.",
          "citations": [
            "pmid-42542926",
            "pmid-34324435"
          ]
        }
      ]
    },
    {
      "slug": "cagrilintide",
      "names": [
        "Cagrilintide"
      ],
      "title": "Cagrilintide",
      "kind": "compound",
      "summary": "Human studies investigate the amylin analogue alone and in combination with semaglutide. A combination's result must not be presented as the isolated effect of cagrilintide.",
      "identity": "Cagrilintide is a long-acting amylin analogue. Cagrilintide alone and the cagrilintide-semaglutide combination are different study interventions.",
      "evidenceOverview": "A dose-finding phase 2 trial directly studied cagrilintide. REDEFINE 1 later compared a combination, its components and placebo, with the main comparison focused on the combination.",
      "whatResearchShows": [
        "The phase 2 trial reported greater average weight reduction than placebo over 26 weeks, together with gastrointestinal adverse events [1].",
        "REDEFINE 1 supports conclusions about its studied combination, not an assumption that every combination benefit is attributable to cagrilintide alone [2].",
        "REDEFINE 9 adds two lower-strength clinical combination arms versus placebo, without an isolated cagrilintide arm [5]."
      ],
      "limitations": [
        "No selected trial tested a HeartPep vial or nasal formulation, or confirmed commercial batch comparability.",
        "Study phase, population, analysis strategy and the exact intervention matter. These sources do not establish a catalogue product as a clinical medicine."
      ],
      "openQuestions": [
        "What is the independently replicated contribution of each component in combination studies?",
        "What do longer-term outcome and safety data show for cagrilintide alone?"
      ],
      "studies": [
        {
          "id": "pmid-34798060",
          "title": "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial",
          "authors": "Lau DCW, Erichsen L, Francisco AM, et al.",
          "year": 2021,
          "journal": "The Lancet",
          "url": "https://pubmed.ncbi.nlm.nih.gov/34798060/",
          "doi": "10.1016/S0140-6736(21)01751-7",
          "pmid": "34798060",
          "evidenceType": "human",
          "design": "26-week dose-finding trial with 706 randomized participants, without diabetes, including placebo and liraglutide comparisons.",
          "findings": "Mean weight reduction across cagrilintide groups was approximately 6.0%-10.8%, versus 3.0% with placebo under the trial-product estimand. Gastrointestinal events were more frequent than with placebo.",
          "limitations": "Phase 2 and manufacturer-funded; follow-up and population are limited. The results do not validate catalogue formulations.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-40544433",
          "title": "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity",
          "authors": "Garvey WT, Blüher M, Osorto Contreras CK, et al.; REDEFINE 1 Study Group",
          "year": 2025,
          "journal": "New England Journal of Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40544433/",
          "doi": "10.1056/NEJMoa2502081",
          "pmid": "40544433",
          "evidenceType": "human",
          "design": "68-week phase 3a randomized trial in 3,417 adults, including combination, individual-component and placebo groups.",
          "findings": "The main combination-versus-placebo comparison reported mean weight changes of -20.4% and -3.0%, with substantially more gastrointestinal events in the combination group.",
          "limitations": "The headline comparison concerns two compounds together. It is not an estimate of cagrilintide alone or of the effect of a commercial research product.",
          "appliesTo": "related-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-42251859",
          "title": "Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study",
          "authors": "Buse JB, Bajaj HS, Dalskov SM, et al.; REIMAGINE 2 study group",
          "year": 2026,
          "journal": "The Lancet Diabetes & Endocrinology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/42251859/",
          "evidenceType": "human",
          "design": "68-week trial in 2,713 adults with inadequately controlled type 2 diabetes; combination and component arms were included.",
          "findings": "The primary comparison concerns HbA1c with the combination versus semaglutide, rather than a stand-alone cagrilintide weight-loss estimate.",
          "limitations": "A published correction is linked, PMID42320507. Its full text was not retrieved here, so numerical effect estimates are not reproduced. The trial is manufacturer-funded.",
          "appliesTo": "related-compound",
          "verification": "abstract",
          "doi": "10.1016/S2213-8587(26)00125-7",
          "pmid": "42251859"
        },
        {
          "id": "pmid-42320507",
          "title": "Correction to Lancet Diabetes Endocrinol 2026; published online June 7. https://doi.org/10.1016/S2213-8587(26)00125-7",
          "authors": "The Lancet Diabetes & Endocrinology, no named author listed in PubMed",
          "year": 2026,
          "journal": "The Lancet Diabetes & Endocrinology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/42320507/",
          "evidenceType": "reference",
          "design": "Published erratum linked to the REIMAGINE 2 primary report.",
          "findings": "The primary bibliographic record verifies the correction linkage.",
          "limitations": "No abstract available; the correction text was not reviewed. Its existence alone establishes neither that the results were invalid nor that all quantitative results remained unchanged.",
          "appliesTo": "related-compound",
          "verification": "record",
          "doi": "10.1016/S2213-8587(26)00157-9",
          "pmid": "42320507"
        },
        {
          "id": "pmid-43033821",
          "title": "Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial",
          "authors": "Wharton S, Broholm C, Horn D, et al.",
          "year": 2026,
          "journal": "The Lancet Diabetes & Endocrinology",
          "url": "https://www.sciencedirect.com/science/article/pii/S2213858726002755",
          "doi": "10.1016/S2213-8587(26)00275-5",
          "pmid": "43033821",
          "evidenceType": "human",
          "design": "REDEFINE 9 (NCT06388187), a randomized phase 3b trial of two subcutaneous cagrilintide–semaglutide combinations versus placebo in 309 adults without diabetes. Published 14 November 2026.",
          "findings": "At week 68, the efficacy analysis estimated placebo-adjusted differences in weight change of −18.8 and −19.0 percentage points. Adverse events were common in all arms, mostly mild or moderate and gastrointestinal.",
          "limitations": "Sponsor-funded. There was no single-component arm. The primary comparisons each tested an active regimen against placebo. Publisher abstract and accessible excerpts consulted.",
          "appliesTo": "related-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-16",
        "method": "Targeted PubMed and publisher check of new and existing combination evidence.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov/34798060 Cagrilintide",
          "site.pubmed.ncbi.nlm.nih.gov cagrilintide REDEFINE 1 2025",
          "site.pubmed.ncbi.nlm.nih.gov/40544433 3417",
          "site.pubmed.ncbi.nlm.nih.gov cagrilintide phase 3 2026",
          "site.pubmed.ncbi.nlm.nih.gov 42251859 Authors",
          "site.pubmed.ncbi.nlm.nih.gov 42320507 Correction",
          "PMID 43033821 / DOI 10.1016/S2213-8587(26)00275-5"
        ],
        "scope": "Selected phase 2 monotherapy, phase 3a obesity combination and 2026 diabetes combination studies, with the linked REIMAGINE 2 correction record. Reviewed the REDEFINE 9 publisher abstract and accessible article excerpts.",
        "limitations": "REDEFINE 9 was assessed from the publisher abstract and excerpts. The existing correction to REIMAGINE 2 remains linked. The selected trials do not cover all preparations or outcomes."
      },
      "discussion": [
        {
          "heading": "A combination result is not a monotherapy result",
          "body": "REDEFINE 1 contains component arms, but its main headline comparison is the combination against placebo. Reporting that number as the effect of cagrilintide alone would remove a second active compound from the intervention being described. The earlier dose-finding study is more direct evidence for cagrilintide monotherapy, although it is shorter and smaller. Interpretation should also preserve which estimand is reported: an estimate assuming adherence answers a different question from an estimate retaining outcomes after discontinuation. This is a reason to inspect the statistical plan, not to select whichever percentage appears largest.",
          "citations": [
            "pmid-34798060",
            "pmid-40544433"
          ]
        },
        {
          "heading": "New diabetes evidence introduces another endpoint and a correction",
          "body": "The 2026 REIMAGINE 2 study examines glycaemic control in a population receiving background diabetes treatment. Its primary HbA1c comparison cannot be substituted for a weight-management endpoint or for cagrilintide monotherapy efficacy. The linked published correction also belongs in the reading trail. Because its text was not retrieved in this review, numerical results from that report are withheld rather than assuming what changed. A correction is distinct from an expression of concern or retraction; the record should prompt examination of the corrected paper without making an unsupported judgement about its validity.",
          "citations": [
            "pmid-42251859",
            "pmid-42320507"
          ]
        },
        {
          "heading": "REDEFINE 9 studied a specific combination",
          "body": "The study randomised adults to the two combination regimens or placebo within a dose level. The similar point estimates do not establish that the regimens are equivalent. The results cannot isolate either ingredient’s contribution or validate another preparation.",
          "citations": [
            "pmid-43033821"
          ]
        }
      ]
    },
    {
      "slug": "cjc-1295-no-dac",
      "names": [
        "CJC 1295 N/Dac",
        "CJC-1295 No DAC"
      ],
      "title": "CJC-1295 (no DAC)",
      "kind": "compound",
      "summary": "The cited long-acting CJC-1295 literature is related background, not direct evidence for a no-DAC listing.",
      "identity": "Both catalogue aliases explicitly say no DAC. The supplied label alone does not fully document sequence, modifications or formulation. We do not silently equate this material with the albumin-binding analogue.",
      "evidenceOverview": "The selected source concerns a different, albumin-binding GHRF analogue in cells and rats. No direct study of these exact supplier-labelled materials was verified for this entry.",
      "whatResearchShows": [
        "The related paper explains why an albumin-binding modification changes persistence and why it matters when reading CJC literature."
      ],
      "limitations": [
        "The cited preclinical results cannot establish no-DAC pharmacokinetics, human outcomes or nasal absorption.",
        "A similar compound name is insufficient evidence of molecular equivalence."
      ],
      "openQuestions": [
        "What exact sequence, terminal groups and chemical form does no DAC identify here?",
        "Is there a primary experiment on that precise molecule and the intended research model?"
      ],
      "studies": [
        {
          "id": "pmid-15817669",
          "title": "Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog",
          "authors": "Jetté L, Léger R, Thibaudeau K, et al.",
          "year": 2005,
          "journal": "Endocrinology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/15817669/",
          "doi": "10.1210/en.2004-1286",
          "pmid": "15817669",
          "evidenceType": "animal",
          "design": "Chemical synthesis, cultured rat pituitary-cell assays and pharmacokinetic experiments in male rats.",
          "findings": "Albumin-binding hGRF analogues retained activity in cells. The selected CJC-1295 analogue stimulated rat GH secretion and remained detectable beyond 72 hours.",
          "limitations": "This work concerns an albumin-binding analogue. It does not test a no-DAC catalogue product or show muscle or strength benefits in people.",
          "appliesTo": "related-compound",
          "verification": "abstract"
        },
        {
          "id": "fda-cjc-1295-2024",
          "title": "FDA Evaluation of CJC-1295-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee briefing document",
          "authors": "U.S. Food and Drug Administration.",
          "year": 2024,
          "journal": "FDA briefing document, December 4, 2024 meeting",
          "url": "https://www.fda.gov/media/183819/download",
          "evidenceType": "reference",
          "design": "Official evaluation of five named CJC-1295-related substances, including chemical identity and the scope of identified clinical evidence. Relevant chemistry and clinical-evidence sections were consulted.",
          "findings": "The document distinguishes the no-DAC and DAC active moieties and separate salt forms. FDA did not identify human studies of the specified no-DAC free base or acetate in its review.",
          "limitations": "A dated government evidence and identity review, not an intervention trial or a current legal-status determination. It does not authenticate any supplier material.",
          "appliesTo": "identity-only",
          "verification": "full-text",
          "fullTextUrl": "https://www.fda.gov/media/183819/download"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov CJC-1295 no DAC modified GRF 1-29 trial",
          "site.fda.gov CJC-1295 without DAC tetrasubstituted GHRH 2024 chemistry review"
        ],
        "scope": "Selected primary background research plus an explicitly labelled FDA identity/evidence review; no direct trial of the exact supplier-labelled no-DAC material was verified.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research."
      },
      "discussion": [
        {
          "heading": "The missing modification changes the identity question",
          "body": "The FDA chemistry review treats CJC-1295 and CJC-1295 DAC as distinct active moieties and lists salt forms separately. That is a concrete reason to resist treating no DAC as a minor wording difference. Its 2024 review did not identify human studies of the specified no-DAC free base or acetate. This is a dated evidence finding, not proof that no later research exists or a current regulatory conclusion.",
          "citations": [
            "fda-cjc-1295-2024"
          ]
        },
        {
          "heading": "Why the related rat paper remains background",
          "body": "The Jetté experiment deliberately joined GHRF-derived molecules to albumin to extend persistence, then measured activity in pituitary cells and rats. Removing that design feature removes a central reason for citing the prolonged exposure. The paper can explain the development programme, but cannot provide the half-life or outcomes of a no-DAC material. For a literature search to become directly applicable, its molecular specification must first match the material under discussion.",
          "citations": [
            "pmid-15817669"
          ]
        }
      ]
    },
    {
      "slug": "cjc-1295-with-dac",
      "names": [
        "CJC-1295 with DAC"
      ],
      "title": "CJC-1295 with DAC",
      "kind": "compound",
      "summary": "Human experiments support prolonged GH and IGF-I signalling from a defined long-acting CJC-1295 analogue. Those endocrine findings do not establish a muscle or strength benefit.",
      "identity": "The long-acting analogue in these papers contains an albumin-binding modification. Its results must stay separate from no-DAC listings.",
      "evidenceOverview": "The selected evidence connects preclinical albumin-binding pharmacology with short controlled human hormone-response trials. It is strongest for the measured endocrine response, rather than a performance outcome.",
      "whatResearchShows": [
        "The human trials below measured circulating hormones and drug persistence, rather than athletic performance."
      ],
      "limitations": [
        "Short follow-up cannot resolve long-term safety. A catalogue name does not establish the studied formulation or an equivalent delivery profile."
      ],
      "openQuestions": [
        "Which exact sequence and albumin-binding modification are documented for the material?",
        "Is the proposed experimental endpoint a hormone marker, or an independently measured functional outcome?"
      ],
      "studies": [
        {
          "id": "pmid-16352683",
          "title": "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults",
          "authors": "Teichman SL, Neale A, Lawrence B, et al.",
          "year": 2006,
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/",
          "doi": "10.1210/jc.2005-1536",
          "pmid": "16352683",
          "evidenceType": "human",
          "design": "Two randomized, double-blind, placebo-controlled ascending-exposure trials, lasting 28 and 49 days, in healthy adults aged 21–61.",
          "findings": "The defined long-acting analogue produced sustained increases in GH and IGF-I. Its estimated half-life was 5.8–8.1 days.",
          "limitations": "Hormone concentrations and short-term tolerability were assessed. These trials did not establish improved strength, muscle performance or long-term safety.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-17018654",
          "title": "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog",
          "authors": "Ionescu M, Frohman LA.",
          "year": 2006,
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/17018654/",
          "doi": "10.1210/jc.2006-1702",
          "pmid": "17018654",
          "evidenceType": "human",
          "design": "Healthy men underwent overnight blood sampling before and one week after a defined long-acting CJC-1295 intervention.",
          "findings": "GH pulses persisted, while trough and mean GH concentrations increased. Pulse frequency and magnitude were not significantly changed.",
          "limitations": "An endocrine time-course experiment. Preserved pulses do not demonstrate normalisation of a disease state, improved performance or long-term safety.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov 16352683 CJC-1295 Teichman",
          "site.pubmed.ncbi.nlm.nih.gov CJC-1295 no DAC modified GRF 1-29 trial",
          "site.pubmed.ncbi.nlm.nih.gov CJC-1295 pulsatile secretion randomized Teichman 2006",
          "\"17018654\" DOI Ionescu"
        ],
        "scope": "Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research."
      },
      "discussion": [
        {
          "heading": "A preserved pulse is only part of the hormone profile",
          "body": "The overnight sampling study adds a useful qualification to the phrase preserved pulsatility. Pulse frequency and size did not significantly change, while trough GH rose. A pulsatile pattern can therefore coexist with a higher background concentration. This is evidence about the shape of an endocrine response, not proof that normal physiology has been restored or that a favourable clinical outcome follows. The paper is especially useful when a secondary account presents pulsatility as a complete safety argument.",
          "citations": [
            "pmid-17018654"
          ]
        },
        {
          "heading": "What the controlled trials can establish",
          "body": "The ascending-exposure trials support a causal effect of the defined long-acting analogue on measured hormone concentrations in healthy adults. Randomisation helps answer that narrow question. It does not supply an unmeasured outcome: strength, functional recovery and treatment of a deficient population would each need appropriate participants and direct endpoints. The reported persistence also belongs to the modified study molecule. It is not a generic property of every product using the CJC name.",
          "citations": [
            "pmid-16352683"
          ]
        }
      ]
    },
    {
      "slug": "cjc-ipamorelin",
      "names": [
        "CJC/Ipamorelin"
      ],
      "title": "CJC/Ipamorelin",
      "kind": "blend",
      "summary": "The references concern separately studied components. They do not demonstrate that this combination has the same effects, additive effects or a particular safety profile.",
      "identity": "The supplier label names CJC and ipamorelin but does not establish the CJC form, exact sequences or component proportions. These details are material to interpreting the literature.",
      "evidenceOverview": "Selected human studies establish component-level endocrine observations. No trial of the exact catalogue blend was verified for this entry.",
      "whatResearchShows": [
        "A component study can generate a hypothesis for a combination experiment. It cannot supply that experiment’s result."
      ],
      "limitations": [
        "The studied long-acting CJC form may differ from the blend.",
        "Component findings do not establish chemical compatibility, stability, absorption or outcomes for a combined vial or spray."
      ],
      "openQuestions": [
        "Which CJC analogue and component proportions are documented?",
        "Has the exact mixture been independently characterized and tested in a relevant model?"
      ],
      "studies": [
        {
          "id": "pmid-16352683",
          "title": "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults",
          "authors": "Teichman SL, Neale A, Lawrence B, et al.",
          "year": 2006,
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/",
          "doi": "10.1210/jc.2005-1536",
          "pmid": "16352683",
          "evidenceType": "human",
          "design": "Two randomized, double-blind, placebo-controlled ascending-exposure trials, lasting 28 and 49 days, in healthy adults aged 21–61.",
          "findings": "The defined long-acting analogue produced sustained increases in GH and IGF-I. Its estimated half-life was 5.8–8.1 days.",
          "limitations": "This study tested a defined long-acting CJC-1295 analogue alone. It did not test a CJC/ipamorelin blend, and the catalogue does not establish which CJC form the blend contains.",
          "appliesTo": "components-only",
          "verification": "abstract"
        },
        {
          "id": "pmid-10496658",
          "title": "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers",
          "authors": "Gobburu JV, Agersø H, Jusko W, Ynddal L.",
          "year": 1999,
          "journal": "Pharmaceutical Research",
          "url": "https://pubmed.ncbi.nlm.nih.gov/10496658/",
          "doi": "10.1023/a:1018955126402",
          "pmid": "10496658",
          "evidenceType": "human",
          "design": "Dose-escalation infusion experiment with eight healthy male volunteers at each of five exposure levels.",
          "findings": "A short GH-release episode followed ipamorelin exposure; the investigators developed a model relating drug concentration to GH response.",
          "limitations": "Ipamorelin-alone hormone pharmacology cannot establish the behaviour, compatibility, efficacy or safety of a CJC/ipamorelin blend.",
          "appliesTo": "components-only",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov 16352683 CJC-1295 Teichman",
          "site.pubmed.ncbi.nlm.nih.gov ipamorelin randomized postoperative ileus trial",
          "site.pubmed.ncbi.nlm.nih.gov \"CJC-1295\" \"ipamorelin\" trial"
        ],
        "scope": "Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research."
      },
      "discussion": [
        {
          "heading": "A plausible combination remains a separate experimental claim",
          "body": "The component papers show that each specified research preparation can change a GH-related endpoint. Neither assigns participants to the catalogue combination. An effect from one component, or an interaction between pathways, cannot be quantified by putting results from separate studies side by side. A useful combination study would need the mixture characterised and suitable single-component comparisons, so that any additional effect could be distinguished from either component’s contribution. This is a study-design requirement inferred from the evidence gap, not a result reported by these papers.",
          "citations": [
            "pmid-16352683",
            "pmid-10496658"
          ]
        },
        {
          "heading": "Identity uncertainty comes before an effect estimate",
          "body": "The CJC paper concerns a long-acting albumin-binding analogue; the blend name does not establish that this is its CJC constituent. The ipamorelin paper concerns a single peptide preparation. Consequently, even the starting molecular comparison remains incomplete. A defensible review of the exact blend would need confirmed component identities and proportions before examining mixture-specific stability, exposure or outcomes. Component evidence remains useful background, with its limits kept visible.",
          "citations": [
            "pmid-16352683",
            "pmid-10496658"
          ]
        }
      ]
    },
    {
      "slug": "dhexa",
      "names": [
        "DhexA"
      ],
      "title": "DhexA",
      "kind": "identity-pending",
      "summary": "The exact chemical identity behind this catalogue label has not been verified. A near-match to another research compound is not a sound basis for an evidence review.",
      "identity": "The catalogue name is a supplier label, not an authenticated molecular specification. This note preserves the exact published names without assigning an unverified identity.",
      "evidenceOverview": "Identity unresolved. No biological evidence is attributed to this product here. This is an evidence-matching gap, not a statement that no research exists.",
      "whatResearchShows": [
        "A meaningful literature review needs an identified substance or a defined mixture. Studies of an assumed ingredient would answer a different question."
      ],
      "limitations": [
        "No confirmed sequence, complete composition or matched chemical specification is available in the catalogue record used for this note.",
        "A general research paper or another seller’s blend formula cannot establish the contents, stability or effects of this listing."
      ],
      "openQuestions": [
        "Obtain a full identity specification and authenticated analytical record. Screen any subsequently matched papers for corrections or retractions.",
        "Once the identity is confirmed, which primary studies match that exact compound, route and formulation?"
      ],
      "studies": [],
      "search": {
        "date": "2026-11-08",
        "method": "Identity-gated catalogue review",
        "queries": [],
        "scope": "Exact supplier labels and published catalogue specifications were checked. Biological literature was not attributed while the identity remained unresolved.",
        "limitations": "This is an identity note, not a negative literature search. It cannot show that relevant studies do not exist."
      }
    },
    {
      "slug": "disinfectant-swabs",
      "names": [
        "Disinfectant Swabs"
      ],
      "title": "Disinfectant swabs: specification guide",
      "kind": "supply",
      "summary": "The catalogue label does not yet state the active substance, concentration or pack specification. Those details are needed to judge suitability for a laboratory procedure.",
      "identity": "The UK/EU supplier lists Disinfectant Swabs with specification pending. This note makes no assumption about alcohol concentration or antimicrobial performance.",
      "evidenceOverview": "Specification review, with a technical laboratory-quality reference. No biological benefit is assigned to this supply.",
      "whatResearchShows": [
        "The name alone cannot establish the active formulation or its validated performance.",
        "A laboratory should match the specified supply to its own documented method."
      ],
      "limitations": [
        "Published quality guidance is not an assay or certification of a HeartPep product.",
        "The listing is not a substitute for the manufacturer’s complete specification or lot documentation."
      ],
      "openQuestions": [
        "Confirm the active substance, concentration, substrate, pack size and manufacturer.",
        "Obtain supporting performance and shelf-life documentation for the actual product."
      ],
      "studies": [
        {
          "id": "who-trs-1052-annex-4",
          "title": "WHO good practices for pharmaceutical quality control laboratories",
          "authors": "World Health Organization",
          "year": 2024,
          "journal": "WHO Technical Report Series 1052, Annex 4",
          "url": "https://www.who.int/publications/m/item/who-good-practices-for-pharmaceutical-quality-control-laboratories",
          "evidenceType": "reference",
          "design": "Technical guidance, sections 4.1, 5.3 and 5.4 consulted.",
          "findings": "Laboratory supplies require appropriate specifications and documented suitability checks.",
          "limitations": "General guidance does not test or certify these catalogue items.",
          "appliesTo": "identity-only",
          "verification": "full-text",
          "fullTextUrl": "https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/trs1052_annex4.pdf"
        }
      ],
      "search": {
        "date": "2026-11-08",
        "method": "Catalogue specification review and official technical-reference check",
        "queries": [
          "site.who.int \"TRS 1052\" \"Annex 4\" \"quality control laboratories\""
        ],
        "scope": "Regional catalogue labels and WHO 2024 guidance on laboratory supplies, equipment and reagents.",
        "limitations": "No independent performance testing of the supplied items was undertaken. This is a specification guide, not a biological literature review."
      }
    },
    {
      "slug": "dsip",
      "names": [
        "DSIP"
      ],
      "title": "DSIP",
      "kind": "compound",
      "summary": "Delta sleep-inducing peptide has been investigated in small sleep experiments. Early positive observations coexist with later studies reporting weak or clinically limited effects, so the name should not be read as a proven sleep-aid claim.",
      "identity": "DSIP is the abbreviation used for delta sleep-inducing peptide in the selected papers. The catalogue label does not independently confirm the sequence, identity or preparation used in those experiments.",
      "evidenceOverview": "The human studies selected here are old, small and short. Their mixed findings do not establish a reliable modern insomnia treatment or effects of supplied nasal or vial products.",
      "whatResearchShows": [
        "An early six-volunteer experiment reported acute and subsequent sleep changes.",
        "Two later insomnia investigations found that apparent improvements were weak, affected by baseline or placebo differences, or unlikely to provide substantial clinical benefit.",
        "A 14-patient report described improved sleep and daytime performance, illustrating the inconsistency across small studies rather than resolving it."
      ],
      "limitations": [
        "Brief laboratory observations cannot establish sustained benefit, everyday functioning or long-term safety.",
        "Different populations and study designs make simple comparison of positive and negative results difficult.",
        "These reports do not validate any catalogue formulation, its delivery characteristics or its batch quality."
      ],
      "openQuestions": [
        "Would larger independently replicated studies using meaningful patient-reported outcomes show a durable effect?",
        "Can any result be reproduced with a precisely identified, characterized formulation?"
      ],
      "studies": [
        {
          "id": "pmid-6895513",
          "title": "Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior",
          "authors": "Schneider-Helmert D et al.",
          "year": 1981,
          "journal": "Int J Clin Pharmacol Ther Toxicol",
          "url": "https://pubmed.ncbi.nlm.nih.gov/6895513/",
          "pmid": "6895513",
          "evidenceType": "human",
          "design": "Double-blind crossover experiment in six healthy volunteers.",
          "findings": "The investigators reported more acute sleep and later changes in sleep onset and efficiency.",
          "limitations": "Extremely small early experiment in healthy volunteers, not proof of sustained insomnia relief.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-3583493",
          "title": "Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs",
          "authors": "Monti JM et al.",
          "year": 1987,
          "journal": "Int J Clin Pharmacol Res",
          "url": "https://pubmed.ncbi.nlm.nih.gov/3583493/",
          "pmid": "3583493",
          "evidenceType": "human",
          "design": "Double-blind crossover insomnia study using polysomnography.",
          "findings": "Several sleep comparisons were not significant; other differences already existed at baseline. The authors judged clinical relevance limited.",
          "limitations": "Short observation period and baseline imbalances complicate interpretation.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-1299794",
          "title": "Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study",
          "authors": "Bes F et al.",
          "year": 1992,
          "journal": "Neuropsychobiology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/1299794/",
          "doi": "10.1159/000118919",
          "pmid": "1299794",
          "evidenceType": "human",
          "design": "Double-blind parallel-groups laboratory study in 16 chronic insomnia patients.",
          "findings": "Some objective changes were weak; subjective sleep quality did not improve. The authors found little basis for major therapeutic benefit.",
          "limitations": "Small and short study; some apparent differences may reflect change in the placebo group.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-3622582",
          "title": "Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia",
          "authors": "Schneider-Helmert D.",
          "year": 1987,
          "journal": "Eur Neurol",
          "url": "https://pubmed.ncbi.nlm.nih.gov/3622582/",
          "pmid": "3622582",
          "evidenceType": "human",
          "design": "Placebo-controlled double-blind study of 14 chronic insomnia patients with sleep and daytime-performance measurements.",
          "findings": "The report describes improved night sleep and daytime alertness/performance over a short observation period.",
          "limitations": "Very small, brief study; its positive conclusions conflict with later reports of clinically limited benefit.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "doi": "10.1159/000116143"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted PubMed searches for controlled sleep experiments, retaining both positive and weak or negative results. Initial selection on 8 November was substantively extended on 9 November, with clinical searches, accessible full-text consultation and bounded publication-notice checks.",
        "queries": [
          "site:pubmed.ncbi.nlm.nih.gov DSIP 1299794",
          "site:pubmed.ncbi.nlm.nih.gov/1299794/",
          "site:pubmed.ncbi.nlm.nih.gov delta sleep inducing peptide double blind crossover healthy volunteers sleep 1981",
          "site:pubmed.ncbi.nlm.nih.gov \"delta sleep-inducing peptide\" placebo insomnia",
          "site:pubmed.ncbi.nlm.nih.gov/3622582/"
        ],
        "scope": "Selected primary human sleep experiments; not a survey of all DSIP biology.",
        "limitations": "Abstract-based narrative selection, not a systematic review. Older full texts and comprehensive adverse-event data were not assessed. Incomplete PubMed record retrieval limits linked-notice checking; absence of a located correction is not complete publication-status clearance."
      },
      "discussion": [
        {
          "heading": "Why the positive reports do not settle the question",
          "body": "The early healthy-volunteer experiment and the 14-patient insomnia report provide reasons to investigate DSIP, but neither supplies a large, durable clinical comparison. Later weak or negative results must remain visible alongside them. Counting how many papers are positive is less informative than examining their design, baseline balance, population and measured outcome.",
          "citations": [
            "pmid-6895513",
            "pmid-3622582",
            "pmid-3583493"
          ]
        },
        {
          "heading": "Meaningful sleep outcomes need consistent evidence",
          "body": "A shift in one sleep stage or a laboratory-night measurement may not correspond to a worthwhile improvement in perceived sleep or daytime functioning. The 1992 study is informative because apparent objective changes coexisted with unchanged subjective sleep quality. Replication should reconcile these outcomes rather than selecting whichever measure looks most favourable.",
          "citations": [
            "pmid-1299794"
          ]
        }
      ]
    },
    {
      "slug": "epithalon",
      "names": [
        "Epithalon"
      ],
      "title": "Epithalon",
      "kind": "compound",
      "summary": "Epithalon research includes cell-culture telomerase findings and animal ageing experiments. These do not demonstrate longer human lifespan. A cited mouse study found no change in mean lifespan despite changes among the longest survivors.",
      "identity": "The synthetic tetrapeptide is also spelled Epitalon in the cited mouse study. Evidence on the broader pineal extract epithalamin should not be silently substituted for evidence on this defined peptide.",
      "evidenceOverview": "Selected evidence includes early human-cell culture work, a female-mouse survival experiment and a 2025 comparative cell-line study with a linked figure correction. These studies do not measure human lifespan or establish clinical safety.",
      "whatResearchShows": [
        "Khavinson and colleagues reported telomerase-related changes in cultured fetal fibroblasts. These were cells, not people receiving treatment.",
        "Anisimov and colleagues reported no mean-lifespan increase in the studied mice, with a longer survival tail and selected biomarker changes."
      ],
      "limitations": [
        "Telomerase activation in culture is not a demonstration of safe whole-organism rejuvenation.",
        "Maximum survival in one mouse experiment is not equivalent to an improvement in average human lifespan.",
        "Neither study establishes human safety, efficacy, or equivalence of HeartPep formats."
      ],
      "openQuestions": [
        "Can independent work reproduce the findings with prespecified survival and functional endpoints?",
        "What controlled human evidence would establish a clinically meaningful outcome and long-term safety?"
      ],
      "studies": [
        {
          "id": "pmid-12937682",
          "title": "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells",
          "authors": "Khavinson VKh, Bondarev IE, Butyugov AA",
          "year": 2003,
          "journal": "Bulletin of Experimental Biology and Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/12937682/",
          "doi": "10.1023/a:1025493705728",
          "pmid": "12937682",
          "evidenceType": "laboratory",
          "design": "Experiment adding Epithalon to telomerase-negative human fetal fibroblast cultures.",
          "findings": "Reported expression of a telomerase component, telomerase activity and telomere elongation.",
          "limitations": "A short cell-culture report. It does not establish human longevity or the safety of altering this pathway.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-14501183",
          "title": "Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice",
          "authors": "Anisimov VN, Khavinson VKh, Popovich IG, et al.",
          "year": 2003,
          "journal": "Biogerontology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/14501183/",
          "doi": "10.1023/a:1025114230714",
          "pmid": "14501183",
          "evidenceType": "animal",
          "design": "Lifetime experiment in female Swiss-derived SHR mice, with 54 mice per group.",
          "findings": "Mean lifespan did not change; the authors reported increases among the last ten percent of survivors and maximum survival, alongside selected biomarkers.",
          "limitations": "One sex and strain context, multiple endpoints and no demonstrated human effect. Overall spontaneous tumour incidence was not reduced.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-40908429",
          "title": "Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity",
          "authors": "Al-Dulaimi S, Thomas R, Matta S, Roberts T",
          "year": 2025,
          "journal": "Biogerontology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40908429/",
          "doi": "10.1007/s10522-025-10315-x",
          "pmid": "40908429",
          "evidenceType": "laboratory",
          "design": "Comparative cultured normal and breast-cancer cell-line experiments using telomere qPCR, hTERT measurements, telomerase assays and alternative-lengthening markers.",
          "findings": "Reported telomere changes with different telomerase and alternative-lengthening patterns across cell types.",
          "limitations": "In vitro study, not human treatment or a clinical cancer-risk assessment. Figures 1–3 were corrected in a separately linked publisher notice.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://link.springer.com/article/10.1007/s10522-025-10315-x"
        },
        {
          "id": "pmid-41240216",
          "title": "Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity",
          "authors": "Al-Dulaimi S, Thomas R, Matta S, Roberts T",
          "year": 2026,
          "journal": "Biogerontology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/41240216/",
          "doi": "10.1007/s10522-025-10326-8",
          "pmid": "41240216",
          "evidenceType": "reference",
          "design": "Publisher correction published online 15 November 2025 and assigned to the 2026 volume; not another experiment.",
          "findings": "Replaced incorrect figures 1, 2 and 3 with corrected versions and states that the original article was corrected.",
          "limitations": "Read the corrected figures when evaluating the parent experiment. A correction is not itself a retraction or independent replication.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://link.springer.com/article/10.1007/s10522-025-10326-8"
        },
        {
          "id": "pmid-42884164",
          "title": "Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence",
          "authors": "Jain A et al.",
          "year": 2026,
          "journal": "International Journal of Molecular Sciences",
          "url": "https://www.mdpi.com/1422-0067/27/19/8922",
          "doi": "10.3390/ijms27198922",
          "pmid": "42884164",
          "evidenceType": "reference",
          "design": "Narrative review of existing evidence, not a new experiment or clinical trial.",
          "findings": "Distinguishes synthetic Epitalon from epithalamin extract and describes gaps in controlled human outcomes and long-term safety evidence.",
          "limitations": "A secondary synthesis without new participants. Evidence about the extract cannot be transferred to the defined peptide, and this source does not establish clinical effects or validate a catalogue product.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-20",
        "method": "Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.",
        "queries": [
          "12937682 Epithalon telomerase",
          "site:pubmed.ncbi.nlm.nih.gov Epithalon mice lifespan Anisimov 2003",
          "\"Epithalon\" correction retraction 2025 2026",
          "\"10.1007/s10522-025-10315-x\" correction",
          "PMID 42884164 / DOI 10.3390/ijms27198922"
        ],
        "scope": "Early cell and mouse survival studies plus a 2025 cell-line study and its 2025-online/2026-volume figure correction. Cell and animal evidence remain distinct from human intervention evidence. Checked the publisher abstract of a 2026 narrative review as a secondary reference, not primary evidence.",
        "limitations": "Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates."
      },
      "discussion": [
        {
          "heading": "Telomere measurements need mechanistic resolution",
          "body": "The 2025 study makes it particularly important to separate hTERT expression, measured telomerase activity and alternative-lengthening markers. Our interpretation is that these are related but nonidentical readouts; a change in gene expression alone cannot establish the activity of the complete enzyme. The authors compare several cell contexts, so the results should remain attached to each model rather than being summarised as a uniform rejuvenation response.",
          "citations": [
            "pmid-40908429",
            "pmid-41240216"
          ]
        },
        {
          "heading": "Cell longevity is not a whole-person endpoint",
          "body": "An assay in a normal or cancer cell line cannot establish either longer human life or a clinical cancer hazard. It also cannot reassure about long-term cancer safety. Those are different questions requiring organism-level outcomes and follow-up. Similarly, the unchanged mean survival in the mouse study should remain visible alongside its survival-tail findings, rather than presenting the most favourable statistic as the complete lifespan result.",
          "citations": [
            "pmid-14501183",
            "pmid-40908429"
          ]
        },
        {
          "heading": "Use the corrected research record",
          "body": "For replication, read the published figure correction before extracting effect sizes or designing a comparison. Neither the correction nor a later study makes earlier work independently reproduced in every respect. The relevant open question is reproducible mechanism and function, not a presumption that a telomere marker is already a validated surrogate for healthy human longevity.",
          "citations": [
            "pmid-12937682",
            "pmid-40908429",
            "pmid-41240216"
          ]
        }
      ]
    },
    {
      "slug": "ghk-cu",
      "names": [
        "GHK-Cu",
        "GHK-Cu Capsules"
      ],
      "title": "GHK-Cu",
      "kind": "compound",
      "summary": "GHK-Cu has cell, animal and human topical research. The human results vary by formulation and endpoint, and do not validate the shop's capsules, sprays, pens or vials.",
      "identity": "GHK-Cu is the copper complex of glycyl-histidyl-lysine. Copper-bound GHK, unbound GHK and a formulated product should be distinguished when interpreting experiments.",
      "evidenceOverview": "Foundational matrix experiments are supplemented here by a positive topical diabetic-ulcer trial, a small post-laser trial with null objective endpoints, and a recent preliminary eyebrow-serum conference report. These are distinct research questions.",
      "whatResearchShows": [
        "Fibroblast and rat experiments support investigation of extracellular-matrix biology.",
        "Human topical studies report both favourable and null results, depending on population, formulation and outcome."
      ],
      "limitations": [
        "More collagen or extracellular matrix in an experimental system does not necessarily mean better clinical healing or appearance.",
        "The cited studies do not measure human oral or nasal bioavailability or validate catalogue formulations."
      ],
      "openQuestions": [
        "Which independently replicated human endpoints, formulations and delivery systems are supported by sufficiently controlled research?"
      ],
      "studies": [
        {
          "id": "pmid-3169264",
          "title": "Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+",
          "authors": "Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP",
          "year": 1988,
          "journal": "FEBS Letters",
          "url": "https://pubmed.ncbi.nlm.nih.gov/3169264/",
          "doi": "10.1016/0014-5793(88)80509-X",
          "pmid": "3169264",
          "evidenceType": "laboratory",
          "design": "Fibroblast culture experiment measuring collagen synthesis after GHK-Cu exposure.",
          "findings": "The authors reported stimulation of collagen synthesis.",
          "limitations": "A cell-culture biochemical endpoint, without a human clinical outcome or validation of a retail formulation.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-8227353",
          "title": "In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds",
          "authors": "Maquart FX, Bellon G, Chaqour B, et al.",
          "year": 1993,
          "journal": "Journal of Clinical Investigation",
          "url": "https://pubmed.ncbi.nlm.nih.gov/8227353/",
          "doi": "10.1172/JCI116842",
          "pmid": "8227353",
          "evidenceType": "animal",
          "design": "Rat subcutaneous wound chambers with saline or GHK-Cu, followed by biochemical tissue analysis.",
          "findings": "Collagen, glycosaminoglycans and other matrix-related measurements increased; a control tripeptide had no significant effect.",
          "limitations": "An artificial wound-chamber model does not establish human wound outcomes or rejuvenation.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://www.jci.org/articles/view/116842"
        },
        {
          "id": "pmid-17147644",
          "title": "Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper",
          "authors": "Mulder GD, Patt LM, Sanders L, et al.",
          "year": 1994,
          "journal": "Wound Repair and Regeneration",
          "url": "https://pubmed.ncbi.nlm.nih.gov/17147644/",
          "doi": "10.1046/j.1524-475X.1994.20406.x",
          "pmid": "17147644",
          "evidenceType": "human",
          "design": "Multicentre randomised evaluator-blinded vehicle-controlled study of a topical copper-peptide gel with standardised diabetic-ulcer care.",
          "findings": "The report describes greater plantar-ulcer area closure and fewer infections in the relevant treated comparison.",
          "limitations": "A specific gel, wound type and co-intervention protocol. Abstract-level review does not resolve the full sample flow, subgroup structure or modern reporting-quality questions.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-16847171",
          "title": "Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin",
          "authors": "Miller TR, Wagner JD, Baack BR, Eisbach KJ",
          "year": 2006,
          "journal": "Archives of Facial Plastic Surgery",
          "url": "https://pubmed.ncbi.nlm.nih.gov/16847171/",
          "doi": "10.1001/archfaci.8.4.252",
          "pmid": "16847171",
          "evidenceType": "human",
          "design": "Randomised post-laser topical-regimen comparison, 13 completers; objective and blinded assessments over 12 weeks.",
          "findings": "No significant between-group objective advantage in erythema resolution, wrinkles or skin quality. Patient satisfaction favoured GHK-Cu.",
          "limitations": "Small study of whole topical regimens after a procedure, with subjective and objective outcomes giving different signals.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "bo-2026-eyebrow",
          "title": "The efficacy of 2% copper peptide (GHK-Cu) serum for eyebrow hypotrichosis: a randomized, double-blind, vehicle-controlled, split-face comparative study",
          "authors": "Bo SL, Nararatwanchai T, Supornpun N, Poomarapan K, Thaploka S",
          "year": 2026,
          "journal": "Procedia of Multidisciplinary Research (conference proceedings)",
          "url": "https://so09.tci-thaijo.org/index.php/PMR/article/view/9318",
          "evidenceType": "human",
          "design": "Single-centre split-face serum comparison in 18 adults over 12 weeks, published as a conference-proceedings report.",
          "findings": "The authors report improved eyebrow hair count, diameter and photographic scores on the active-serum side.",
          "limitations": "Small preliminary conference report; no independent replication or detailed copper-complex identity/exposure characterisation established. Eyebrow findings do not establish scalp or systemic outcomes.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://so09.tci-thaijo.org/index.php/PMR/article/download/9318/5826"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary literature searches and journal/PubMed checks of foundational matrix studies.",
        "queries": [
          "GHK-Cu 8227353 Maquart 1993",
          "site.pubmed.ncbi.nlm.nih.gov GHK Cu collagen fibroblasts 1988 3169264",
          "Stimulation of collagen synthesis in fibroblast cultures retracted",
          "GHK-Cu copper tripeptide CO2 laser resurfaced skin randomized 2006 PubMed",
          "Enhanced healing of ulcers in patients with diabetes by topical treatment glycyl 1994",
          "GHK-Cu eyebrow randomized 2026 trial",
          "Effects of topical copper correction 8.4.232"
        ],
        "scope": "Selected foundational studies and contrasting human topical reports, including a 2026 preliminary conference-proceedings study.",
        "limitations": "The ulcer and laser reports were reviewed at abstract level; eyebrow methods/results were checked in full text. The laser publisher's View correction link was followed and led to the issue Highlights article (10.1001/archfaci.8.4.232), not a displayed substantive erratum. This is not comprehensive correction/retraction clearance."
      },
      "discussion": [
        {
          "heading": "A matrix signal and a clinical outcome answer different questions",
          "body": "The early experiments identify a biological response under controlled exposure conditions. Their matrix measurements are useful for developing hypotheses, but more collagen is not a universal proxy for better healing. The diabetic-ulcer trial tested a particular gel alongside a structured care programme. Its favourable result belongs to that setting; it cannot be transferred to an oral or nasal format, or treated as a general rejuvenation result.",
          "citations": [
            "pmid-3169264",
            "pmid-8227353",
            "pmid-17147644"
          ]
        },
        {
          "heading": "Read the mixed human evidence by endpoint",
          "body": "The post-laser trial illustrates why a single success label loses information. Patients preferred the copper-peptide regimen, yet blinded and computer-based assessments did not show an objective advantage. Both results should remain visible. The newer eyebrow study is a positive but preliminary conference report with a small sample and a specific topical serum. Neither its cosmetic endpoints nor its short adverse-event observation settles long-term safety or the effectiveness of a different supplied formulation. Independent replication and chemically explicit test materials would make subsequent evidence more transferable.",
          "citations": [
            "pmid-16847171",
            "bo-2026-eyebrow"
          ]
        },
        {
          "heading": "Formulation is part of the scientific question",
          "body": "A topical gel, a post-procedure skin regimen and an eyebrow serum are different interventions. Reading them as interchangeable would erase differences in exposure, other ingredients and clinical context. A useful next study would specify its active material and vehicle and then connect that definition to the outcome measured.",
          "citations": [
            "pmid-17147644",
            "pmid-16847171",
            "bo-2026-eyebrow"
          ]
        }
      ]
    },
    {
      "slug": "ghrp-2",
      "names": [
        "GHRP-2"
      ],
      "title": "GHRP-2",
      "kind": "compound",
      "summary": "A small human experiment found increased food intake and GH release. Appetite stimulation in that experiment is not evidence of weight loss or muscle gain.",
      "identity": "GHRP-2 is a synthetic GH secretagogue used to investigate ghrelin-related physiology. The cited experiment used a defined research preparation.",
      "evidenceOverview": "The selected primary study is an acute, controlled human physiology experiment. Its direct findings concern one meal and hormone measurements.",
      "whatResearchShows": [
        "The appetite endpoint is particularly relevant when interpreting a metabolism category: metabolism research can include greater food intake."
      ],
      "limitations": [
        "The small male sample limits generalisability.",
        "A single meal does not show a sustained change in weight, body composition or performance. Supplied-product identity and quality remain separate questions."
      ],
      "openQuestions": [
        "Would a follow-up study measure sustained intake, energy expenditure, body composition or functional outcomes?",
        "Does the intended model match the population and exposure in the cited experiment?"
      ],
      "studies": [
        {
          "id": "pmid-15699539",
          "title": "Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men",
          "authors": "Laferrère B, Abraham C, Russell CD, Bowers CY.",
          "year": 2005,
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/15699539/",
          "doi": "10.1210/jc.2004-1719",
          "pmid": "15699539",
          "evidenceType": "human",
          "design": "Acute controlled experiment comparing GHRP-2 with saline in seven lean healthy men, followed by a buffet meal.",
          "findings": "Participants consumed more food during GHRP-2 exposure, and circulating GH increased.",
          "limitations": "Seven participants and a single meal cannot establish sustained weight change, muscle growth or long-term safety.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2824650/"
        },
        {
          "id": "pmid-16861611",
          "title": "Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake",
          "authors": "Laferrère B, Hart AB, Bowers CY.",
          "year": 2006,
          "journal": "Obesity",
          "url": "https://pubmed.ncbi.nlm.nih.gov/16861611/",
          "doi": "10.1038/oby.2006.121",
          "pmid": "16861611",
          "evidenceType": "human",
          "design": "Double-blind randomized three-visit experiment in 19 healthy weight-stable participants, including 10 lean and 9 obese people; GHRP-2 exposures were compared with placebo.",
          "findings": "Food intake increased with GHRP-2 exposure in both lean and obese participants. Greater appetite before the meal did not translate into greater fullness afterwards.",
          "limitations": "Acute controlled-meal research. It does not establish long-term energy balance, sustained weight change or an obesity treatment.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2824649/"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov/15699539/ (direct record check)",
          "site.pubmed.ncbi.nlm.nih.gov GHRP-2 chronic infusion food intake human randomized",
          "\"Obese Subjects Respond\" \"GHRP-2\" Laferrere DOI"
        ],
        "scope": "Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research."
      },
      "discussion": [
        {
          "heading": "An acute appetite finding is more specific than a metabolism claim",
          "body": "The seven-man experiment directly measured food eaten during a controlled meal. Its strongest conclusion concerns acute intake under those conditions. The later three-visit study included lean and obese participants and again found increased intake. This extends the population studied, while retaining a short laboratory time window. Neither paper follows the adaptive changes in intake, expenditure and behaviour that determine longer-term body weight.",
          "citations": [
            "pmid-15699539",
            "pmid-16861611"
          ]
        },
        {
          "heading": "How to read the meal-study design",
          "body": "The expanded experiment used randomised, double-blind comparisons, a fixed breakfast and a subsequent buffet. Those controls help attribute differences in that meal to the intervention rather than obvious differences in meal availability. They do not make the buffet a measure of sustained nutrition or patient benefit. The observation that fullness afterwards was similar also cautions against translating one appetite rating into a general account of eating behaviour. The relevant endpoint here is greater food intake, not fat loss or improved muscle function.",
          "citations": [
            "pmid-16861611"
          ]
        }
      ]
    },
    {
      "slug": "ghrp-6",
      "names": [
        "GHRP-6"
      ],
      "title": "GHRP-6",
      "kind": "compound",
      "summary": "An acute human challenge study supports an interaction between GHRP-6 and endogenous GHRH in GH secretion. It does not establish a strength or recovery benefit.",
      "identity": "The cited material is the named GH-releasing peptide GHRP-6. Similar GH-axis activity does not make other GHRPs interchangeable.",
      "evidenceOverview": "Selected acute human studies examine GH-axis mechanism, EEG sleep stages and route-dependent endocrine responses. None of these endpoints establishes a muscle or strength benefit.",
      "whatResearchShows": [
        "A receptor-axis experiment can show how a hormone response depends on another signal. It cannot show that changing the signal improves a person’s performance."
      ],
      "limitations": [
        "Only nine healthy men were studied in this experiment.",
        "The results do not establish effects of long-term exposure, a nasal formulation or a supplier product."
      ],
      "openQuestions": [
        "Which functional endpoint, beyond a circulating hormone marker, would test the proposed hypothesis?",
        "What is the exact material specification and how does it relate to the cited preparation?"
      ],
      "studies": [
        {
          "id": "pmid-9543138",
          "title": "Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation",
          "authors": "Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA.",
          "year": 1998,
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/9543138/",
          "doi": "10.1210/jcem.83.4.4711",
          "pmid": "9543138",
          "evidenceType": "human",
          "design": "Physiological challenge experiment in nine healthy men, comparing GHRP-6 responses with and without a GHRH antagonist.",
          "findings": "Blocking GHRH removed most of the GH response to GHRP-6, supporting a role for endogenous GHRH in that response.",
          "limitations": "An acute endocrine mechanism experiment, not a trial of strength, recovery, weight control or nasal products.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-7617137",
          "title": "Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man",
          "authors": "Frieboes RM, Murck H, Maier P, et al.",
          "year": 1995,
          "journal": "Neuroendocrinology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/7617137/",
          "doi": "10.1159/000126883",
          "pmid": "7617137",
          "evidenceType": "human",
          "design": "Placebo-comparison sleep-laboratory experiment in healthy men, combining overnight EEG with GH, ACTH and cortisol measurements.",
          "findings": "Stage 2 sleep increased, but slow-wave sleep and other sleep-EEG variables did not. ACTH and cortisol rose alongside GH.",
          "limitations": "Acute experimental sleep architecture and hormone measurements, without an insomnia-treatment or next-day-function outcome. The response was not GH-selective.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-10336729",
          "title": "Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration",
          "authors": "Frieboes RM, Murck H, Antonijevic IA, Steiger A.",
          "year": 1999,
          "journal": "Journal of Neuroendocrinology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/10336729/",
          "doi": "10.1046/j.1365-2826.1999.00364.x",
          "pmid": "10336729",
          "evidenceType": "human",
          "design": "Placebo comparisons of oral, intranasal and sublingual experimental GHRP-6 preparations in healthy young men, with overnight EEG and hormone sampling.",
          "findings": "Results differed by route. Intranasal exposure significantly increased GH; several sleep and ACTH findings were only statistical trends. The oral preparation did not increase the measured hormones.",
          "limitations": "Exposure and study conditions differed across routes. Statistical trends should not be reported as demonstrated sleep benefits, and study preparations do not establish catalogue-spray performance.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov GHRP-6 growth hormone 9543138",
          "site.pubmed.ncbi.nlm.nih.gov \"Growth hormone-releasing peptide-6 stimulates sleep\" Frieboes",
          "\"10.1046/j.1365-2826.1999.00364.x\" PMID"
        ],
        "scope": "Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research."
      },
      "discussion": [
        {
          "heading": "Separate a mechanistic test from a sleep outcome",
          "body": "The antagonist experiment supports a role for endogenous GHRH in the acute GH response. The sleep-laboratory experiment asks a different question and records stage 2 sleep alongside GH, ACTH and cortisol. Slow-wave sleep did not increase in that experiment. A change in one EEG stage cannot establish improved insomnia, restorative sleep or next-day functioning, and the accompanying adrenal-hormone changes mean the response should not be described as selectively releasing GH.",
          "citations": [
            "pmid-9543138",
            "pmid-7617137"
          ]
        },
        {
          "heading": "Route-specific findings include null results and trends",
          "body": "The later study compared specified oral, nasal and sublingual preparations under placebo conditions. Results varied by route; several reported differences were trends rather than statistically established effects. This is useful evidence against collapsing all delivery formats into a single outcome claim. It also prevents a significant GH result in the nasal arm from being presented as a demonstrated sleep benefit. The study concerns its own preparations and experimental schedule, not every spray carrying the GHRP-6 name.",
          "citations": [
            "pmid-10336729"
          ]
        }
      ]
    },
    {
      "slug": "glow",
      "names": [
        "GLOW",
        "Glow"
      ],
      "title": "GLOW",
      "kind": "identity-pending",
      "summary": "A supplier blend label, with composition not confirmed in the available catalogue specification. Ingredient research cannot establish what this product contains or how the mixture behaves.",
      "identity": "The catalogue name is a supplier label, not an authenticated molecular specification. This note preserves the exact published names without assigning an unverified identity.",
      "evidenceOverview": "Identity unresolved. No biological evidence is attributed to this product here. This is an evidence-matching gap, not a statement that no research exists.",
      "whatResearchShows": [
        "A meaningful literature review needs an identified substance or a defined mixture. Studies of an assumed ingredient would answer a different question."
      ],
      "limitations": [
        "No confirmed sequence, complete composition or matched chemical specification is available in the catalogue record used for this note.",
        "A general research paper or another seller’s blend formula cannot establish the contents, stability or effects of this listing."
      ],
      "openQuestions": [
        "Obtain the complete ingredient list, amounts, salt forms and blend-specific assay. Do not substitute a recipe from another seller.",
        "Once the identity is confirmed, which primary studies match that exact compound, route and formulation?"
      ],
      "studies": [],
      "search": {
        "date": "2026-11-08",
        "method": "Identity-gated catalogue review",
        "queries": [],
        "scope": "Exact supplier labels and published catalogue specifications were checked. Biological literature was not attributed while the identity remained unresolved.",
        "limitations": "This is an identity note, not a negative literature search. It cannot show that relevant studies do not exist."
      }
    },
    {
      "slug": "glp1-s",
      "names": [
        "GLP1-S"
      ],
      "title": "GLP1-S",
      "kind": "identity-pending",
      "summary": "This abbreviated supplier code does not establish an exact chemical identity. It is not mapped to a named medicine or a clinical evidence base in this library.",
      "identity": "The catalogue name is a supplier label, not an authenticated molecular specification. This note preserves the exact published names without assigning an unverified identity.",
      "evidenceOverview": "Identity unresolved. No biological evidence is attributed to this product here. This is an evidence-matching gap, not a statement that no research exists.",
      "whatResearchShows": [
        "A meaningful literature review needs an identified substance or a defined mixture. Studies of an assumed ingredient would answer a different question."
      ],
      "limitations": [
        "No confirmed sequence, complete composition or matched chemical specification is available in the catalogue record used for this note.",
        "A general research paper or another seller’s blend formula cannot establish the contents, stability or effects of this listing."
      ],
      "openQuestions": [
        "Confirm the chemical name, structure or sequence and formulation rather than interpreting the code as a medicine name.",
        "Once the identity is confirmed, which primary studies match that exact compound, route and formulation?"
      ],
      "studies": [],
      "search": {
        "date": "2026-11-08",
        "method": "Identity-gated catalogue review",
        "queries": [],
        "scope": "Exact supplier labels and published catalogue specifications were checked. Biological literature was not attributed while the identity remained unresolved.",
        "limitations": "This is an identity note, not a negative literature search. It cannot show that relevant studies do not exist."
      }
    },
    {
      "slug": "glp2-t",
      "names": [
        "GLP2-T"
      ],
      "title": "GLP2-T",
      "kind": "identity-pending",
      "summary": "This supplier code is recorded as supplied. Its chemical identity is not confirmed, so evidence for a similarly named hormone or medicine is not assigned to the listing.",
      "identity": "The catalogue name is a supplier label, not an authenticated molecular specification. This note preserves the exact published names without assigning an unverified identity.",
      "evidenceOverview": "Identity unresolved. No biological evidence is attributed to this product here. This is an evidence-matching gap, not a statement that no research exists.",
      "whatResearchShows": [
        "A meaningful literature review needs an identified substance or a defined mixture. Studies of an assumed ingredient would answer a different question."
      ],
      "limitations": [
        "No confirmed sequence, complete composition or matched chemical specification is available in the catalogue record used for this note.",
        "A general research paper or another seller’s blend formula cannot establish the contents, stability or effects of this listing."
      ],
      "openQuestions": [
        "Obtain the full chemical identity, sequence, salt form and assay before choosing relevant literature.",
        "Once the identity is confirmed, which primary studies match that exact compound, route and formulation?"
      ],
      "studies": [],
      "search": {
        "date": "2026-11-08",
        "method": "Identity-gated catalogue review",
        "queries": [],
        "scope": "Exact supplier labels and published catalogue specifications were checked. Biological literature was not attributed while the identity remained unresolved.",
        "limitations": "This is an identity note, not a negative literature search. It cannot show that relevant studies do not exist."
      }
    },
    {
      "slug": "glutathione",
      "names": [
        "Glutathione"
      ],
      "title": "Glutathione",
      "kind": "compound",
      "summary": "Glutathione is an endogenous tripeptide involved in cellular redox biology. Selected oral human trials produced differing biomarker results, and neither trial validates a nasal or vial product.",
      "identity": "The cited supplementation studies concern glutathione, commonly abbreviated GSH. Its biological presence in the body and its antioxidant role do not by themselves establish benefits from an externally supplied formulation.",
      "evidenceOverview": "A four-week trial did not change measured glutathione or oxidative-stress markers. A six-month study reported increased stores in several compartments. Different durations, methods and populations limit direct comparison; neither establishes lifespan extension or reduced infections.",
      "whatResearchShows": [
        "Allen and Bradley found no significant effect on the selected oxidative-stress or glutathione-status markers.",
        "Richie and colleagues reported increased compartment glutathione stores and selected secondary immune-marker changes after longer supplementation."
      ],
      "limitations": [
        "The evidence described here involves oral study formulations, not HeartPep nasal or vial products.",
        "A biomarker change is not automatically a functional or clinical benefit.",
        "Small trials and selected immune-marker subsets do not establish broad immune protection or long-term clinical safety."
      ],
      "openQuestions": [
        "Which formulation and exposure explain apparently different biomarker results?",
        "Do reproducible changes translate into prespecified patient-important outcomes?"
      ],
      "studies": [
        {
          "id": "pmid-21875351",
          "title": "Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers",
          "authors": "Allen J, Bradley RD",
          "year": 2011,
          "journal": "Journal of Alternative and Complementary Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/21875351/",
          "doi": "10.1089/acm.2010.0716",
          "pmid": "21875351",
          "evidenceType": "human",
          "design": "Four-week randomised double-blind placebo-controlled study in 40 healthy adults; 39 completed per protocol.",
          "findings": "No significant between-group changes in urinary oxidative-stress biomarkers or measured glutathione status.",
          "limitations": "Short study in healthy volunteers. It does not establish the result for other populations, durations or delivery formats.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3162377/"
        },
        {
          "id": "pmid-24791752",
          "title": "Randomized controlled trial of oral glutathione supplementation on body stores of glutathione",
          "authors": "Richie JP Jr, Nichenametla S, Neidig W, et al.",
          "year": 2015,
          "journal": "European Journal of Nutrition",
          "url": "https://pubmed.ncbi.nlm.nih.gov/24791752/",
          "doi": "10.1007/s00394-014-0706-z",
          "pmid": "24791752",
          "evidenceType": "human",
          "design": "Six-month randomised double-blind placebo-controlled oral-supplement study in 54 non-smoking adults.",
          "findings": "Reported higher glutathione stores in several compartments and changes in selected redox and immune markers.",
          "limitations": "Marker-focused and small; immune measures were assessed in a subset. It did not establish general disease prevention or catalogue-format efficacy.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-41897500",
          "title": "A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans: A Randomized Crossover Clinical Trial",
          "authors": "Solnier J, et al.",
          "year": 2026,
          "journal": "Antioxidants",
          "url": "https://pubmed.ncbi.nlm.nih.gov/41897500/",
          "doi": "10.3390/antiox15030354",
          "pmid": "41897500",
          "evidenceType": "human",
          "design": "Small randomised double-blind crossover oral-formulation comparison in 14 adults, followed by a single-arm short safety follow-up.",
          "findings": "Reported formulation-dependent differences in baseline-adjusted whole-blood glutathione exposure.",
          "limitations": "Pharmacokinetic pilot, not clinical efficacy. Administered amounts differed; dose-normalised analyses require careful interpretation. Relevant commercial and patent interests are disclosed.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13023597/"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.",
        "queries": [
          "24791752 glutathione randomized controlled trial",
          "site:pubmed.ncbi.nlm.nih.gov oral glutathione 2011 randomized trial oxidative stress Allen Bradley",
          "\"21875351\" \"10.\" Allen Bradley",
          "\"41897500\" glutathione crossover 2026",
          "\"10.1007/s00394-014-0706-z\" correction retraction",
          "\"10.1089/acm.2010.0716\" correction retraction"
        ],
        "scope": "Two selected oral biomarker trials and a 2026 formulation-dependent pharmacokinetic pilot. Accessible records and linked notices checked; direct PMC full-text access to some papers was blocked, so those records remain abstract-led.",
        "limitations": "Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates."
      },
      "discussion": [
        {
          "heading": "A disagreement worth preserving",
          "body": "The short and longer supplementation trials do not support a single universal claim that oral glutathione always works or never works. Their durations, assays and measured compartments differ. Our interpretation is that the apparent disagreement is a research question about exposure and measurement, not a reason to discard the negative trial. A stronger synthesis would compare prespecified between-group effects and uncertainty for the same compartment and time point before considering pooled estimates.",
          "citations": [
            "pmid-21875351",
            "pmid-24791752"
          ]
        },
        {
          "heading": "Formulation comparisons require the actual contrast",
          "body": "The 2026 pilot adds a pharmacokinetic comparison, not evidence of fewer illnesses or longer life. Because formulations and administered amounts differ, a reader should distinguish the observed comparison from a dose-normalised calculation. Neither should be translated directly into a nasal or vial claim. The study is also small and commercially connected, making independent replication with preregistered analyses particularly useful.",
          "citations": [
            "pmid-41897500"
          ]
        },
        {
          "heading": "Markers are a starting point",
          "body": "A clinically informative programme would connect reproducible exposure with a specific functional outcome and a meaningful safety window. Redox markers and selected immune assays can help test mechanisms, but are not interchangeable with disease prevention or patient wellbeing.",
          "citations": [
            "pmid-21875351",
            "pmid-24791752",
            "pmid-41897500"
          ]
        }
      ]
    },
    {
      "slug": "h-frag",
      "names": [
        "H Frag"
      ],
      "title": "H Frag",
      "kind": "identity-pending",
      "summary": "This abbreviated label does not specify a peptide sequence or fragment boundaries. Research on a particular growth-hormone fragment cannot identify the supplied material.",
      "identity": "The catalogue name is a supplier label, not an authenticated molecular specification. This note preserves the exact published names without assigning an unverified identity.",
      "evidenceOverview": "Identity unresolved. No biological evidence is attributed to this product here. This is an evidence-matching gap, not a statement that no research exists.",
      "whatResearchShows": [
        "A meaningful literature review needs an identified substance or a defined mixture. Studies of an assumed ingredient would answer a different question."
      ],
      "limitations": [
        "No confirmed sequence, complete composition or matched chemical specification is available in the catalogue record used for this note.",
        "A general research paper or another seller’s blend formula cannot establish the contents, stability or effects of this listing."
      ],
      "openQuestions": [
        "Confirm the residue sequence, modifications and analytical identity. Do not assume equivalence to AOD-9604 or another fragment.",
        "Once the identity is confirmed, which primary studies match that exact compound, route and formulation?"
      ],
      "studies": [],
      "search": {
        "date": "2026-11-08",
        "method": "Identity-gated catalogue review",
        "queries": [],
        "scope": "Exact supplier labels and published catalogue specifications were checked. Biological literature was not attributed while the identity remained unresolved.",
        "limitations": "This is an identity note, not a negative literature search. It cannot show that relevant studies do not exist."
      }
    },
    {
      "slug": "hcg",
      "names": [
        "HCG"
      ],
      "title": "Human chorionic gonadotropin (hCG)",
      "kind": "compound",
      "summary": "Human studies address reproductive endocrine responses and formulation-dependent pharmacokinetics. Those results do not establish a general sexual-performance benefit.",
      "identity": "hCG is a reproductive hormone. Source, molecular preparation, activity units and formulation matter; a catalogue label alone is insufficient to establish equivalence to a studied medicine.",
      "evidenceOverview": "Selected studies address an intratesticular hormone response, a two-preparation pharmacokinetic comparison, and sperm outcomes during hCG plus FSH treatment in a specific diagnosis.",
      "whatResearchShows": [
        "Intratesticular testosterone is a physiological measurement, distinct from sperm outcomes, conception or sexual performance.",
        "The comparison of specified medicines demonstrates the importance of formulation-specific exposure data."
      ],
      "limitations": [
        "The endocrine experiment used induced gonadotropin suppression and short follow-up.",
        "These sources do not establish effects of catalogue nasal hCG or interchangeability between preparations."
      ],
      "openQuestions": [
        "Does the material documentation specify source, biological activity and complete formulation?",
        "Is the outcome being discussed hormonal, reproductive or sexual, and was it directly measured?"
      ],
      "studies": [
        {
          "id": "pmid-15713727",
          "title": "Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression",
          "authors": "Coviello AD, Matsumoto AM, Bremner WJ, et al.",
          "year": 2005,
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/15713727/",
          "doi": "10.1210/jc.2004-0802",
          "pmid": "15713727",
          "evidenceType": "human",
          "design": "Twenty-nine men were randomized to testosterone-induced gonadotropin suppression plus placebo or graded hCG exposure for three weeks; testicular-fluid testosterone was measured.",
          "findings": "hCG exposure was associated with dose-related maintenance of intratesticular testosterone despite gonadotropin suppression.",
          "limitations": "An experimentally altered endocrine setting with a hormone endpoint. The study did not establish improved fertility, sexual performance or the effects of nasal hCG.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "doi-10.1007-s40261-022-01118-w",
          "title": "Randomized Pharmacokinetic Study of a Highly Purified Human Chorionic Gonadotropin and of a Recombinant Human Chorionic Gonadotropin Following Single Subcutaneous Administration in Healthy Women",
          "authors": "Radicioni M, Leuratti C, Cometti B.",
          "year": 2022,
          "journal": "Clinical Drug Investigation",
          "url": "https://doi.org/10.1007/s40261-022-01118-w",
          "doi": "10.1007/s40261-022-01118-w",
          "evidenceType": "human",
          "design": "Randomized two-way crossover comparison of two specified hCG medicines in 26 healthy women;24 were included in the pharmacokinetic analysis.",
          "findings": "The preparations produced differing exposure and peak-concentration results, illustrating why formulations and sources cannot be treated as automatically interchangeable.",
          "limitations": "A formulation-specific pharmacokinetic comparison. It was not a comparison with catalogue hCG or a study of sexual-function outcomes.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8930902/"
        },
        {
          "id": "pmid-18930190",
          "title": "Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism",
          "authors": "Matsumoto AM, Snyder PJ, Bhasin S, et al.",
          "year": 2009,
          "journal": "Fertility and Sterility",
          "url": "https://pubmed.ncbi.nlm.nih.gov/18930190/",
          "doi": "10.1016/j.fertnstert.2008.07.1742",
          "pmid": "18930190",
          "evidenceType": "human",
          "design": "Open-label noncomparative multicentre study in 36 men with severe hypogonadotropic hypogonadism. hCG treatment was followed by combined hCG and follitropin alfa.",
          "findings": "Sperm production developed in many participants during combination treatment, and five clinical pregnancies were reported.",
          "limitations": "No comparator and a combination intervention: the study cannot isolate an hCG-alone effect or predict results in men without this diagnosis.",
          "appliesTo": "components-only",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.",
        "queries": [
          "15713727 human chorionic gonadotropin",
          "\"Low-dose human chorionic gonadotropin maintains intratesticular testosterone\"",
          "\"Randomized Pharmacokinetic Study\" \"Choriomon\" authors",
          "site.pubmed.ncbi.nlm.nih.gov hCG recombinant FSH hypogonadotropic men spermatogenesis multicenter prospective",
          "\"18930190\" authors DOI"
        ],
        "scope": "Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research."
      },
      "discussion": [
        {
          "heading": "The hormone marker is not the fertility outcome",
          "body": "The testosterone-suppression experiment directly sampled intratesticular testosterone, an informative local endocrine measurement. It was not designed to establish conception or a sexual-function benefit. The longer study reaches sperm and pregnancy outcomes, but adds follitropin alfa after an hCG phase in men with severe hypogonadotropic hypogonadism. Its results belong to that combined regimen and diagnosis. They cannot isolate what hCG alone contributed or predict a similar outcome in a different population.",
          "citations": [
            "pmid-15713727",
            "pmid-18930190"
          ]
        },
        {
          "heading": "Preparation-specific exposure is an evidence question",
          "body": "The crossover comparison of highly purified and recombinant hCG provides a practical reason to retain the preparation details in a citation. Exposure differed between the two specified medicines, even though both were described as hCG. A biological name therefore does not settle formulation equivalence. It is particularly important not to transfer an injected-medicine result to a catalogue nasal label without a direct pharmacokinetic bridge. That gap concerns measured delivery, not merely the wording of the product name.",
          "citations": [
            "doi-10.1007-s40261-022-01118-w"
          ]
        }
      ]
    },
    {
      "slug": "igf-1-lr3",
      "names": [
        "IGF-1 LR3"
      ],
      "title": "IGF-1 LR3",
      "kind": "compound",
      "summary": "In a rat food-restriction experiment, higher retained body weight did not mean preserved skeletal-muscle protein. This distinction matters when evaluating growth-related claims.",
      "identity": "LR 3 IGF-I is an IGF-I analogue. Findings on native IGF-I or another analogue should not be silently assigned to this material.",
      "evidenceOverview": "The selected primary experiment is preclinical and short term. It provides a direct counterexample to treating a favourable weight marker as evidence of muscle preservation.",
      "whatResearchShows": [
        "The authors separately measured body weight, nitrogen balance and muscle-protein outcomes. Those measures did not all move in the same direction."
      ],
      "limitations": [
        "The experiment cannot establish human muscle growth, strength or a treatment benefit.",
        "Age and nutritional restriction affected the model’s response. It does not validate a supplied vial or nasal format."
      ],
      "openQuestions": [
        "Does a study measure muscle protein and function, or only body weight?",
        "Is its molecule actually LR 3 IGF-I, and are its nutritional conditions relevant to the proposed experiment?"
      ],
      "studies": [
        {
          "id": "pmid-11472075",
          "title": "Insulin-like growth factor-I (IGF-I) analogue, LR(3)IGF-I, ameliorates the loss of body weight but not of skeletal muscle during food restriction",
          "authors": "Tomas FM.",
          "year": 2001,
          "journal": "Growth Hormone & IGF Research",
          "url": "https://pubmed.ncbi.nlm.nih.gov/11472075/",
          "doi": "10.1054/ghir.2000.0194",
          "pmid": "11472075",
          "evidenceType": "animal",
          "design": "Seven-day food-restriction experiment in young and adult rats receiving LR 3 IGF-I or vehicle.",
          "findings": "Treated animals retained more body weight and nitrogen, but skeletal-muscle protein loss was not prevented. Adult rats showed adverse changes in muscle-protein turnover under restriction.",
          "limitations": "Animal experiment under restricted nutrition. Body weight and nitrogen retention were not evidence of preserved muscle, and findings cannot establish a human strength benefit.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-8708565",
          "title": "Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection",
          "authors": "Tomas FM, Lemmey AB, Read LC, Ballard FJ.",
          "year": 1996,
          "journal": "Journal of Endocrinology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/8708565/",
          "doi": "10.1677/joe.0.1500077",
          "pmid": "8708565",
          "evidenceType": "animal",
          "design": "Seven-day rat experiments comparing IGF-I with LR 3 IGF-I, continuous infusion with injection, and normal growth with dexamethasone-induced catabolism.",
          "findings": "Relative effects depended on delivery and endpoint. Greater effects on body weight or other markers did not mean proportionately greater reversal of carcass-muscle loss.",
          "limitations": "Preclinical growth and catabolism models. Neither relative potency in rats nor delivery comparisons establish human muscle growth, strength or a validated nasal formulation.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov/11472075/ (direct record check)",
          "site.pubmed.ncbi.nlm.nih.gov \"LR(3)IGF-I\" \"muscle\" \"rats\"",
          "\"8708565\" DOI authors"
        ],
        "scope": "Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research."
      },
      "discussion": [
        {
          "heading": "Body weight and muscle are not interchangeable outcomes",
          "body": "The food-restriction experiment measured several aspects of nutrient handling. Higher retained body weight and nitrogen did not prevent skeletal-muscle protein loss. This is why an anabolic headline needs the actual tissue and endpoint attached to it. The result applies to short-term restriction in rats; it neither proves a human benefit nor establishes that the compound can never have an anabolic effect in another model.",
          "citations": [
            "pmid-11472075"
          ]
        },
        {
          "heading": "Delivery and experimental stress change the comparison",
          "body": "The earlier study compared continuous delivery with injections in normally growing and dexamethasone-treated rats. LR3IGF-I’s relative potency varied by outcome, and stronger effects on some markers did not produce proportionately better reversal of carcass-muscle loss. Together, these studies show why binding-protein affinity or a body-weight response cannot serve as a shortcut to a human hypertrophy estimate. Species, nutritional state, induced catabolism and the method of exposure all remain part of the result.",
          "citations": [
            "pmid-8708565"
          ]
        }
      ]
    },
    {
      "slug": "ipamorelin",
      "names": [
        "Ipamorelin"
      ],
      "title": "Ipamorelin",
      "kind": "compound",
      "summary": "Human research includes GH-response experiments and a postoperative bowel-function trial. Endocrine activity did not translate into a significant efficacy result in the selected surgical trial.",
      "identity": "Ipamorelin is the named GH-releasing peptide and ghrelin-receptor agonist used in these studies. A compound name does not establish a supplier product’s composition or delivery.",
      "evidenceOverview": "Different study purposes need different conclusions: an acute GH response supports a pharmacology observation, while a clinical endpoint requires a suitable controlled trial.",
      "whatResearchShows": [
        "The pharmacokinetic study characterized the relationship between exposure and GH release.",
        "The bowel-surgery trial provides an important negative efficacy result alongside the hormone literature."
      ],
      "limitations": [
        "These studies do not establish improved muscle strength or exercise recovery.",
        "Short clinical studies cannot establish the safety or effectiveness of another route or a commercial blend."
      ],
      "openQuestions": [
        "Which endpoint is the proposed research intended to measure?",
        "Does a source test ipamorelin alone or a combination, and does its formulation match the material under investigation?"
      ],
      "studies": [
        {
          "id": "pmid-10496658",
          "title": "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers",
          "authors": "Gobburu JV, Agersø H, Jusko W, Ynddal L.",
          "year": 1999,
          "journal": "Pharmaceutical Research",
          "url": "https://pubmed.ncbi.nlm.nih.gov/10496658/",
          "doi": "10.1023/a:1018955126402",
          "pmid": "10496658",
          "evidenceType": "human",
          "design": "Dose-escalation infusion experiment with eight healthy male volunteers at each of five exposure levels.",
          "findings": "A short GH-release episode followed ipamorelin exposure; the investigators developed a model relating drug concentration to GH response.",
          "limitations": "A pharmacokinetic and hormone-response study, without a strength, body-composition or recovery efficacy endpoint.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-25331030",
          "title": "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients",
          "authors": "Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group.",
          "year": 2014,
          "journal": "International Journal of Colorectal Disease",
          "url": "https://pubmed.ncbi.nlm.nih.gov/25331030/",
          "doi": "10.1007/s00384-014-2030-8",
          "pmid": "25331030",
          "evidenceType": "human",
          "design": "Multicentre double-blind placebo-controlled phase 2 trial after bowel surgery;117 patients enrolled,114 included in the safety and modified intention-to-treat populations.",
          "findings": "The key meal-tolerance endpoint and secondary efficacy analyses did not differ significantly from placebo.",
          "limitations": "Small proof-of-concept study with diverse underlying surgical conditions. It cannot establish effectiveness for a different indication or catalogue formulation.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-9879640",
          "title": "Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption",
          "authors": "Johansen PB, Hansen KT, Andersen JV, Johansen NL.",
          "year": 1998,
          "journal": "Xenobiotica",
          "url": "https://pubmed.ncbi.nlm.nih.gov/9879640/",
          "doi": "10.1080/004982598238976",
          "pmid": "9879640",
          "evidenceType": "animal",
          "design": "Comparative pharmacokinetic experiment in male rats using different administration routes for ipamorelin and related peptides.",
          "findings": "The study measured nasal uptake of ipamorelin in rats and differences in clearance and excretion between peptides.",
          "limitations": "Animal absorption data, not a human nasal efficacy study. Species, formulation and delivery differences prevent assigning this exposure result to a commercial spray.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov ipamorelin randomized postoperative ileus trial",
          "site.pubmed.ncbi.nlm.nih.gov \"9879640\"",
          "site.pubmed.ncbi.nlm.nih.gov \"ipamorelin\" \"bioavailability\""
        ],
        "scope": "Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research."
      },
      "discussion": [
        {
          "heading": "Pharmacology and clinical efficacy answer different questions",
          "body": "The healthy-volunteer study characterises how ipamorelin exposure relates to a GH-release episode. The bowel-surgery trial instead asks whether a defined intervention improves a functional recovery measure. That trial did not show a significant meal-tolerance benefit. Its small proof-of-concept design does not exclude every possible effect, but it also cannot be cited as positive efficacy evidence. Reading the two papers together prevents a hormone response from standing in for a clinical result.",
          "citations": [
            "pmid-10496658",
            "pmid-25331030"
          ]
        },
        {
          "heading": "The nasal evidence has an explicit species boundary",
          "body": "The route-comparison study measured ipamorelin absorption in male rats. It helps identify a formulation question worth investigating, but does not establish human exposure. Differences in peptide, species and delivery preparation matter even within this small family of secretagogues. A human infusion experiment and a rat nasal experiment cannot be combined into a verified human nasal treatment effect. That would require evidence connecting the actual formulation to measured exposure and an appropriate outcome.",
          "citations": [
            "pmid-9879640"
          ]
        }
      ]
    },
    {
      "slug": "kisspeptin",
      "names": [
        "Kisspeptin"
      ],
      "title": "Kisspeptin",
      "kind": "compound",
      "summary": "Small crossover trials of kisspeptin-54 found acute changes in sexual-stimulus processing. The supplier’s unspecified kisspeptin fragment cannot automatically be assigned those findings.",
      "identity": "Kisspeptin describes related peptide forms. Both selected trials used kisspeptin-54; the catalogue label does not specify which fragment is supplied.",
      "evidenceOverview": "Selected kisspeptin-54 studies include acute crossover sexual-response experiments and an IVF feasibility study. Fragment, setting and endpoint remain central to interpretation.",
      "whatResearchShows": [
        "Brain-response changes can support a mechanistic hypothesis while leaving long-term patient benefit unresolved.",
        "Evidence for kisspeptin-54 is not evidence for every peptide fragment carrying the kisspeptin name."
      ],
      "limitations": [
        "Small, selected populations and acute study visits limit generalisation.",
        "The supplied fragment, formulation, exposure and route are not established by these studies."
      ],
      "openQuestions": [
        "Which kisspeptin fragment and molecular form does the material contain?",
        "Would a longer trial show a meaningful, sustained outcome beyond the immediate laboratory response?"
      ],
      "studies": [
        {
          "id": "pmid-36287566",
          "title": "Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial",
          "authors": "Thurston L, Hunjan T, Ertl N, et al.",
          "year": 2022,
          "journal": "JAMA Network Open",
          "url": "https://pubmed.ncbi.nlm.nih.gov/36287566/",
          "doi": "10.1001/jamanetworkopen.2022.36131",
          "pmid": "36287566",
          "evidenceType": "human",
          "design": "Double-masked placebo-controlled crossover trial of intravenous kisspeptin-54 in premenopausal women with hypoactive sexual desire disorder;32 completed both visits.",
          "findings": "Kisspeptin-54 altered brain responses to sexual and facial-attraction stimuli. Some imaging changes correlated with baseline distress or sexual aversion.",
          "limitations": "Small acute mechanistic study, primarily using imaging endpoints. It does not establish durable clinical improvement or effects of unspecified kisspeptin fragments.",
          "appliesTo": "related-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9606846/"
        },
        {
          "id": "pmid-36735255",
          "title": "Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial",
          "authors": "Mills EG, Ertl N, Wall MB, et al.",
          "year": 2023,
          "journal": "JAMA Network Open",
          "url": "https://pubmed.ncbi.nlm.nih.gov/36735255/",
          "doi": "10.1001/jamanetworkopen.2022.54313",
          "pmid": "36735255",
          "evidenceType": "human",
          "design": "Double-blind placebo-controlled crossover trial of intravenous kisspeptin-54;32 men with hypoactive sexual desire disorder completed both study visits.",
          "findings": "Brain responses to sexual stimuli changed; secondary analyses found increased penile tumescence and some self-reported arousal measures.",
          "limitations": "Acute laboratory endpoints in 32 right-handed heterosexual men. Full-text methods and limitations were consulted. Generalisation to other groups or sustained real-world sexual outcomes remains unresolved.",
          "appliesTo": "related-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9898824/"
        },
        {
          "id": "pmid-25036713",
          "title": "Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization",
          "authors": "Jayasena CN, Abbara A, Comninos AN, et al.",
          "year": 2014,
          "journal": "Journal of Clinical Investigation",
          "url": "https://pubmed.ncbi.nlm.nih.gov/25036713/",
          "doi": "10.1172/JCI75730",
          "pmid": "25036713",
          "evidenceType": "human",
          "design": "Dose-finding feasibility study in 53 women undergoing a controlled IVF protocol. Oocyte maturation was the primary endpoint; pregnancies and births were followed.",
          "findings": "Egg maturation and subsequent pregnancies and live births were observed after kisspeptin-54 within the IVF protocol.",
          "limitations": "No randomized standard-trigger comparison. Concomitant fertility treatment and the selected setting prevent assigning a general fertility benefit to an unspecified kisspeptin fragment.",
          "appliesTo": "related-compound",
          "verification": "full-text",
          "fullTextUrl": "https://www.jci.org/articles/view/75730"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.",
        "queries": [
          "36287566 kisspeptin",
          "\"Effects of Kisspeptin Administration in Women\" \"Abstract\"",
          "site.pubmed.ncbi.nlm.nih.gov kisspeptin 54 oocyte maturation IVF live birth 2014",
          "site.pmc.ncbi.nlm.nih.gov/articles/PMC9898824 \"Limitations\""
        ],
        "scope": "Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research."
      },
      "discussion": [
        {
          "heading": "Acute arousal experiments need an acute interpretation",
          "body": "The crossover design compares each participant with themselves, reducing confounding from stable differences between people. The male study also standardised stimuli and timing, and excluded several potentially confounding conditions. That improves interpretation of the immediate laboratory response. It does not establish a sustained change in day-to-day desire, relationship outcomes or effectiveness across sexual orientations and clinical groups. Imaging, tumescence and reported experience remain related but distinct measures.",
          "citations": [
            "pmid-36287566",
            "pmid-36735255"
          ]
        },
        {
          "heading": "The fertility literature studies another question and a defined fragment",
          "body": "The IVF feasibility study followed oocyte maturation and subsequent pregnancies and births after kisspeptin-54 within a controlled fertility-treatment protocol. These are more direct reproductive outcomes than a hormone response alone. However, the study lacked a randomised standard-trigger comparison and included other essential IVF interventions. It therefore cannot establish superiority to standard triggers or a general fertility effect. All three selected human papers concern kisspeptin-54, leaving the catalogue’s unspecified fragment unresolved.",
          "citations": [
            "pmid-25036713"
          ]
        }
      ]
    },
    {
      "slug": "klow",
      "names": [
        "KLOW",
        "KLOW Capsules"
      ],
      "title": "KLOW",
      "kind": "identity-pending",
      "summary": "A blend label used across several formats. The actual component identities and proportions remain unconfirmed in the reviewed supplier records.",
      "identity": "The catalogue name is a supplier label, not an authenticated molecular specification. This note preserves the exact published names without assigning an unverified identity.",
      "evidenceOverview": "Identity unresolved. No biological evidence is attributed to this product here. This is an evidence-matching gap, not a statement that no research exists.",
      "whatResearchShows": [
        "A meaningful literature review needs an identified substance or a defined mixture. Studies of an assumed ingredient would answer a different question."
      ],
      "limitations": [
        "No confirmed sequence, complete composition or matched chemical specification is available in the catalogue record used for this note.",
        "A general research paper or another seller’s blend formula cannot establish the contents, stability or effects of this listing."
      ],
      "openQuestions": [
        "Confirm the composition separately for each format. A shared blend label does not show that capsules, vials and sprays contain equivalent mixtures.",
        "Once the identity is confirmed, which primary studies match that exact compound, route and formulation?"
      ],
      "studies": [],
      "search": {
        "date": "2026-11-08",
        "method": "Identity-gated catalogue review",
        "queries": [],
        "scope": "Exact supplier labels and published catalogue specifications were checked. Biological literature was not attributed while the identity remained unresolved.",
        "limitations": "This is an identity note, not a negative literature search. It cannot show that relevant studies do not exist."
      }
    },
    {
      "slug": "kpv",
      "names": [
        "KPV"
      ],
      "title": "KPV",
      "kind": "compound",
      "summary": "KPV has mechanistic cell and mouse-colitis evidence. The cited work is preclinical and does not establish a treatment for inflammatory bowel disease or a general immune benefit in people.",
      "identity": "KPV denotes the Lys-Pro-Val tripeptide in the cited experiments. An exact molecular identity and relevant laboratory specification would still need confirmation for any supplied sample.",
      "evidenceOverview": "The selected paper examines how peptide transport relates to inflammatory signalling, using human-derived cell lines and two chemically induced mouse-colitis models. Human-origin cells do not make an experiment a human clinical trial.",
      "whatResearchShows": [
        "Dalmasso and colleagues linked cellular KPV uptake with the PepT1 transporter.",
        "Inflammatory signalling, cytokine and tissue outcomes changed in the tested cell and mouse models."
      ],
      "limitations": [
        "Cell-line signalling and chemically induced disease models may not reproduce human disease or exposure.",
        "The paper is not evidence of clinical symptom relief, remission or long-term human safety.",
        "The publication does not authenticate the identity, content or suitability of a HeartPep vial."
      ],
      "openQuestions": [
        "Can independent experiments reproduce the transport-dependent effects across relevant models?",
        "Which controlled human studies could test translation without assuming it from the mouse findings?"
      ],
      "studies": [
        {
          "id": "pmid-18061177",
          "title": "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation",
          "authors": "Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al.",
          "year": 2008,
          "journal": "Gastroenterology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/18061177/",
          "doi": "10.1053/j.gastro.2007.10.026",
          "pmid": "18061177",
          "evidenceType": "animal",
          "design": "Human epithelial/T-cell lines and DSS- and TNBS-induced colitis models in mice, studying transport and inflammatory pathways.",
          "findings": "Reported PepT1-associated uptake, reduced inflammatory signalling and lower inflammation in the tested mouse models.",
          "limitations": "Preclinical study with no human treatment arm. Findings do not establish efficacy or safety in inflammatory bowel disease patients.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.",
        "queries": [
          "18061177 KPV PepT1 colitis Dalmasso",
          "\"PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation\" doi authors",
          "\"10.1053/j.gastro.2007.10.026\" correction retraction"
        ],
        "scope": "One selected primary mechanistic paper; accessible full-text discussion and transport experiments were consulted. No comprehensive human-trial or unpublished-data search.",
        "limitations": "Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates."
      },
      "discussion": [
        {
          "heading": "Why the transport mechanism matters",
          "body": "The central mechanistic question is not simply whether an inflammatory marker falls after exposure. It is whether cellular entry is needed for that response. Comparing transporter-expressing systems and competing substrates helps make this a testable explanation. Our interpretation is that such experiments strengthen a mechanism within the model, while leaving open whether the same transport conditions occur at a proposed human site of action.",
          "citations": [
            "pmid-18061177"
          ]
        },
        {
          "heading": "Two mouse models are not two clinical populations",
          "body": "Using more than one induced-colitis model can test whether a finding depends entirely on one experimental insult. It does not recreate the heterogeneous causes, chronic course and concurrent treatments of human inflammatory disease. A translational study would need to define exposure and a disease-relevant outcome, rather than assume that reduced model inflammation establishes clinical remission.",
          "citations": [
            "pmid-18061177"
          ]
        },
        {
          "heading": "How to read a sparse evidence base",
          "body": "One mechanistic paper can be useful for forming an experiment, but cannot estimate rare harms, long-term outcomes or the reproducibility of an entire field. Absence of a human trial in this selected entry is a coverage limit, not proof that no research exists. Stronger evidence would require independent replication and appropriately controlled human investigation before clinical conclusions.",
          "citations": [
            "pmid-18061177"
          ]
        }
      ]
    },
    {
      "slug": "l-carnitine",
      "names": [
        "L-Carnitine"
      ],
      "title": "L-Carnitine",
      "kind": "compound",
      "summary": "Selected human studies address different questions, muscle fuel metabolism and weight loss. A positive metabolic measurement cannot substitute for a demonstrated weight-loss effect.",
      "identity": "L-carnitine is an amino-acid-derived compound, not a peptide. It is distinct from acetyl-L-carnitine, and study formulations and co-interventions must be matched precisely.",
      "evidenceOverview": "One small study tested oral L-carnitine with carbohydrate in men. Another tested supplementation plus walking in women and did not demonstrate a weight-loss advantage.",
      "whatResearchShows": [
        "A 24-week experiment reported increased muscle carnitine and altered fuel use during exercise [1].",
        "An 8-week randomized study found no significant between-group weight or fat-mass advantage over placebo [2]. These are different populations and endpoints, not direct contradictions."
      ],
      "limitations": [
        "Both studies are small and test oral preparations with co-interventions. Neither validates catalogue vials or nasal products.",
        "Exercise-test performance, tissue metabolite levels, body composition and clinical outcomes should be interpreted separately."
      ],
      "openQuestions": [
        "Which effects replicate in larger samples with equivalent co-interventions and prespecified outcomes?",
        "How do baseline status, formulation and population affect interpretation?"
      ],
      "studies": [
        {
          "id": "pmid-21224234",
          "title": "Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans",
          "authors": "Wall BT, Stephens FB, Constantin-Teodosiu D, et al.",
          "year": 2011,
          "journal": "The Journal of Physiology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/21224234/",
          "doi": "10.1113/jphysiol.2010.201343",
          "pmid": "21224234",
          "evidenceType": "human",
          "design": "24-week randomized double-blind experiment in 14 healthy men, comparing carbohydrate with or without oral L-carnitine-L-tartrate.",
          "findings": "Muscle carnitine increased and several exercise-metabolism measures changed in the supplemented group. A within-group work-output improvement was also reported.",
          "limitations": "Very small male-only sample and substantial carbohydrate co-intervention. It does not establish muscle-size gains, general weight loss or non-oral formulation effectiveness.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3060373/"
        },
        {
          "id": "pmid-10861338",
          "title": "L-Carnitine supplementation combined with aerobic training does not promote weight loss in moderately obese women",
          "authors": "Villani RG, Gannon J, Self M, Rich PA",
          "year": 2000,
          "journal": "International Journal of Sport Nutrition and Exercise Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/10861338/",
          "doi": "10.1123/ijsnem.10.2.199",
          "pmid": "10861338",
          "evidenceType": "human",
          "design": "8-week double-blind randomized oral-supplementation trial in 36 women, with a walking programme in both groups.",
          "findings": "Among completers, no significant between-group advantage was found for weight, fat mass or resting lipid use. Five participants receiving carnitine withdrew with nausea or diarrhoea.",
          "limitations": "Small, short study with attrition. A negative result for this protocol is not proof of no possible effect in every setting, but it does not support a general weight-loss claim.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-23563705",
          "title": "Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis",
          "authors": "Koeth RA, Wang Z, Levison BS, et al.",
          "year": 2013,
          "journal": "Nature Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/23563705/",
          "evidenceType": "human",
          "design": "Human isotope-tracer challenges and a cardiac-evaluation cohort, alongside microbiota-dependent mouse experiments.",
          "findings": "The work connects dietary carnitine metabolism to TMAO production; cardiovascular associations in the clinical cohort depended on TMAO context, and mouse experiments supplied mechanistic evidence.",
          "limitations": "The human cardiovascular component is observational, not a randomized supplementation-outcome trial. Mouse causality does not by itself establish a human event risk from every carnitine preparation.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "doi": "10.1038/nm.3145",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3650111/",
          "pmid": "23563705"
        },
        {
          "id": "pmid-43026709",
          "title": "Correction to: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate",
          "authors": "Toxicological Sciences",
          "journal": "Toxicological Sciences",
          "year": 2026,
          "url": "https://academic.oup.com/toxsci/article/209/11/kfag143/9031306",
          "doi": "10.1093/toxsci/kfag143",
          "pmid": "43026709",
          "evidenceType": "reference",
          "design": "Publisher correction dated 13 November 2026 for the 2017 preclinical paper PMID 28973641.",
          "findings": "The original article’s Figure 5A contained the wrong representative histology image for one L-carnitine group. The notice supplies the corrected panel. The authors report that the quantitative analysis and conclusions were unaffected.",
          "limitations": "Full publisher notice consulted. The authors’ statement does not independently verify the underlying data or extend the experiment to human outcomes.",
          "appliesTo": "exact-compound",
          "verification": "full-text"
        }
      ],
      "search": {
        "date": "2026-11-16",
        "method": "Targeted primary-study searches including a negative controlled weight-loss result. Added an original publisher notice check for a separate preclinical paper.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov/21224234 Chronic oral ingestion",
          "L-carnitine supplementation Villani 2000",
          "site.pubmed.ncbi.nlm.nih.gov/10861338",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC3650111/",
          "site.pubmed.ncbi.nlm.nih.gov 23563705 Correction",
          "site.pubmed.ncbi.nlm.nih.gov 23563705 Erratum",
          "PMID 43026709 / DOI 10.1093/toxsci/kfag143"
        ],
        "scope": "Selected exercise-metabolism and weight-loss trials, plus human/animal microbiota-mechanism work with observational cardiovascular data. Reviewed the full Toxicological Sciences correction.",
        "limitations": "Not a systematic review of all carnitine indications or related compounds. The two supplementation trials were appraised at abstract level; selected full-text sections of the microbiota paper were checked. No claim of causal human cardiovascular harm or catalogue-product equivalence is made. The underlying preclinical data were not independently audited."
      },
      "discussion": [
        {
          "heading": "A tissue mechanism does not guarantee the advertised outcome",
          "body": "Carnitine has a biological role in fuel handling, but that role is not the same as demonstrating that an added preparation improves a chosen outcome. The exercise study tests muscle loading under a carbohydrate co-intervention in a small male sample. The weight-loss study asks a separate question in women following a walking programme and did not find a between-group advantage. Neither can settle every use, and their findings should not be reduced to a single works-or-does-not-work verdict. In particular, a measured metabolite or an exercise-test change is not evidence of increased muscle size.",
          "citations": [
            "pmid-21224234",
            "pmid-10861338"
          ]
        },
        {
          "heading": "Separate mechanistic safety questions from human event causality",
          "body": "The microbiota paper adds an important research question that an efficacy-only reading would miss: ingested carnitine can be processed differently depending on microbial and dietary context. However, its cardiovascular associations in people are observational, while much of the causal experimental work is in mice. It would overstate the evidence to conclude that every carnitine preparation causes cardiovascular events, or to infer that bypassing oral exposure is safe. The route, baseline status and endpoint must remain explicit. This study motivates further investigation and careful interpretation rather than a universal clinical conclusion.",
          "citations": [
            "pmid-23563705"
          ]
        },
        {
          "heading": "A corrected image in a separate preclinical study",
          "body": "Readers using the 2017 toxicology paper should consult the correction alongside the original figure. This notice concerns an animal-model image and does not change the interpretation of the human exercise or weight studies above.",
          "citations": [
            "pmid-43026709"
          ]
        }
      ]
    },
    {
      "slug": "lipo-c",
      "names": [
        "Lipo-C"
      ],
      "title": "Lipo-C",
      "kind": "identity-pending",
      "summary": "This supplier mixture name does not disclose a verified formula. It has no compound-specific biological review until the ingredients and amounts are confirmed.",
      "identity": "The catalogue name is a supplier label, not an authenticated molecular specification. This note preserves the exact published names without assigning an unverified identity.",
      "evidenceOverview": "Identity unresolved. No biological evidence is attributed to this product here. This is an evidence-matching gap, not a statement that no research exists.",
      "whatResearchShows": [
        "A meaningful literature review needs an identified substance or a defined mixture. Studies of an assumed ingredient would answer a different question."
      ],
      "limitations": [
        "No confirmed sequence, complete composition or matched chemical specification is available in the catalogue record used for this note.",
        "A general research paper or another seller’s blend formula cannot establish the contents, stability or effects of this listing."
      ],
      "openQuestions": [
        "Obtain the complete formula, amount of each component, excipients and formulation-specific documentation.",
        "Once the identity is confirmed, which primary studies match that exact compound, route and formulation?"
      ],
      "studies": [],
      "search": {
        "date": "2026-11-08",
        "method": "Identity-gated catalogue review",
        "queries": [],
        "scope": "Exact supplier labels and published catalogue specifications were checked. Biological literature was not attributed while the identity remained unresolved.",
        "limitations": "This is an identity note, not a negative literature search. It cannot show that relevant studies do not exist."
      }
    },
    {
      "slug": "ll-37",
      "names": [
        "LL-37"
      ],
      "title": "LL-37",
      "kind": "compound",
      "summary": "LL-37 has been investigated as a topical wound-healing drug. The selected phase IIb trial did not show a significant benefit across the overall study population, despite exploratory subgroup signals.",
      "identity": "The research concerns LL-37, a host-defence peptide. A pharmaceutical topical preparation used alongside compression therapy is different from a catalogue vial or nasal format.",
      "evidenceOverview": "The overall trial result is the primary interpretive anchor. Post-hoc findings in participants with larger ulcers can generate hypotheses, but do not turn a negative overall trial into established efficacy.",
      "whatResearchShows": [
        "Mahlapuu and colleagues studied a defined topical preparation in hard-to-heal venous leg ulcers.",
        "No significant overall healing improvement was detected; some larger-ulcer subgroup findings were exploratory."
      ],
      "limitations": [
        "The study concerns venous leg ulcers with concurrent standard compression care.",
        "Post-hoc subgroup analyses need prospective confirmation and careful attention to multiple comparisons.",
        "The trial does not establish systemic antimicrobial, immune-enhancing or nasal effects, or verify a HeartPep batch."
      ],
      "openQuestions": [
        "Can a prospective trial reproduce the proposed subgroup effect?",
        "Which formulation and wound context, if any, yield a reproducible clinical benefit?"
      ],
      "studies": [
        {
          "id": "pmid-34687253",
          "title": "Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial",
          "authors": "Mahlapuu M, Sidorowicz A, Mikosinski J, et al.",
          "year": 2021,
          "journal": "Wound Repair and Regeneration",
          "url": "https://pubmed.ncbi.nlm.nih.gov/34687253/",
          "doi": "10.1111/wrr.12977",
          "pmid": "34687253",
          "evidenceType": "human",
          "design": "Phase IIb double-blind randomised placebo-controlled topical trial, with 148 treated patients receiving compression therapy.",
          "findings": "No significant healing improvement in the overall population. Post-hoc analyses suggested effects in some patients with larger ulcers.",
          "limitations": "Selected subgroup results were not a substitute for the overall result. The studied topical drug does not validate other delivery formats.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9298190/"
        },
        {
          "id": "pmid-25041740",
          "title": "Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial",
          "authors": "Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O",
          "year": 2014,
          "journal": "Wound Repair and Regeneration",
          "url": "https://pubmed.ncbi.nlm.nih.gov/25041740/",
          "doi": "10.1111/wrr.12211",
          "pmid": "25041740",
          "evidenceType": "human",
          "design": "First-in-human trial with 34 participants, a randomised double-blind treatment phase and follow-up after a placebo run-in.",
          "findings": "Reported healing-predictor signals at lower studied topical concentrations; the highest concentration did not differ from placebo.",
          "limitations": "Small multi-group early trial. The result is not equivalent to confirmed complete-healing efficacy or long-term clinical safety.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.",
        "queries": [
          "Direct review of existing reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC9298190/",
          "LL37 first human venous leg ulcer trial 2014 randomized 2014 Gronberg",
          "\"10.1111/wrr.12977\" correction retraction"
        ],
        "scope": "Early topical trial and later phase IIb trial. Later full-text endpoints, subgroup methods and participant flow consulted; no claim of comprehensive wound-literature coverage.",
        "limitations": "Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates."
      },
      "discussion": [
        {
          "heading": "Early signals need later confirmation",
          "body": "The earlier trial was useful for exploring a response pattern and informing a subsequent experiment. Its size and several treatment groups make a precise general efficacy estimate difficult. The later overall null result therefore belongs beside the early signal, not behind it. Our interpretation is that this sequence shows the value of follow-up trials: a plausible and initially encouraging candidate still needs confirmation on defined clinical outcomes.",
          "citations": [
            "pmid-25041740",
            "pmid-34687253"
          ]
        },
        {
          "heading": "A subgroup finding is a new question",
          "body": "A larger-ulcer signal can be biologically interesting without being a proven treatment effect. When subgroups and several correlated wound measures are examined, their statistical dependence and the number of comparisons matter. The most informative next trial would define the subgroup, endpoint and analysis before enrolment, rather than choose them after an overall negative result.",
          "citations": [
            "pmid-34687253"
          ]
        },
        {
          "heading": "Keep the endpoint and care setting attached",
          "body": "A healing rate, area reduction and sustained complete closure are different outcomes. Their clinical importance should be evaluated with time, uncertainty and concurrent standard care visible. The selected topical trials also cannot answer whether systemic host-defence signalling would improve unrelated infections. The research programme and its formulation should remain the unit of interpretation.",
          "citations": [
            "pmid-25041740",
            "pmid-34687253"
          ]
        }
      ]
    },
    {
      "slug": "melanotan-i",
      "names": [
        "Melanotan I",
        "Melanotan 1"
      ],
      "title": "Melanotan I",
      "kind": "compound",
      "summary": "Human pigmentation and afamelanotide research exists, but early experiments and disease-specific implant trials do not validate catalogue vials or sprays or establish safe cosmetic tanning.",
      "identity": "Melanotan I is the name used for the linear alpha-MSH analogue studied in the early pharmacokinetic paper. Afamelanotide research uses a specifically manufactured clinical formulation; matching a name does not establish product equivalence.",
      "evidenceOverview": "A three-person pharmacokinetic study and two randomised disease-specific implant trials illustrate both biological activity and the importance of formulation and population.",
      "whatResearchShows": [
        "The small early study found pigmentation changes after parenteral exposure, while oral exposure produced no detectable plasma drug.",
        "Clinical afamelanotide implants increased pain-free sunlight exposure in patients with erythropoietic protoporphyria."
      ],
      "limitations": [
        "A three-person experiment cannot establish uncommon or long-term harms.",
        "Rare-disease trial results do not establish cosmetic safety, cancer prevention or equivalent delivery from a research spray."
      ],
      "openQuestions": [
        "What identity, exposure and safety evidence exists for the exact supplied format rather than the clinical implant?"
      ],
      "studies": [
        {
          "id": "pmid-9113347",
          "title": "Skin pigmentation and pharmacokinetics of melanotan-I in humans",
          "authors": "Ugwu SO, Blanchard J, Dorr RT, et al.",
          "year": 1997,
          "journal": "Biopharmaceutics and Drug Disposition",
          "url": "https://pubmed.ncbi.nlm.nih.gov/9113347/",
          "doi": "10.1002/(SICI)1099-081X(199704)18:3<259::AID-BDD20>3.0.CO;2-X",
          "pmid": "9113347",
          "evidenceType": "human",
          "design": "Randomised crossover pharmacokinetic and pigmentation experiment in three male volunteers.",
          "findings": "Parenteral routes produced measurable exposure and pigmentation; oral exposure yielded no detectable drug. Gastrointestinal upset and flushing occurred.",
          "limitations": "Very small sample, short follow-up and no validation of catalogue formulations.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-26132941",
          "title": "Afamelanotide for Erythropoietic Protoporphyria",
          "authors": "Langendonk JG, Balwani M, Anderson KE, et al.",
          "year": 2015,
          "journal": "New England Journal of Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/26132941/",
          "doi": "10.1056/NEJMoa1411481",
          "pmid": "26132941",
          "evidenceType": "human",
          "design": "Two multicentre double-blind placebo-controlled implant trials, with 74 EU and 94 US patients with erythropoietic protoporphyria.",
          "findings": "Pain-free sunlight exposure and quality-of-life measures improved versus placebo; adverse events were mostly mild during follow-up.",
          "limitations": "Clinical implant in a defined rare-disease population. Diary outcomes, some partial unblinding from pigmentation and differing trial protocols limit interpretation; this does not validate catalogue formats.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4780255/"
        },
        {
          "id": "pmid-11045725",
          "title": "Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans",
          "authors": "Dorr RT, Dvorakova K, Brooks C, et al.",
          "year": 2000,
          "journal": "Photochemistry and Photobiology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/11045725/",
          "doi": "10.1562/0031-8655(2000)072<0526:ieeati>2.0.co;2",
          "pmid": "11045725",
          "evidenceType": "human",
          "design": "Seven-person before-and-after pigmentation study with skin-biopsy pigment chemistry.",
          "findings": "Eumelanin measurements increased at sampled sites. The change in the eumelanin-to-pheomelanin ratio did not meet the conventional significance threshold.",
          "limitations": "Very small uncontrolled study of pigment markers, not cancer incidence, long-term safety or catalogue-product performance.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-42678656",
          "title": "Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study",
          "authors": "Griffin LL et al.",
          "year": 2026,
          "journal": "Photochemical & Photobiological Sciences",
          "url": "https://link.springer.com/article/10.1007/s43630-026-00986-x",
          "doi": "10.1007/s43630-026-00986-x",
          "pmid": "42678656",
          "evidenceType": "human",
          "design": "Small, open-label exploratory comparison in healthy volunteers before and after use of a defined afamelanotide implant.",
          "findings": "Overall ultraviolet-associated skin redness decreased, but the redness threshold did not change significantly. Pigment measures did not all agree.",
          "limitations": "Nine participants completed the study. The short-term results do not establish broad UV protection or apply to Melanotan II or other preparations. The implant findings do not establish a catalogue product's identity or performance.",
          "appliesTo": "related-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-41793078",
          "title": "Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients",
          "authors": "Seidl-Philipp M et al.",
          "year": 2026,
          "journal": "Journal der Deutschen Dermatologischen Gesellschaft",
          "url": "https://onlinelibrary.wiley.com/doi/10.1111/ddg.15996",
          "doi": "10.1111/ddg.15996",
          "pmid": "41793078",
          "evidenceType": "human",
          "design": "Small before-and-after observational cohort in patients with erythropoietic protoporphyria receiving a defined afamelanotide treatment.",
          "findings": "The cohort reported improvements in quality of life and light tolerance after treatment.",
          "limitations": "No comparison group; this disease-specific observational report does not address general UV protection, other preparations, Melanotan II, or any catalogue product.",
          "appliesTo": "related-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-20",
        "method": "Targeted primary-record searches for early Melanotan-I pharmacokinetics and later afamelanotide clinical studies. Also checked newly indexed or previously omitted original abstracts and identifiers.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov 9113347 Melanotan",
          "site.pubmed.ncbi.nlm.nih.gov afamelanotide erythropoietic protoporphyria 2015 randomized",
          "Skin pigmentation and pharmacokinetics of melanotan-I retracted",
          "Dorr 2000 melanotan I seven volunteers eumelanin pheomelanin human biopsies PubMed",
          "PMID 42678656 / DOI 10.1007/s43630-026-00986-x",
          "PMID 41793078 / DOI 10.1111/ddg.15996"
        ],
        "scope": "Selected pigmentation/pharmacokinetic experiments, pigment chemistry and disease-specific clinical evidence. Afamelanotide full-text methods, outcomes and limitations were consulted. Added selected human study records dated 2026, with study-specific limitations.",
        "limitations": "Not a comprehensive regulatory, dermatology or long-term safety review. Most early experiments were checked at abstract level. Clinical-drug evidence does not authenticate a supplier product."
      },
      "discussion": [
        {
          "heading": "Pigment chemistry is not a cancer-prevention endpoint",
          "body": "The biopsy study helps connect visible pigmentation with a measured pigment change. It does not test whether participants develop fewer cancers or whether repeated exposure remains safe over years. Even within this small experiment, the eumelanin increase and the eumelanin-to-pheomelanin ratio are distinct analyses with different statistical results. Converting either into a blanket protection claim would exceed what was measured.",
          "citations": [
            "pmid-11045725"
          ]
        },
        {
          "heading": "Preserve the clinical question and the formulation",
          "body": "The afamelanotide trials address painful photosensitivity in erythropoietic protoporphyria. Their primary endpoint is meaningful for that disease, but diary-reported sunlight exposure and partial unblinding complicate measurement. They do not compare cosmetic tanning methods or establish interchangeability with a supplied spray or vial. The earlier pharmacokinetic study also illustrates that the route can change detectable exposure. A defensible summary therefore keeps the studied drug, population, route and outcome together instead of transferring a clinical result to every product carrying a related name.",
          "citations": [
            "pmid-26132941",
            "pmid-9113347"
          ]
        },
        {
          "heading": "Positive primary results do not make every endpoint positive",
          "body": "The afamelanotide report also shows why outcome labels matter. Disease-specific quality-of-life findings and broader dermatology scores did not give identical results. A critical account can recognise a positive primary endpoint while preserving mixed secondary outcomes, rather than describing all measurements as uniformly improved.",
          "citations": [
            "pmid-26132941"
          ]
        }
      ]
    },
    {
      "slug": "melanotan-ii",
      "names": [
        "Melanotan II"
      ],
      "title": "Melanotan II",
      "kind": "compound",
      "summary": "Small early human experiments recorded pigmentation and erection-related effects alongside adverse effects. They do not establish safe tanning, a reliable treatment or the performance of catalogue products.",
      "identity": "Melanotan II is a cyclic melanocortin analogue, distinct from Melanotan I and bremelanotide/PT-141. Evidence for these molecules is not interchangeable.",
      "evidenceOverview": "Small experimental human studies show biological activity; a separate case report illustrates a serious harm signal after reported exposure. These evidence types inform different questions and cannot provide a reliable population risk estimate.",
      "whatResearchShows": [
        "The pilot observed pigmentation in two participants and nausea, fatigue/somnolence and erection-related effects.",
        "A small crossover study found measurable erection responses in some men with psychogenic erectile dysfunction."
      ],
      "limitations": [
        "Short experiments cannot resolve uncommon or long-term adverse outcomes.",
        "A monitored experimental preparation and route do not establish equivalence to a commercial vial or nasal spray."
      ],
      "openQuestions": [
        "What would adequately powered, longer-term research show about benefit, harms and the exact formulation?"
      ],
      "studies": [
        {
          "id": "pmid-8637402",
          "title": "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study",
          "authors": "Dorr RT, Lines R, Levine N, et al.",
          "year": 1996,
          "journal": "Life Sciences",
          "url": "https://pubmed.ncbi.nlm.nih.gov/8637402/",
          "doi": "10.1016/0024-3205(96)00160-9",
          "pmid": "8637402",
          "evidenceType": "human",
          "design": "Single-blind saline-controlled early study in three healthy men.",
          "findings": "Pigmentation increased in two men. Nausea, yawning, erections and fatigue/somnolence were observed.",
          "limitations": "Three participants and brief follow-up cannot establish general safety or a dependable clinical effect.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-9679884",
          "title": "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study",
          "authors": "Wessells H, Fuciarelli K, Hansen J, et al.",
          "year": 1998,
          "journal": "Journal of Urology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/9679884/",
          "doi": "10.1016/S0022-5347(01)62903-3",
          "pmid": "9679884",
          "evidenceType": "human",
          "design": "Double-blind placebo-controlled crossover experiment in ten men, using instrumental erection monitoring.",
          "findings": "Clinically apparent erections developed in eight of ten men after Melanotan II.",
          "limitations": "Small selected population and acute experimental responses, not a long-term safety or treatment trial for supplied formats.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-33460908",
          "title": "Melanotan Tanning Injection: A Rare Cause of Priapism",
          "authors": "Mallory CW, Lopategui DM, Cordon BH",
          "year": 2021,
          "journal": "Sexual Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/33460908/",
          "doi": "10.1016/j.esxm.2020.100298",
          "pmid": "33460908",
          "evidenceType": "human",
          "design": "Clinical case report following self-reported Melanotan-II exposure.",
          "findings": "Prolonged ischaemic priapism required surgery; impaired erectile function was reported during follow-up.",
          "limitations": "One case cannot estimate event frequency or isolate causality, and the reported product was not independently chemically verified.",
          "appliesTo": "related-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7930850/"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Primary PubMed and journal discovery for early human experiments.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov melanotan II erections 1998 double blind crossover",
          "Synthetic melanotropic peptide initiates erections Wessells",
          "9679884 doi",
          "Melanotan II priapism case report PubMed renal infarction"
        ],
        "scope": "Selected early pigmentation/erection experiments and a full-text serious-adverse-event case report.",
        "limitations": "Not exhaustive pharmacovigilance. The case report does not establish product composition, causality or event incidence; no current clinical approval claim is made."
      },
      "discussion": [
        {
          "heading": "An acute response is not a treatment outcome",
          "body": "The early studies measured pigmentation or erections under experimental monitoring. Those observations show a pharmacological signal, but not durable improvement in health, sexual wellbeing or cosmetic safety. The selected participants and brief observation also limit generalisability. Small experiments are particularly poor at identifying uncommon outcomes, so a response in most participants should not be presented as a dependable benefit-to-risk estimate.",
          "citations": [
            "pmid-8637402",
            "pmid-9679884"
          ]
        },
        {
          "heading": "Case reports identify possibilities, not probabilities",
          "body": "The priapism report matters because the outcome was serious, not because it establishes how frequently it occurs. Temporal association and a plausible exposure history warrant attention, while the absence of chemical verification and an unexposed comparison limit causal inference. It would be equally misleading to dismiss it because it is one case or to assign its event rate to all products. The evidence gap is a need for reliable exposure, formulation and safety data, not an invitation to infer safety from the small favourable experiments.",
          "citations": [
            "pmid-33460908"
          ]
        },
        {
          "heading": "Do not substitute a related melanocortin",
          "body": "A response to Melanotan II is evidence about the molecule and preparation actually tested. It cannot establish an equivalent response to Melanotan I, PT-141 or another receptor agonist. Likewise, a study of a related clinical drug cannot settle the identity, benefit or safety of this catalogue material.",
          "citations": [
            "pmid-8637402",
            "pmid-9679884"
          ]
        }
      ]
    },
    {
      "slug": "mots-c",
      "names": [
        "MOTS-c",
        "MOTS-C"
      ],
      "title": "MOTS-c",
      "kind": "compound",
      "summary": "MOTS-c has mechanistic and mouse-intervention evidence involving metabolic signalling and physical performance. The human exercise observations cited here concern naturally occurring MOTS-c, not a trial of a purchased peptide.",
      "identity": "The foundational study describes MOTS-c as a 16-amino-acid peptide encoded by a short open reading frame associated with mitochondrial 12S rRNA. A supplier label alone does not verify the sequence of supplied material.",
      "evidenceOverview": "Two selected primary studies connect cell pathways with mouse physiology. Human measurements in the later paper add biological context, but do not demonstrate that supplementing MOTS-c improves human strength, weight or lifespan.",
      "whatResearchShows": [
        "Lee and colleagues linked MOTS-c to folate/purine metabolism and AMPK signalling, alongside metabolic changes in mice.",
        "Reynolds and colleagues reported performance changes in treated mice and exercise-associated changes in endogenous MOTS-c in ten young men."
      ],
      "limitations": [
        "Observation of an exercise response is different from randomising people to receive an intervention.",
        "Mouse performance and healthspan measurements do not establish human lifespan extension or clinical weight management.",
        "The selected studies do not validate the identity, exposure, effectiveness or safety of HeartPep vial or nasal products."
      ],
      "openQuestions": [
        "Can independently replicated human intervention studies establish a clinically meaningful effect?",
        "Which study materials, analytical methods and exposure measurements would allow a valid formulation comparison?"
      ],
      "studies": [
        {
          "id": "pmid-25738459",
          "title": "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance",
          "authors": "Lee C, Zeng J, Drew BG, et al.",
          "year": 2015,
          "journal": "Cell Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/25738459/",
          "doi": "10.1016/j.cmet.2015.02.009",
          "pmid": "25738459",
          "evidenceType": "animal",
          "design": "Mechanistic cell experiments and mouse models of ageing and high-fat-diet-associated metabolic dysfunction.",
          "findings": "Reported AMPK-associated metabolic signalling and prevention of insulin resistance and diet-induced obesity in the studied mouse models.",
          "limitations": "Preclinical intervention evidence. It does not demonstrate human treatment effects or validate a commercial formulation.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4350682/"
        },
        {
          "id": "pmid-33473109",
          "title": "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis",
          "authors": "Reynolds JC, Lai RW, Woodhead JST, et al.",
          "year": 2021,
          "journal": "Nature Communications",
          "url": "https://pubmed.ncbi.nlm.nih.gov/33473109/",
          "doi": "10.1038/s41467-020-20790-0",
          "pmid": "33473109",
          "evidenceType": "animal",
          "design": "Mouse intervention and muscle/cell experiments, with exercise-related human measurements in ten young men.",
          "findings": "Reported enhanced physical capacity in mice and an exercise-associated rise in naturally occurring MOTS-c in human muscle and blood.",
          "limitations": "The human component was not a peptide-treatment trial. Study authors disclosed relevant commercial interests.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7817689/"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.",
        "queries": [
          "25738459 MOTS-c Lee 2015 Cell metabolism Pubmed",
          "\"MOTS-c\" randomized human trial 2025 2026",
          "MOTS-c Reynolds 2021 correction retraction 33473109",
          "\"10.1016/j.cmet.2015.02.009\" correction retraction"
        ],
        "scope": "Foundational metabolic study and a later muscle/ageing study, separating mouse intervention from human exercise observation.",
        "limitations": "Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Searches can return exercise or heat studies that measure endogenous MOTS-c; these must not be counted as trials administering MOTS-c. Direct full-text retrieval was intermittent, and full methods were not comprehensively audited. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates."
      },
      "discussion": [
        {
          "heading": "Separate the human observation from the animal intervention",
          "body": "The exercise observations establish an association with an endogenous signal under the studied conditions. They do not supply the missing comparison between people assigned to a supplied peptide and people assigned to a control. Our interpretation is that an adaptive exercise response may identify a useful biological pathway while leaving supplementation efficacy unresolved. Treating the observation as a treatment trial would erase that distinction.",
          "citations": [
            "pmid-33473109"
          ]
        },
        {
          "heading": "Mechanistic coherence is useful, but insufficient",
          "body": "Linking cellular pathways with physiological changes in mice is stronger than a mechanism-only speculation, because it provides several testable levels of evidence. It still requires scrutiny of model selection, exposure measurement and whether the proposed pathway is necessary for the observed phenotype. Replication with prospectively specified outcomes would be more informative than simply adding further pathway measurements to a favourable model.",
          "citations": [
            "pmid-25738459",
            "pmid-33473109"
          ]
        },
        {
          "heading": "What would make translation convincing?",
          "body": "A useful next step would preserve the exact sequence and analytical specification, establish relevant human exposure and test a defined functional outcome. Fitness, body composition and lifespan are separate endpoints. A result on one should not be used as an unmeasured answer to the others. We therefore treat the current selected evidence as a basis for research hypotheses rather than a demonstrated human performance effect.",
          "citations": [
            "pmid-25738459",
            "pmid-33473109"
          ]
        }
      ]
    },
    {
      "slug": "nad-plus",
      "names": [
        "NAD+"
      ],
      "title": "NAD+",
      "kind": "compound",
      "summary": "NAD+ is a metabolic cofactor rather than a peptide. Research on cellular NAD+ biology, NAD+ precursors and direct NAD+ infusion addresses different questions and should not be merged into one efficacy claim.",
      "identity": "Nicotinamide adenine dinucleotide in its oxidised form, NAD+, participates in redox and other cellular reactions. Compounds such as NMN and NR are precursors, not interchangeable names for NAD+.",
      "evidenceOverview": "The mechanistic ageing paper primarily concerns cells and mice, including an intervention that raises NAD+ through a precursor. A small direct-infusion human study measured metabolic handling, not longevity, energy benefits or disease treatment.",
      "whatResearchShows": [
        "Gomes and colleagues connected declining nuclear NAD+ with disrupted mitochondrial communication in experimental ageing models.",
        "Grant and colleagues tracked plasma and urinary metabolites during and after direct NAD+ infusion, showing substantial metabolic handling before a sustained plasma increase."
      ],
      "limitations": [
        "A precursor intervention cannot directly establish the effect of an NAD+ vial or spray.",
        "Changes in metabolite concentrations do not establish a meaningful health outcome.",
        "The small infusion pilot does not resolve long-term safety or validate a catalogue formulation."
      ],
      "openQuestions": [
        "Do sufficiently controlled human trials show durable functional outcomes from direct NAD+ itself?",
        "Which analytical measures establish tissue exposure rather than only a change in circulating metabolites?"
      ],
      "studies": [
        {
          "id": "pmid-24360282",
          "title": "Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging",
          "authors": "Gomes AP, Price NL, Ling AJY, et al.",
          "year": 2013,
          "journal": "Cell",
          "url": "https://pubmed.ncbi.nlm.nih.gov/24360282/",
          "doi": "10.1016/j.cell.2013.11.037",
          "pmid": "24360282",
          "evidenceType": "animal",
          "design": "Cell and mouse experiments investigating SIRT1, NAD+ and nuclear-mitochondrial signalling during ageing.",
          "findings": "Linked declining NAD+ to altered mitochondrial gene expression and reported reversal of selected mitochondrial changes when NAD+ was raised in old mice.",
          "limitations": "Mechanistic and precursor-related evidence, not a trial of a direct NAD+ catalogue product.",
          "appliesTo": "related-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4076149/"
        },
        {
          "id": "pmid-31572171",
          "title": "A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+",
          "authors": "Grant R, Berg J, Mestayer R, et al.",
          "year": 2019,
          "journal": "Frontiers in Aging Neuroscience",
          "url": "https://pubmed.ncbi.nlm.nih.gov/31572171/",
          "doi": "10.3389/fnagi.2019.00257",
          "pmid": "31572171",
          "evidenceType": "human",
          "design": "Small human metabolic pilot with eleven men, eight receiving NAD+ and three saline controls.",
          "findings": "Measured time-dependent plasma and urinary NAD+ metabolites; plasma NAD+ did not rise during the first two hours.",
          "limitations": "Very small, short metabolic study without a clinical efficacy endpoint. It cannot substantiate anti-ageing or cognitive benefit.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6751327/"
        },
        {
          "id": "pmid-33888596",
          "title": "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women",
          "authors": "Yoshino M, Yoshino J, Kayser BD, et al.",
          "year": 2021,
          "journal": "Science",
          "url": "https://pubmed.ncbi.nlm.nih.gov/33888596/",
          "doi": "10.1126/science.abe9985",
          "pmid": "33888596",
          "evidenceType": "human",
          "design": "Ten-week double-blind placebo-controlled NMN study in 25 postmenopausal women with prediabetes who were overweight or obese, using metabolic clamps and muscle biopsies.",
          "findings": "Reported increased muscle insulin sensitivity and signalling, without corresponding changes in several body-composition, physical-function or other metabolic measures.",
          "limitations": "This is an NMN precursor study in a selected population, not direct NAD+ treatment or a longevity trial.",
          "appliesTo": "related-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8550608/"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.",
        "queries": [
          "site:pubmed.ncbi.nlm.nih.gov NAD+ intravenous infusion pilot study plasma urine metabolome 2019 Grant",
          "\"31572171\" \"10.\" Grant",
          "\"A Pilot Study Investigating Changes\" \"Grant\" 2019 NAD metabolome",
          "nicotinamide mononucleotide muscle insulin sensitivity prediabetic women randomized 2021 Yoshino PubMed",
          "\"10.1016/j.cell.2013.11.037\" correction retraction"
        ],
        "scope": "Mechanistic NAD+ biology, a small direct-infusion metabolic pilot and a human NMN precursor contrast. Selected full-text sections consulted; the NMN source was also intermittently blocked on direct retrieval.",
        "limitations": "Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates."
      },
      "discussion": [
        {
          "heading": "Concentration, flux and clinical benefit are different endpoints",
          "body": "NAD+ research often moves between circulating concentrations, intracellular pools and enzyme activity. A change in one compartment cannot automatically establish a change in another. The infusion pilot is useful for identifying metabolic handling and future sampling questions, but its design does not supply a counterfactual for improved cognition or ageing. Those outcomes would need their own adequately controlled measurements rather than being inferred from a metabolite curve.",
          "citations": [
            "pmid-31572171",
            "pmid-24360282"
          ]
        },
        {
          "heading": "The precursor contrast is informative, not interchangeable",
          "body": "The NMN trial gives an example of a specific human physiological endpoint changing while several broader outcomes do not. Our interpretation is that a positive mechanistic or metabolic signal should stay attached to the actual compound and endpoint. It is not evidence that an equal labelled quantity of NAD+ produces the same exposure or effect. A literature review should therefore extract intervention identity and route before grouping studies under a common NAD biology heading.",
          "citations": [
            "pmid-33888596"
          ]
        },
        {
          "heading": "A useful next experiment",
          "body": "The unresolved bridge is reproducible exposure to direct NAD+ together with a prespecified functional outcome. Suitable controls, validated handling of unstable metabolites and tissue-relevant measurements would help distinguish target engagement from a clinically useful effect. Longer lifespan is a separate hypothesis, not a synonym for either.",
          "citations": [
            "pmid-24360282",
            "pmid-31572171",
            "pmid-33888596"
          ]
        }
      ]
    },
    {
      "slug": "needles",
      "names": [
        "18G Needle",
        "31G 5/16-inch needles"
      ],
      "title": "Needles: specification guide",
      "kind": "supply",
      "summary": "This entry concerns a laboratory supply, not a biological effect. A gauge label is only part of the specification needed to match equipment to a documented procedure.",
      "identity": "The US catalogue lists 18G needle packs and a 10-pack of 31G, 5/16-inch needles. Check the exact listing and manufacturer specification for dimensions, connector, material and certification.",
      "evidenceOverview": "Specification review, with a technical laboratory-quality reference. No biological benefit is assigned to this supply.",
      "whatResearchShows": [
        "A pack count identifies the number of items, not their material or performance.",
        "Dimensions, compatibility and any sterility claim require the manufacturer’s specification."
      ],
      "limitations": [
        "Published quality guidance is not an assay or certification of a HeartPep product.",
        "The listing is not a substitute for the manufacturer’s complete specification or lot documentation."
      ],
      "openQuestions": [
        "Confirm length, connection, material, manufacturer and exact model.",
        "Obtain packaging, lot traceability and any required sterility or conformity records."
      ],
      "studies": [
        {
          "id": "who-trs-1052-annex-4",
          "title": "WHO good practices for pharmaceutical quality control laboratories",
          "authors": "World Health Organization",
          "year": 2024,
          "journal": "WHO Technical Report Series 1052, Annex 4",
          "url": "https://www.who.int/publications/m/item/who-good-practices-for-pharmaceutical-quality-control-laboratories",
          "evidenceType": "reference",
          "design": "Technical guidance, sections 4.1, 5.3 and 5.4 consulted.",
          "findings": "Laboratory supplies require appropriate specifications and documented suitability checks.",
          "limitations": "General guidance does not test or certify these catalogue items.",
          "appliesTo": "identity-only",
          "verification": "full-text",
          "fullTextUrl": "https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/trs1052_annex4.pdf"
        }
      ],
      "search": {
        "date": "2026-11-08",
        "method": "Catalogue specification review and official technical-reference check",
        "queries": [
          "site.who.int \"TRS 1052\" \"Annex 4\" \"quality control laboratories\""
        ],
        "scope": "Regional catalogue labels and WHO 2024 guidance on laboratory supplies, equipment and reagents.",
        "limitations": "No independent performance testing of the supplied items was undertaken. This is a specification guide, not a biological literature review."
      }
    },
    {
      "slug": "oxytocin",
      "names": [
        "Oxytocin"
      ],
      "title": "Oxytocin",
      "kind": "compound",
      "summary": "A neuropeptide studied in social processing, relationships and sexual function. Laboratory signals of partner-related responses have not translated into a dependable general claim that a supplied product improves intimacy, relationships or mental health.",
      "identity": "This dossier covers the catalogue name Oxytocin. The studied clinical preparations and the supplier's listed material are not assumed to have the same formulation, exposure or manufacturing quality.",
      "evidenceOverview": "The selected evidence includes small partner-related experiments, a sexual-function placebo comparison, a larger autism trial and registered trust-game replications. The latter challenge a simple claim that oxytocin reliably increases trust.",
      "whatResearchShows": [
        "Two small experiments reported partner-specific attractiveness ratings and reward-region imaging responses in pair-bonded men.",
        "A sexual-function crossover trial found improvement over time in both oxytocin and placebo conditions, without a significant treatment difference.",
        "A larger autism trial did not find a significant advantage on its main social-function outcome. This is a different population and question, not a test of couples' relationships.",
        "Registered trust-game replications did not confirm a general increase in trusting behaviour; the 2026 pooled analysis includes the earlier 2020 cohort and must not be counted as wholly independent evidence."
      ],
      "limitations": [
        "Brain responses and laboratory ratings do not establish lasting relationship change or clinical effectiveness.",
        "Results in selected men, women with sexual dysfunction or autistic children cannot be generalized across populations.",
        "None of these studies validates catalogue batch quality, a particular supplied format or personal use."
      ],
      "openQuestions": [
        "Which reproducible outcomes, if any, depend on population and social context?",
        "Can well-controlled replication connect laboratory effects with meaningful longer-term outcomes?"
      ],
      "studies": [
        {
          "id": "pmid-24277856",
          "title": "Oxytocin enhances brain reward system responses in men viewing the face of their female partner",
          "authors": "Scheele D et al.",
          "year": 2013,
          "journal": "Proc Natl Acad Sci U S A",
          "url": "https://pubmed.ncbi.nlm.nih.gov/24277856/",
          "doi": "10.1073/pnas.1314190110",
          "pmid": "24277856",
          "evidenceType": "human",
          "design": "Two double-blind placebo-controlled within-person fMRI experiments, each involving 20 pair-bonded men.",
          "findings": "Partner-face ratings and selected reward-region responses increased relative to comparison faces.",
          "limitations": "Small, selected population and laboratory endpoints; no durable relationship outcome established.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3864312/"
        },
        {
          "id": "pmid-26151620",
          "title": "Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial",
          "authors": "Muin DA et al.",
          "year": 2015,
          "journal": "Fertil Steril",
          "url": "https://pubmed.ncbi.nlm.nih.gov/26151620/",
          "doi": "10.1016/j.fertnstert.2015.06.010",
          "pmid": "26151620",
          "evidenceType": "human",
          "design": "Randomized double-blind placebo-controlled crossover trial in 30 women with sexual dysfunction.",
          "findings": "Both conditions improved over time, with no significant treatment difference in the reported analyses.",
          "limitations": "Small clinical population; improvement cannot be attributed to oxytocin over placebo.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-34644471",
          "title": "Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder",
          "authors": "Sikich L et al.",
          "year": 2021,
          "journal": "N Engl J Med",
          "url": "https://pubmed.ncbi.nlm.nih.gov/34644471/",
          "doi": "10.1056/NEJMoa2103583",
          "pmid": "34644471",
          "evidenceType": "human",
          "design": "Randomized placebo-controlled 24-week trial enrolling 290 children and adolescents with autism.",
          "findings": "The primary social-function comparison was not significant; secondary results were generally similar between groups.",
          "limitations": "The modified primary scale was not validated and formulation-dependent exposure remained uncertain; sensitivity analyses were also negative. Not a study of adult intimacy.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9701092/"
        },
        {
          "id": "pmid-32514040",
          "title": "A registered replication study on oxytocin and trust",
          "authors": "Declerck CH et al.",
          "year": 2020,
          "journal": "Nat Hum Behav",
          "url": "https://pubmed.ncbi.nlm.nih.gov/32514040/",
          "pmid": "32514040",
          "evidenceType": "human",
          "design": "Large double-blind placebo-controlled registered replication of a trust-game experiment, including minimal-social-contact and no-contact conditions.",
          "findings": "No oxytocin effect was found in the planned minimal-social-contact condition; an exploratory subgroup observation required confirmation.",
          "limitations": "Economic-game transfers are a specific behavioural endpoint, not a general measure of intimacy, relationship health or all social behaviour.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "doi": "10.1038/s41562-020-0878-x"
        },
        {
          "id": "pmid-41880977",
          "title": "Absence of a meaningful effect of intranasal oxytocin on trusting behavior: a registered report with pooled equivalence testing",
          "authors": "Kroll CF et al.",
          "year": 2026,
          "journal": "Cortex",
          "url": "https://pubmed.ncbi.nlm.nih.gov/41880977/",
          "pmid": "41880977",
          "evidenceType": "human",
          "design": "Registered replication in 211 participants plus pooled analysis with the 321-participant Declerck dataset.",
          "findings": "No increased trust was identified. Pooled equivalence testing in 532 participants supported an effect within the study's predefined small range.",
          "limitations": "The pooled analysis reuses the 2020 participants and is not an independent additional cohort. Conclusions are specific to this task and equivalence margin.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "doi": "10.1016/j.cortex.2026.03.006",
          "fullTextUrl": "https://www.sciencedirect.com/science/article/pii/S0010945226000808"
        },
        {
          "id": "pmid-42998617",
          "title": "A UHPLC-MS/MS method for the quantification of oxytocin in human saliva",
          "authors": "Soloperto S, Mula J, Chiara F, et al.",
          "year": 2026,
          "journal": "Psychoneuroendocrinology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/42998617/",
          "doi": "10.1016/j.psyneuen.2026.108078",
          "pmid": "42998617",
          "evidenceType": "analytical",
          "design": "Analytical method validation for oxytocin quantification in human saliva using UHPLC–tandem mass spectrometry, including application to human samples.",
          "findings": "The authors reported usable measurements from collected saliva samples, with greater variability at low concentrations.",
          "limitations": "Abstract consulted. Assay performance applies to the studied sample matrix. The study did not establish a saliva-to-brain relationship or a treatment effect.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-42931765",
          "title": "Preoperative Intranasal Oxytocin and Probable Acute Stress Disorder After Traumatic Fracture Surgery: A Randomized Clinical Trial",
          "authors": "Huang Q et al.",
          "year": 2026,
          "journal": "JAMA Internal Medicine",
          "url": "https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2855600",
          "doi": "10.1001/jamainternmed.2026.5326",
          "pmid": "42931765",
          "evidenceType": "human",
          "design": "Single-centre randomized clinical trial in adults undergoing traumatic-fracture surgery.",
          "findings": "Fewer participants in the oxytocin group screened positive for probable acute stress disorder during early postoperative follow-up.",
          "limitations": "The screening result was not a diagnostic assessment. The trial does not establish longer-term outcomes, generalizability, or applicability to a catalogue product.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-20",
        "method": "Targeted PubMed-domain searches and original abstract checks, including controlled negative findings alongside laboratory social-response studies. Initial selection on 8 November was substantively extended on 9 November, with clinical searches, accessible full-text consultation and bounded publication-notice checks. Added a targeted November 2026 analytical source check. Also checked newly indexed or previously omitted original abstracts and identifiers.",
        "queries": [
          "site:pubmed.ncbi.nlm.nih.gov oxytocin 26151620 24277856",
          "site:pubmed.ncbi.nlm.nih.gov/26151620/",
          "site:pubmed.ncbi.nlm.nih.gov/24277856/",
          "site:pubmed.ncbi.nlm.nih.gov oxytocin autism randomized trial 2021 Sikich",
          "site:pubmed.ncbi.nlm.nih.gov oxytocin registered replication trust placebo large trial",
          "\"A registered replication study on oxytocin and trust\" correction",
          "site:sciencedirect.com \"10.1016/j.cortex.2026.03.006\"",
          "PMID 42998617 / DOI 10.1016/j.psyneuen.2026.108078",
          "PMID 42931765 / DOI 10.1001/jamainternmed.2026.5326"
        ],
        "scope": "Selected sexual/social human experiments, a larger clinical autism trial and registered trust-game replication evidence including a 2026 pooled analysis. Checked the PubMed abstract and DOI for the salivary oxytocin assay. Added selected human study records dated 2026, with study-specific limitations.",
        "limitations": "Not exhaustive. Full methods, results and limitations of PMID34644471 were consulted in PMC; other included studies remain abstract-verified. Nature subscription content and ScienceDirect access limits prevented full appraisal of the trust papers. Its complete retrieved PubMed record showed no linked retraction/erratum section; incomplete retrieval limited other notice checks. The new analytical source was reviewed at abstract level."
      },
      "discussion": [
        {
          "heading": "Replication narrows a broad trust narrative",
          "body": "The registered replications test a more specific proposition than whether oxytocin has any social effect. Their results weaken a general trust-increasing claim under the studied conditions. The 2026 pooled analysis also provides more precise evidence about the size of a possible effect, while depending partly on the 2020 dataset rather than supplying a third independent replication.",
          "citations": [
            "pmid-32514040",
            "pmid-41880977"
          ]
        },
        {
          "heading": "A substantial null clinical result still has boundaries",
          "body": "The larger autism trial found no treatment advantage, including in sensitivity analyses. Its full report also notes uncertainty about its modified primary scale and preparation-dependent absorption. Those limitations help define what was tested; they do not turn a null result into proof of effectiveness. Equally, this clinical study cannot determine whether every social context or another precisely defined outcome is unaffected.",
          "citations": [
            "pmid-34644471"
          ]
        },
        {
          "heading": "Laboratory attraction is not a relationship outcome",
          "body": "The small partner-face experiments examine ratings and neural responses. They do not demonstrate lasting trust, improved conflict resolution or healthier relationships. Those outcomes would require direct study rather than extrapolation from a scan.",
          "citations": [
            "pmid-24277856"
          ]
        },
        {
          "heading": "Saliva is a separate measurement question",
          "body": "The validated procedure addresses how to measure oxytocin in a particular specimen. Salivary concentration cannot by itself explain social behaviour, central exposure or responses to a nasal preparation.",
          "citations": [
            "pmid-42998617"
          ]
        }
      ]
    },
    {
      "slug": "pt-141",
      "names": [
        "PT-141"
      ],
      "title": "PT-141 (bremelanotide)",
      "kind": "compound",
      "summary": "Bremelanotide has controlled clinical evidence in a defined sexual-desire disorder and earlier intranasal pharmacology research. The study products are not interchangeable with catalogue materials.",
      "identity": "PT-141 is also known as bremelanotide, a melanocortin analogue. Identifying the compound does not establish a supplier product’s composition, delivery characteristics or batch quality.",
      "evidenceOverview": "The selected papers span early route-specific experiments, placebo-controlled phase 3 trials and an optional 52-week open-label extension with substantial attrition.",
      "whatResearchShows": [
        "A positive questionnaire endpoint in a defined disorder cannot be generalized to everyone or every sexual-function outcome.",
        "An intranasal research paper is relevant background for that route, but does not validate another spray formulation."
      ],
      "limitations": [
        "Adverse effects and tolerability are part of the results, not evidence that catalogue products are suitable for personal use.",
        "No cited trial tested the supplied research products or their exact containers and formulations."
      ],
      "openQuestions": [
        "Is the paper studying desire, distress, erectile response or another endpoint?",
        "Does the experimental material match the molecule, formulation and analytical specification in the source?"
      ],
      "studies": [
        {
          "id": "pmid-31599840",
          "title": "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials",
          "authors": "Kingsberg SA, Clayton AH, Portman D, et al.",
          "year": 2019,
          "journal": "Obstetrics & Gynecology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/31599840/",
          "doi": "10.1097/AOG.0000000000003500",
          "pmid": "31599840",
          "evidenceType": "human",
          "design": "Two 24-week randomized double-blind placebo-controlled RECONNECT trials;1,267 premenopausal women with hypoactive sexual desire disorder were randomized.",
          "findings": "The clinical formulation improved desire and related-distress scores versus placebo. The key secondary count of satisfying sexual events did not differ significantly; nausea, flushing and headache were more common.",
          "limitations": "Differential withdrawal rates and last-observation-carried-forward analyses complicate interpretation. Selected full-text methods, endpoint hierarchy and limitations sections were consulted.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6819021/"
        },
        {
          "id": "pmid-14963471",
          "title": "Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction",
          "authors": "Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB.",
          "year": 2004,
          "journal": "International Journal of Impotence Research",
          "url": "https://pubmed.ncbi.nlm.nih.gov/14963471/",
          "doi": "10.1038/sj.ijir.3901139",
          "pmid": "14963471",
          "evidenceType": "human",
          "design": "Early double-blind placebo-controlled intranasal studies in healthy men and sildenafil-responsive men with erectile dysfunction; objective erectile responses were measured.",
          "findings": "An erectile response was observed with the study formulation. Flushing and nausea were the common reported adverse effects.",
          "limitations": "Early pharmacology experiments in selected men. A matching route name does not make a current catalogue spray equivalent in composition, delivery or quality.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-31599847",
          "title": "Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder",
          "authors": "Simon JA, Kingsberg SA, Portman D, et al.",
          "year": 2019,
          "journal": "Obstetrics & Gynecology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/31599847/",
          "doi": "10.1097/AOG.0000000000003514",
          "pmid": "31599847",
          "evidenceType": "human",
          "design": "Optional 52-week open-label extension for eligible completers of the RECONNECT trials, with descriptive analyses and no continued placebo arm.",
          "findings": "Of 684 women entering the extension,272 completed it. Desire and distress improvements were described in the continuing cohort; nausea, flushing and headache remained prominent adverse effects.",
          "limitations": "Participants were selected from trial completers without serious core-phase adverse events. Attrition and lack of blinding/comparator limit causal interpretation of sustained benefit and safety.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.",
        "queries": [
          "\"31599840\" bremelanotide",
          "site.pubmed.ncbi.nlm.nih.gov PT-141 intranasal double blind 2004 men",
          "\"Bremelanotide for the Treatment of Hypoactive\" \"Kingsberg\" \"2019\"",
          "site.pubmed.ncbi.nlm.nih.gov bremelanotide long term safety 52 week extension 2019",
          "site.pmc.ncbi.nlm.nih.gov/articles/PMC6819021 \"satisfying sexual events\""
        ],
        "scope": "Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research."
      },
      "discussion": [
        {
          "heading": "The endpoint hierarchy limits the headline",
          "body": "RECONNECT met its desire and distress coprimary endpoints. The key secondary count of satisfying sexual events did not significantly differ, after which later ranked endpoints were supportive or exploratory. This does not erase the primary findings; it identifies what improved and what did not. Differential withdrawals and the handling of missing observations further matter when interpreting the size and persistence of the effect. A review should retain this endpoint structure rather than flatten every sexual-function measure into one positive result.",
          "citations": [
            "pmid-31599840"
          ]
        },
        {
          "heading": "Longer follow-up is useful, but the cohort is selected",
          "body": "The 52-week extension describes people who completed the core trial, remained eligible and chose to continue; only 272 of 684 entrants completed the extension. Without continued blinding and a placebo comparator, changes in that group cannot provide the same causal estimate as the original randomised phase. The earlier nasal paper is also route-specific experimental evidence, not proof of equivalence between any commercial nasal preparation and the later injected medicine. These sources answer different questions about time, population and delivery.",
          "citations": [
            "pmid-31599847",
            "pmid-14963471"
          ]
        }
      ]
    },
    {
      "slug": "r3ta",
      "names": [
        "R3ta"
      ],
      "title": "R3ta",
      "kind": "identity-pending",
      "summary": "The catalogue uses an abbreviated label. This review does not treat the spelling as confirmation of retatrutide or transfer clinical trial results to an unidentified product.",
      "identity": "The catalogue name is a supplier label, not an authenticated molecular specification. This note preserves the exact published names without assigning an unverified identity.",
      "evidenceOverview": "Identity unresolved. No biological evidence is attributed to this product here. This is an evidence-matching gap, not a statement that no research exists.",
      "whatResearchShows": [
        "A meaningful literature review needs an identified substance or a defined mixture. Studies of an assumed ingredient would answer a different question."
      ],
      "limitations": [
        "No confirmed sequence, complete composition or matched chemical specification is available in the catalogue record used for this note.",
        "A general research paper or another seller’s blend formula cannot establish the contents, stability or effects of this listing."
      ],
      "openQuestions": [
        "Confirm the exact peptide identity and formulation against the supplier specification and analytical report.",
        "Once the identity is confirmed, which primary studies match that exact compound, route and formulation?"
      ],
      "studies": [],
      "search": {
        "date": "2026-11-08",
        "method": "Identity-gated catalogue review",
        "queries": [],
        "scope": "Exact supplier labels and published catalogue specifications were checked. Biological literature was not attributed while the identity remained unresolved.",
        "limitations": "This is an identity note, not a negative literature search. It cannot show that relevant studies do not exist."
      }
    },
    {
      "slug": "retatrutide",
      "names": [
        "Retatrutide"
      ],
      "title": "Retatrutide",
      "kind": "compound",
      "summary": "Retatrutide research now includes phase 3 human results as well as earlier phase 2 work. That progress concerns defined investigational preparations, not validation of catalogue products.",
      "identity": "Retatrutide is a single peptide with GIP, GLP-1 and glucagon receptor agonist activity. The opaque catalogue label R3ta is not assumed to identify the same material.",
      "evidenceOverview": "Selected evidence includes phase 2 and 3 obesity trials, a phase 3 knee osteoarthritis report and registry results from a phase 2b kidney function trial.",
      "whatResearchShows": [
        "The phase 2 trial reported dose-related weight changes and gastrointestinal adverse events [1].",
        "TRIUMPH-1 provides larger, longer placebo-controlled evidence, including prespecified osteoarthritis and sleep-apnoea subgroup outcomes [2].",
        "The 2026 knee osteoarthritis report adds a stand-alone randomized comparison and a fuller account of the previously reported TRIUMPH-1 subgroup [4].",
        "Phase 2b registry results did not show a clear difference in the trial’s primary kidney filtration measure [5]."
      ],
      "limitations": [
        "A trial publication does not establish a current marketing authorization, nor equivalence to any catalogue vial or nasal product.",
        "Different analysis strategies for different outcomes require care. Manufacturer funding, missing-data handling and uncommon adverse effects require full-paper appraisal."
      ],
      "openQuestions": [
        "How do the results replicate across populations, longer follow-up and outcome-specific studies?",
        "What do complete protocols, supplementary data and independent analyses add to the abstract-level findings?"
      ],
      "studies": [
        {
          "id": "pmid-37366315",
          "title": "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial",
          "authors": "Jastreboff AM, Kaplan LM, Frías JP, et al.",
          "year": 2023,
          "journal": "New England Journal of Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/37366315/",
          "doi": "10.1056/NEJMoa2301972",
          "pmid": "37366315",
          "evidenceType": "human",
          "design": "48-week double-blind randomized placebo-controlled phase 2 trial involving 338 adults.",
          "findings": "The largest mean weight reduction reported at 48 weeks was 24.2%, versus 2.1% with placebo. Gastrointestinal events and increases in heart rate were reported.",
          "limitations": "Dose-finding trial, not a comparison with other medicines or evidence for a supplied research formulation. Long-term and rare harms are not settled by this sample.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-42814954",
          "title": "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity",
          "authors": "Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators",
          "year": 2026,
          "journal": "New England Journal of Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/42814954/",
          "doi": "10.1056/NEJMoa2604169",
          "pmid": "42814954",
          "evidenceType": "human",
          "design": "80-week double-blind randomized phase 3 placebo-controlled trial in 2,339 adults with obesity without diabetes.",
          "findings": "Mean weight change ranged from -17.6% to -25.0% across retatrutide groups, versus -3.9% with placebo. Gastrointestinal events were the most common adverse events.",
          "limitations": "Defined investigational formulation and selected population. Subgroup outcomes use specified estimands, and the abstract is not a complete safety assessment. No catalogue product was tested.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-42810372",
          "title": "Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial",
          "authors": "Bellido V, le Roux CW, Ekinci EI, et al.",
          "year": 2026,
          "journal": "The Lancet",
          "url": "https://pubmed.ncbi.nlm.nih.gov/42810372/",
          "evidenceType": "human",
          "design": "80-week randomized placebo-controlled trial in 1,152 adults with obesity or overweight and type 2 diabetes.",
          "findings": "Average weight reductions favoured retatrutide. Gastrointestinal events, hypotension and dysesthesia were more frequent in active groups, and discontinuation varied by trial group.",
          "limitations": "Different population from TRIUMPH-1, with background glucose-lowering treatment in most participants. Manufacturer-funded and not a direct comparison against another weight-management medicine.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "doi": "10.1016/S0140-6736(26)01861-1",
          "pmid": "42810372"
        },
        {
          "id": "pmid-43001755",
          "title": "Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity",
          "authors": "Schnitzer TJ, Hunter DJ, Conaghan PG, et al.",
          "year": 2026,
          "journal": "New England Journal of Medicine",
          "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2610676",
          "doi": "10.1056/NEJMoa2610676",
          "pmid": "43001755",
          "fullTextUrl": "https://eprints.whiterose.ac.uk/id/eprint/247091/1/NEJMoa2610676-manuscript.pdf",
          "evidenceType": "human",
          "design": "Two double-blind, randomized phase 3 comparisons of subcutaneous retatrutide with placebo in adults with overweight or obesity and painful knee osteoarthritis, without diabetes. TRIUMPH-4 enrolled 445. TRIUMPH-1-OA reports 574 participants already included in TRIUMPH-1.",
          "findings": "In TRIUMPH-4, placebo-adjusted improvements in pain were 1.61 and 1.83 points on the 0–10 WOMAC scale at week 68 under the primary hybrid analysis. Both trials reported gastrointestinal events and more altered sensations (dysesthesia) with retatrutide.",
          "limitations": "Sponsor-funded trials in a selected population. The trials did not test structural progression or avoidance of knee replacement. Consulted the journal abstract and the full peer-reviewed accepted manuscript in a university repository.",
          "appliesTo": "exact-compound",
          "verification": "full-text"
        },
        {
          "id": "nct05936151",
          "title": "TRANSCEND-CKD: retatrutide and renal function (NCT05936151)",
          "authors": "Eli Lilly and Company (sponsor)",
          "year": 2026,
          "journal": "ClinicalTrials.gov registry results",
          "url": "https://clinicaltrials.gov/study/NCT05936151?tab=results",
          "evidenceType": "human",
          "design": "Double-masked, randomized phase 2b trial in 146 adults with overweight or obesity and chronic kidney disease, with or without type 2 diabetes. Registry results first posted 9 November 2026.",
          "findings": "At 24 weeks, the primary analysis of iohexol-measured kidney filtration included 113 participants. The estimated difference was −1.44 mL/min/1.73 m² (95% CI −9.17 to 6.30, p = 0.714). Serious adverse events were reported in 9 of 73 retatrutide recipients and 6 of 69 placebo recipients.",
          "limitations": "Sponsor-submitted registry tables. The short follow-up and missing filtration measurements limit conclusions about long-term kidney outcomes. The available journal paper linked in the record describes the design and baseline characteristics.",
          "appliesTo": "exact-compound",
          "verification": "record"
        },
        {
          "id": "pmid-42904878",
          "title": "Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea",
          "authors": "Grunstein RR et al.",
          "year": 2026,
          "journal": "New England Journal of Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/42904878/",
          "doi": "10.1056/NEJMoa2611477",
          "pmid": "42904878",
          "evidenceType": "human",
          "design": "Prespecified sleep-apnea analyses within the randomized TRIUMPH-1 and TRIUMPH-2 trials.",
          "findings": "The report found greater reductions in the apnea–hypopnea index with retatrutide than with placebo in the analyzed groups.",
          "limitations": "This separate publication uses groups within the parent trials and is not independent replication. It does not establish effects beyond the enrolled populations or validate a catalogue product.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-20",
        "method": "Targeted PubMed, journal, university repository and ClinicalTrials.gov results check. Also checked newly indexed or previously omitted original abstracts and identifiers.",
        "queries": [
          "PubMed: retatrutide OR LY3437943, 6–16 November 2026 entry or publication dates",
          "PMID 43001755 / DOI 10.1056/NEJMoa2610676",
          "ClinicalTrials.gov NCT05931367, NCT05929066 and NCT05936151",
          "PMID 42904878 / DOI 10.1056/NEJMoa2611477"
        ],
        "scope": "Reviewed the knee osteoarthritis accepted manuscript and publisher abstract, checked both registration records and read the posted TRANSCEND-CKD results tables. Added selected human study records dated 2026, with study-specific limitations.",
        "limitations": "Selected outcomes and safety results. Earlier obesity papers are summarised at abstract level. Supplements and individual participant data were outside this review."
      },
      "discussion": [
        {
          "heading": "The 2026 evidence is broader, but populations remain distinct",
          "body": "Describing retatrutide solely as a phase 2 candidate would omit the phase 3 publications now available. TRIUMPH-1 studied obesity without diabetes, while TRIUMPH-2 included type 2 diabetes and generally background medication. Their weight-change percentages should therefore not be treated as interchangeable expectations or compared as though patients were randomized between these populations. The later trial also reports tolerability findings beyond gastrointestinal events. Its value is a larger, separately defined clinical comparison, rather than a reason to transfer results to a differently formulated commercial research product.",
          "citations": [
            "pmid-42814954",
            "pmid-42810372"
          ]
        },
        {
          "heading": "Outcome definitions and analysis choices matter",
          "body": "TRIUMPH-1 combines a main obesity question with prespecified osteoarthritis and sleep-apnoea subgroup questions. Weight and subgroup outcomes do not all use identical strategies for handling treatment interruption, so their effect estimates require the corresponding analysis definition. TRIUMPH-2 explicitly uses a treatment-regimen approach with imputation for missing observations. These features should be examined in protocols and supplements before undertaking a meta-analysis or making comparative claims. None of the trials is a direct head-to-head comparison with semaglutide or tirzepatide, and publication alone does not establish regulatory approval.",
          "citations": [
            "pmid-42814954",
            "pmid-42810372"
          ]
        },
        {
          "heading": "Separate the knee pain result from disease modification",
          "body": "The additional independent comparison is TRIUMPH-4. TRIUMPH-1-OA expands the result for a subgroup already reported by Jastreboff and colleagues, so counting those participants twice would exaggerate the amount of evidence. The intention-to-treat sensitivity analysis also favoured retatrutide on pain, with smaller differences. In TRIUMPH-4, any adverse event led to discontinuation in 12.8–18.2% of the active groups versus 4.0% with placebo. The symptom results leave open whether weight loss accounts for the improvement and whether the treatment alters joint structure or the likelihood of surgery.",
          "citations": [
            "pmid-43001755",
            "pmid-42814954"
          ]
        },
        {
          "heading": "The prespecified kidney filtration endpoint was inconclusive",
          "body": "The trial detected no clear difference in measured filtration. A secondary comparison of urine albumin-to-creatinine ratio favoured retatrutide, based on 42 participants. The smaller sample and secondary status limit interpretation. Neither result establishes whether retatrutide slows chronic kidney disease over time.",
          "citations": [
            "nct05936151"
          ]
        }
      ]
    },
    {
      "slug": "selank",
      "names": [
        "Selank"
      ],
      "title": "Selank",
      "kind": "compound",
      "summary": "An experimental peptide investigated in anxiety-related symptom studies and brain-connectivity experiments. The selected human evidence is preliminary and does not establish dependable clinical effectiveness or the performance of catalogue formulations.",
      "identity": "This dossier covers the exact catalogue name Selank. A supplier name is not analytical confirmation of peptide sequence, composition or pharmaceutical equivalence.",
      "evidenceOverview": "Three small clinical reports and an acute imaging study provide preliminary human evidence. Clinical comparisons use other drugs or adjunct treatment rather than a clearly described, independently replicated placebo-controlled programme.",
      "whatResearchShows": [
        "A 62-patient study reported similar anxiety-related effects for Selank and medazepam in its selected diagnostic groups.",
        "A separate 52-person study examined Semax, Selank and placebo in different groups and reported connectivity differences. It did not test a Semax/Selank mixture.",
        "Additional reports compare Selank with phenazepam or add Selank to phenazepam. Positive authors' conclusions require cautious reading because comparator and adjunct designs answer different questions."
      ],
      "limitations": [
        "The older clinical paper is Russian-language; this review verified its English abstract rather than the complete report.",
        "A small active-comparator study cannot, by itself, establish equivalence to a treatment standard or exclude placebo and bias effects.",
        "Acute imaging findings do not establish durable symptom relief. The papers do not validate any supplied vial or nasal formulation, manufacturing quality or longer-term safety."
      ],
      "openQuestions": [
        "Would larger, independently replicated placebo-controlled trials confirm meaningful symptom changes?",
        "Are effects reproducible across populations and verified formulations, and how durable are they?"
      ],
      "studies": [
        {
          "id": "pmid-18454096",
          "title": "Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia",
          "authors": "Zozulia AA et al.",
          "year": 2008,
          "journal": "Zh Nevrol Psikhiatr Im S S Korsakova",
          "url": "https://pubmed.ncbi.nlm.nih.gov/18454096/",
          "pmid": "18454096",
          "evidenceType": "human",
          "design": "Clinical comparison of Selank and medazepam in 62 patients; PubMed indexes a randomized trial.",
          "findings": "The abstract reports similar anxiety-related effects between groups.",
          "limitations": "Small active-comparator study; Russian full text not reviewed and no placebo arm described in the abstract.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-32342318",
          "title": "Functional Connectomic Approach to Studying Selank and Semax Effects",
          "authors": "Panikratova YR et al.",
          "year": 2020,
          "journal": "Dokl Biol Sci",
          "url": "https://pubmed.ncbi.nlm.nih.gov/32342318/",
          "doi": "10.1134/S001249662001007X",
          "pmid": "32342318",
          "evidenceType": "human",
          "design": "Acute resting-state fMRI study in 52 healthy participants receiving Semax, Selank or placebo separately.",
          "findings": "The authors reported amygdala-to-temporal-cortex connectivity differences.",
          "limitations": "Surrogate imaging endpoints; neither clinical effectiveness nor combined-blend effects established.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-25176261",
          "title": "A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders",
          "authors": "Medvedev VE et al.",
          "year": 2014,
          "journal": "Zh Nevrol Psikhiatr Im S S Korsakova",
          "url": "https://pubmed.ncbi.nlm.nih.gov/25176261/",
          "pmid": "25176261",
          "evidenceType": "human",
          "design": "Clinical comparison with phenazepam in 60 patients with anxiety-related or somatoform diagnoses.",
          "findings": "The abstract reports improved anxiety-related measures and quality of life with Selank.",
          "limitations": "No placebo comparison or clear randomization/blinding description in the accessible abstract; Russian full methods were not reviewed.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-26356395",
          "title": "Optimization of the treatment of anxiety disorders with selank",
          "authors": "Medvedev VE et al.",
          "year": 2015,
          "journal": "Zh Nevrol Psikhiatr Im S S Korsakova",
          "url": "https://pubmed.ncbi.nlm.nih.gov/26356395/",
          "pmid": "26356395",
          "evidenceType": "human",
          "design": "Comparison of phenazepam alone in 30 patients with Selank plus phenazepam in 40 patients.",
          "findings": "The report describes earlier improvement and fewer reported phenazepam-associated adverse effects with adjunct Selank.",
          "limitations": "An adjunct-treatment result does not establish Selank monotherapy. Allocation and blinding are not clear from the abstract.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "doi": "10.17116/jnevro20151156133-40"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted PubMed-domain searches and checks of original indexed study abstracts and citation metadata. Initial selection on 8 November was substantively extended on 9 November, with clinical searches, accessible full-text consultation and bounded publication-notice checks.",
        "queries": [
          "site:pubmed.ncbi.nlm.nih.gov Selank 18454096",
          "site:pubmed.ncbi.nlm.nih.gov/18454096/",
          "site:pubmed.ncbi.nlm.nih.gov/32342318/",
          "site:pubmed.ncbi.nlm.nih.gov \"Selank\" randomized anxiety placebo",
          "site:pubmed.ncbi.nlm.nih.gov Selank clinical trial phenazepam anxiety",
          "site:pubmed.ncbi.nlm.nih.gov/26356395/",
          "site:pubmed.ncbi.nlm.nih.gov/26356395/ \"Material\" \"Results\"",
          "\"Optimization of the treatment of anxiety disorders with selank\" full text"
        ],
        "scope": "Selected human anxiety comparisons, adjunct-treatment evidence and healthy-participant brain-connectivity research.",
        "limitations": "Abstract-based narrative selection; Russian full reports were not reliably available. Some PubMed record pages returned incomplete content. No comprehensive correction/retraction or trial-registry audit is claimed."
      },
      "discussion": [
        {
          "heading": "Comparator and adjunct questions differ",
          "body": "The 2014 study compares one treatment with another; the 2015 study asks about adding Selank to phenazepam. Those results should not be combined into a general claim about Selank alone. In particular, a reported reduction in another drug's adverse effects is not evidence that Selank itself has no adverse effects or clinically important interactions.",
          "citations": [
            "pmid-25176261",
            "pmid-26356395"
          ]
        },
        {
          "heading": "Positive abstracts leave methodological uncertainty",
          "body": "These reports justify examining the full methods and seeking independent replication. Without a clearly documented placebo condition, masking and allocation procedure, improvement can reflect several influences besides a compound-specific effect. Diagnostic differences and different clinical scales also limit comparison across reports. Acute connectivity measurements address yet another question and cannot substitute for durable symptom outcomes.",
          "citations": [
            "pmid-25176261",
            "pmid-26356395",
            "pmid-32342318"
          ]
        }
      ]
    },
    {
      "slug": "semaglutide",
      "names": [
        "Semaglutide"
      ],
      "title": "Semaglutide",
      "kind": "compound",
      "summary": "Large randomized trials support weight outcomes for defined clinical semaglutide preparations. They do not establish equivalence to a research-catalogue vial or nasal product.",
      "identity": "Semaglutide is a GLP-1 receptor agonist. Evidence depends on the actual pharmaceutical preparation, study population and protocol, not the compound name alone.",
      "evidenceOverview": "Selected adult clinical studies cover obesity, heart-failure physiology and cardiovascular events. An adolescent registry result and an ex vivo placental study answer separate questions.",
      "whatResearchShows": [
        "STEP 1 found greater average weight reduction with the studied semaglutide preparation plus lifestyle support than with placebo [1].",
        "SURMOUNT-5 found a larger average reduction with tirzepatide than semaglutide under its particular comparison [2].",
        "An adolescent trial posted descriptive BMI results comparing two care programmes with different counselling intensity [4].",
        "In a small heart-failure trial with obesity, exercise filling pressure was lower with semaglutide than placebo [6].",
        "A secondary analysis of the oral semaglutide SOUL trial reported fewer first and recurrent cardiovascular events in a high-risk population [7].",
        "A short laboratory experiment found fetal-side concentrations below the assay’s quantification limit in term placental tissue [8]."
      ],
      "limitations": [
        "Neither trial tested HeartPep material, nasal formulations or equivalence between catalogue formats.",
        "Trial averages do not predict individual outcomes. Adverse events and treatment discontinuation matter alongside efficacy, and comparisons across unrelated trials can mislead."
      ],
      "openQuestions": [
        "How do outcomes vary across populations and after treatment discontinuation?",
        "What formulation-specific quality, exposure and comparability evidence exists for any material under investigation?"
      ],
      "studies": [
        {
          "id": "pmid-33567185",
          "title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity",
          "authors": "Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group",
          "year": 2021,
          "journal": "New England Journal of Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/",
          "doi": "10.1056/NEJMoa2032183",
          "pmid": "33567185",
          "evidenceType": "human",
          "design": "68-week randomized placebo-controlled trial in 1,961 adults without diabetes, with lifestyle intervention in both groups.",
          "findings": "Mean body-weight change was approximately -14.9% with semaglutide and -2.4% with placebo.",
          "limitations": "A defined clinical preparation and selected population were studied. Gastrointestinal adverse effects were relevant; this is not evidence for catalogue-product equivalence.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-40353578",
          "title": "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity",
          "authors": "Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators",
          "year": 2025,
          "journal": "New England Journal of Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40353578/",
          "doi": "10.1056/NEJMoa2416394",
          "pmid": "40353578",
          "evidenceType": "human",
          "design": "72-week open-label randomized comparison in 751 adults with obesity without diabetes.",
          "findings": "Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide; gastrointestinal events were common.",
          "limitations": "Open-label, manufacturer-funded comparison of defined clinical preparations, without a placebo arm. It did not test commercial research-catalogue products.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-35441470",
          "title": "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension",
          "authors": "Wilding JPH, Batterham RL, Davies M, et al.; STEP 1 Study Group",
          "year": 2022,
          "journal": "Diabetes, Obesity and Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/35441470/",
          "evidenceType": "human",
          "design": "Exploratory one-year off-treatment follow-up of 327 STEP 1 participants; study treatment and lifestyle intervention were both discontinued.",
          "findings": "Participants previously receiving semaglutide regained approximately two-thirds of their prior weight loss on average, with several cardiometabolic measures moving towards baseline.",
          "limitations": "Selected extension subset, not a new randomized withdrawal comparison. Withdrawal of lifestyle support prevents assigning every observed change solely to drug withdrawal.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "doi": "10.1111/dom.14725",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/",
          "pmid": "35441470"
        },
        {
          "id": "nct04873245",
          "title": "Lifestyle Counseling and Medication for Adolescent Weight Management (NCT04873245)",
          "authors": "University of Minnesota (sponsor)",
          "year": 2026,
          "journal": "ClinicalTrials.gov registry results",
          "url": "https://clinicaltrials.gov/study/NCT04873245?tab=results",
          "evidenceType": "human",
          "design": "Open-label randomized phase 2 trial in 121 adolescents with severe obesity. It compared semaglutide plus less intensive behavioural counselling with intensive counselling alone. Registry results first posted 6 November 2026.",
          "findings": "At week 56, the posted mean BMI changes were −22.3% in the medication arm (58 analysed) and −1.8% with intensive counselling (50 analysed). Serious adverse events were reported in 1 of 60 and 2 of 61 participants, respectively.",
          "limitations": "Sponsor-submitted results. The primary table does not display a between-group statistical analysis. The two groups had different counselling schedules, and some randomized participants were excluded from the primary measurements.",
          "appliesTo": "exact-compound",
          "verification": "record"
        },
        {
          "id": "pmid-43033821",
          "title": "Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial",
          "authors": "Wharton S, Broholm C, Horn D, et al.",
          "year": 2026,
          "journal": "The Lancet Diabetes & Endocrinology",
          "url": "https://www.sciencedirect.com/science/article/pii/S2213858726002755",
          "doi": "10.1016/S2213-8587(26)00275-5",
          "pmid": "43033821",
          "evidenceType": "human",
          "design": "REDEFINE 9 (NCT06388187), a randomized phase 3b trial of two subcutaneous cagrilintide–semaglutide combinations versus placebo in 309 adults without diabetes. Published 14 November 2026.",
          "findings": "At week 68, the efficacy analysis estimated placebo-adjusted differences in weight change of −18.8 and −19.0 percentage points. Adverse events were common in all arms, mostly mild or moderate and gastrointestinal.",
          "limitations": "Sponsor-funded. There was no single-component arm. The primary comparisons each tested an active regimen against placebo. Publisher abstract and accessible excerpts consulted.",
          "appliesTo": "related-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-43000472",
          "title": "Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial",
          "authors": "Borlaug BA, Jensen MD, Packer M, et al.",
          "year": 2026,
          "journal": "Nature Medicine",
          "url": "https://www.nature.com/articles/s41591-026-04762-3",
          "doi": "10.1038/s41591-026-04762-3",
          "pmid": "43000472",
          "evidenceType": "human",
          "design": "Double-blind, randomized 52-week study in 81 adults with obesity and heart failure with preserved ejection fraction. Primary endpoint was invasively measured cardiac filling pressure during low-intensity exercise. NCT05371496.",
          "findings": "At 52 weeks, the estimate favoured semaglutide by 10.6 mmHg versus placebo (95% CI 8.0 to 13.3 mmHg lower).",
          "limitations": "Small mechanistic study in a defined population. Publisher and PubMed abstracts consulted.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-43013292",
          "title": "First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial",
          "authors": "Marx N, Deanfield JE, Mulvagh SL, et al.",
          "year": 2026,
          "journal": "JAMA Cardiology",
          "url": "https://jamanetwork.com/journals/jamacardiology/fullarticle/2856457",
          "doi": "10.1001/jamacardio.2026.4944",
          "pmid": "43013292",
          "evidenceType": "human",
          "design": "Prespecified secondary analysis of SOUL (NCT03914326), a randomized oral semaglutide trial in 9,650 adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both.",
          "findings": "The analysis counted 683 first or subsequent major cardiovascular events with oral semaglutide and 791 with placebo (mean ratio 0.86, 95% CI 0.76–0.97). Adverse events led to discontinuation in 15.5% versus 11.6%.",
          "limitations": "Sponsor-funded, secondary analysis of the original cohort. The studied oral formulation and high-risk population define the scope.",
          "appliesTo": "exact-compound",
          "verification": "full-text"
        },
        {
          "id": "pmid-43025349",
          "title": "Evaluation of semaglutide in an ex vivo human placental perfusion model to estimate maternal-fetal transfer",
          "authors": "Chan E, Zabek M, Balluku A, et al.",
          "year": 2026,
          "journal": "Placenta",
          "url": "https://pubmed.ncbi.nlm.nih.gov/43025349/",
          "doi": "10.1016/j.placenta.2026.11.007",
          "pmid": "43025349",
          "evidenceType": "laboratory",
          "design": "Laboratory study using eight perfusions of isolated human term placental tissue under two exposure conditions.",
          "findings": "Semaglutide concentrations in the fetal-side perfusate were below the assay’s quantification limit in both conditions.",
          "limitations": "Short ex vivo experiment in tissue from term pregnancies. PubMed abstract consulted. The result cannot establish absence of transfer in early pregnancy or clinical safety.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-43025770",
          "title": "Weight loss at a cost: Semaglutide and PYY3-36 aggravate pre-existing metabolic osteoporosis in female Wistar rats",
          "authors": "Kloock S, Zytner P, Geiger N, et al.",
          "journal": "Bone",
          "year": 2026,
          "url": "https://pubmed.ncbi.nlm.nih.gov/43025770/",
          "doi": "10.1016/j.bone.2026.118170",
          "pmid": "43025770",
          "evidenceType": "animal",
          "design": "Controlled female rat study with an induced model of metabolic osteoporosis and separate semaglutide, PYY3-36 and combination groups.",
          "findings": "The semaglutide-only group showed a modest reduction in trabecular bone volume fraction. Trabecular changes were more pronounced in the PYY3-36 and combined groups. Cortical measures were unaffected.",
          "limitations": "PubMed abstract consulted. The disease model, species and bone measurements limit translation to human bone health and clinical fracture risk.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-43010688",
          "title": "Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation",
          "authors": "Aubrac G et al.",
          "year": 2026,
          "journal": "Diabetes, Obesity and Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/43010688/",
          "doi": "10.1111/dom.71550",
          "pmid": "43010688",
          "evidenceType": "human",
          "design": "Claims-based observational comparison of adults with overweight or obesity and atherosclerotic cardiovascular disease, without diabetes.",
          "findings": "The adjusted primary comparison did not detect a statistically significant difference in major adverse cardiovascular events between the two groups.",
          "limitations": "This is not a randomized or equivalence trial. Residual confounding is possible, and the study does not establish interchangeability or the performance of a catalogue product.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-43022342",
          "title": "Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes",
          "authors": "Doma M et al.",
          "year": 2026,
          "journal": "American Heart Journal Plus: Cardiology Research and Practice",
          "url": "https://www.sciencedirect.com/science/article/pii/S2666602226002934",
          "doi": "10.1016/j.ahjo.2026.101003",
          "pmid": "43022342",
          "evidenceType": "human",
          "design": "Propensity-matched retrospective TriNetX cohort of people with atherosclerotic cardiovascular disease and without diabetes.",
          "findings": "The analysis did not detect a statistically significant difference between the groups for the reported cardiovascular composite outcomes.",
          "limitations": "Matching does not exclude residual confounding, and a null difference does not establish equivalence. Cohort overlap with other US database studies was not assessed. This is not evidence about any catalogue product.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-20",
        "method": "Targeted PubMed and ClinicalTrials.gov surveillance and review of the QUEST results tables. Also checked newly indexed or previously omitted original abstracts and identifiers.",
        "queries": [
          "PubMed: semaglutide, 6–16 November 2026 entry or publication dates",
          "ClinicalTrials.gov semaglutide results postings",
          "NCT04873245 QUEST adolescent weight management",
          "PMID 43033821 / DOI 10.1016/S2213-8587(26)00275-5",
          "PMID 43000472 / DOI 10.1038/s41591-026-04762-3",
          "PMID 43013292 / DOI 10.1001/jamacardio.2026.4944",
          "PMID 43025349 / DOI 10.1016/j.placenta.2026.11.007",
          "PMID 43025770 / DOI 10.1016/j.bone.2026.118170",
          "PMID 43010688 / DOI 10.1111/dom.71550",
          "PMID 43022342 / DOI 10.1016/j.ahjo.2026.101003"
        ],
        "scope": "Checked the registry methods, participant numbers, primary outcome and adverse-event counts against the existing adult clinical discussion. Reviewed the REDEFINE 9 publisher abstract and accessible article excerpts. Read the CAMEO-SEMA abstract from the publisher and PubMed. Reviewed the SOUL secondary paper’s accessible methods, results and limitations. Read the PubMed abstract for the term-placenta perfusion experiment. Checked a rat bone study at abstract level. Added selected human study records dated 2026, with study-specific limitations.",
        "limitations": "QUEST is registry-only in this review. Access varied by source and is labelled in the bibliography. Selected studies cannot establish effects across formulations, ages or pregnancy stages."
      },
      "discussion": [
        {
          "heading": "Read the comparison, population and preparation together",
          "body": "STEP 1 estimates a treatment effect in a defined population receiving lifestyle support, not an inherent percentage of weight loss attached to a molecule. SURMOUNT-5 improves on comparisons between separate trials by randomly assigning participants directly between two medicines, but it was open-label and compared particular tolerated clinical regimens. Its findings do not prove that one compound will be preferable for every outcome or every person. Neither trial provides a bridge from its controlled pharmaceutical preparation to a catalogue product with a different formulation or route.",
          "citations": [
            "pmid-33567185",
            "pmid-40353578"
          ]
        },
        {
          "heading": "The withdrawal extension changes the durability question",
          "body": "The STEP 1 extension adds a necessary qualification to an end-of-treatment headline: maintaining an effect after withdrawal is a separate research question. Average regain was substantial, but only a subset entered this exploratory follow-up. Both medication and structured lifestyle intervention stopped, so the design does not isolate the causal contribution of each change. Its 327 participants must not be mistaken for the original 1,961-person randomized population. This is valuable follow-up evidence, with different inferential strength from a new randomized continuation-versus-withdrawal trial.",
          "citations": [
            "pmid-35441470"
          ]
        },
        {
          "heading": "The adolescent trial compared two care programmes",
          "body": "The contrast concerns two programmes that differed in both medication and intensity of counselling. The posted results show the direction and size of the observed difference in average BMI change in those analysed. The open-label design, incomplete endpoint data and small serious-event counts limit the conclusions. This is a separate population from the adult STEP 1 trial.",
          "citations": [
            "nct04873245",
            "pmid-33567185"
          ]
        },
        {
          "heading": "REDEFINE 9 studied a specific combination",
          "body": "The study randomised adults to the two combination regimens or placebo within a dose level. The similar point estimates do not establish that the regimens are equivalent. The results cannot isolate either ingredient’s contribution or validate another preparation.",
          "citations": [
            "pmid-43033821"
          ]
        },
        {
          "heading": "Exercise congestion is a distinct clinical endpoint",
          "body": "Lower measured filling pressure helps explain a possible mechanism in this population. The study size and endpoint limit conclusions about admission rates, mortality and other heart-failure populations.",
          "citations": [
            "pmid-43000472"
          ]
        },
        {
          "heading": "Counting recurrent events changes the question",
          "body": "This analysis uses the original SOUL cohort to estimate total event burden, including recurrence. It supplies a complementary estimate rather than a new independent trial population. The effect estimate concerns the specified oral formulation alongside standard care.",
          "citations": [
            "pmid-43013292"
          ]
        },
        {
          "heading": "A placental perfusion model has a narrow scope",
          "body": "Below the quantification limit means the assay did not quantify transfer under those conditions. The model provides no information about developmental outcomes and cannot replace a pregnancy cohort.",
          "citations": [
            "pmid-43025349"
          ]
        },
        {
          "heading": "Bone findings in an animal model",
          "body": "The animal study reported differing effects on trabecular and cortical bone. The result is specific to an induced metabolic osteoporosis model. It cannot establish a fracture outcome or estimate the effect of semaglutide on bone in people.",
          "citations": [
            "pmid-43025770"
          ]
        }
      ]
    },
    {
      "slug": "semax",
      "names": [
        "Semax"
      ],
      "title": "Semax",
      "kind": "compound",
      "summary": "An ACTH-related peptide investigated in neurochemistry, brain imaging and stroke-rehabilitation studies. Human clinical reports exist, but their limitations and disease-specific settings prevent a dependable claim of everyday cognitive enhancement.",
      "identity": "Semax is an ACTH-related seven-residue peptide. This dossier follows the exact catalogue name Semax and does not extend to modified derivatives or certify any supplied material.",
      "evidenceOverview": "The selected evidence now spans animal mechanisms, healthy-participant imaging and two clinical stroke comparisons. These address different questions and have different risks of bias; they should not be pooled as one demonstration of benefit.",
      "whatResearchShows": [
        "A 24-person experiment reported differences in default-mode-network imaging after Semax compared with placebo.",
        "Rodent work reported altered serotonin-related measurements and an interaction with experimentally induced dopamine signalling. Semax alone did not change the measured dopamine concentrations in that experiment.",
        "Stroke studies report neurological or functional improvement, but the accessible abstracts do not establish robust randomization, blinding or separation from concurrent rehabilitation."
      ],
      "limitations": [
        "An imaging difference is a surrogate measurement, not a demonstrated improvement in memory, attention, work performance or a diagnosed condition.",
        "The rodent findings cannot determine clinical effectiveness, interactions or safety in people.",
        "Study preparations do not establish equivalence, absorption, stability, purity or effects of HeartPep catalogue vials or nasal products.",
        "The clinical stroke reports were assessed from indexed abstracts; the Russian full methods were not reliably available for appraisal."
      ],
      "openQuestions": [
        "Can independently replicated, adequately powered trials demonstrate meaningful cognitive outcomes?",
        "How do exact peptide identity and formulation affect exposure, reproducibility and longer-term outcomes?"
      ],
      "studies": [
        {
          "id": "pmid-30225715",
          "title": "Effects of Semax on the Default Mode Network of the Brain",
          "authors": "Lebedeva IS et al.",
          "year": 2018,
          "journal": "Bull Exp Biol Med",
          "url": "https://pubmed.ncbi.nlm.nih.gov/30225715/",
          "doi": "10.1007/s10517-018-4234-3",
          "pmid": "30225715",
          "evidenceType": "human",
          "design": "Resting-state fMRI experiment in 24 healthy adults, with Semax and placebo groups.",
          "findings": "The Semax group showed a larger rostral default-mode-network subcomponent.",
          "limitations": "Small, acute imaging study; no established improvement in practical cognition.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-16362768",
          "title": "Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents",
          "authors": "Eremin KO et al.",
          "year": 2005,
          "journal": "Neurochem Res",
          "url": "https://pubmed.ncbi.nlm.nih.gov/16362768/",
          "doi": "10.1007/s11064-005-8826-8",
          "pmid": "16362768",
          "evidenceType": "animal",
          "design": "Rodent neurochemistry and behaviour experiments, including an amphetamine challenge.",
          "findings": "Serotonin-metabolite measurements changed. Semax alone did not alter measured dopamine concentrations but enhanced amphetamine-associated responses.",
          "limitations": "Experimental animal endpoints and a drug challenge do not establish cognitive benefit or safety in humans.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-11517472",
          "title": "Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)",
          "authors": "Gusev EI et al.",
          "year": 1997,
          "journal": "Zh Nevrol Psikhiatr Im S S Korsakova",
          "url": "https://pubmed.ncbi.nlm.nih.gov/11517472/",
          "pmid": "11517472",
          "evidenceType": "human",
          "design": "Comparative acute-stroke study: 30 Semax-treated patients and 80 conventional-treatment controls.",
          "findings": "The authors reported faster neurological recovery with Semax added to intensive care.",
          "limitations": "Unequal groups; random allocation and blinding are not described in the abstract. Stroke recovery does not establish healthy-person cognitive enhancement.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-29798983",
          "title": "The efficacy of semax in the tretament of patients at different stages of ischemic stroke",
          "authors": "Gusev EI et al.",
          "year": 2018,
          "journal": "Zh Nevrol Psikhiatr Im S S Korsakova",
          "url": "https://pubmed.ncbi.nlm.nih.gov/29798983/",
          "pmid": "29798983",
          "evidenceType": "human",
          "design": "Study of 110 stroke-rehabilitation patients, subdivided by rehabilitation timing and Semax exposure.",
          "findings": "The report associated Semax with higher plasma BDNF and improved functional-recovery scores.",
          "limitations": "Allocation and blinding are unclear from the abstract; rehabilitation timing and other treatment complicate causal interpretation. Plasma BDNF is not direct brain measurement.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "doi": "10.17116/jnevro20181183261-68"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches restricted to PubMed, followed by verification of primary-study abstracts and bibliographic records. Initial selection on 8 November was substantively extended on 9 November, with clinical searches, accessible full-text consultation and bounded publication-notice checks.",
        "queries": [
          "site:pubmed.ncbi.nlm.nih.gov Semax 30225715",
          "site:pubmed.ncbi.nlm.nih.gov/30225715/",
          "site:pubmed.ncbi.nlm.nih.gov/16362768/",
          "site:pubmed.ncbi.nlm.nih.gov \"Semax\" placebo cognition randomized",
          "site:pubmed.ncbi.nlm.nih.gov Semax stroke clinical randomized trial",
          "\"Effectiveness of semax\" \"11517472\" retraction",
          "\"The efficacy of semax\" \"29798983\" correction"
        ],
        "scope": "Selected animal mechanisms, healthy-participant imaging and human stroke-recovery reports, with a deeper clinical pass after the initial review.",
        "limitations": "Not systematic. Russian clinical full methods could not be reliably assessed. The complete retrieved PubMed record for PMID29798983 showed no linked retraction/erratum section; some other records returned incomplete pages, so publication-status clearance is not comprehensive."
      },
      "discussion": [
        {
          "heading": "Clinical reports are relevant, but population matters",
          "body": "The stroke papers add human clinical observations beyond imaging. Their findings concern recovery after neurological injury with concurrent care, not enhancement in healthy people. Treatment allocation and rehabilitation timing need scrutiny before attributing recovery to Semax. These reports are signals for further controlled work rather than evidence that the same effect will occur outside stroke rehabilitation.",
          "citations": [
            "pmid-11517472",
            "pmid-29798983"
          ]
        },
        {
          "heading": "A mechanism is not the final outcome",
          "body": "A changed neurotransmitter measure or brain-scan pattern can motivate a mechanism hypothesis without proving a useful cognitive change. The clinical evidence does not remove that distinction: plasma BDNF, functional ratings and everyday cognition are different outcomes. Replication should specify which outcome matters and assess it directly.",
          "citations": [
            "pmid-16362768",
            "pmid-29798983"
          ]
        }
      ]
    },
    {
      "slug": "semax-selank",
      "names": [
        "Semax/Selank"
      ],
      "title": "Semax / Selank",
      "kind": "blend",
      "summary": "A catalogue blend name combining two individually studied peptides. The selected publications describe the named components, not an established combined formulation or a demonstrated advantage of mixing them.",
      "identity": "The exact catalogue alias is Semax/Selank. The product's own labelled quantities and format remain separate specifications; component names alone do not verify blend composition, compatibility or stability.",
      "evidenceOverview": "No direct clinical trial of this catalogue combination was identified in the bounded search. Three component-only clinical/imaging references and one identity-only analytical paper provide background; none validates the supplied blend.",
      "whatResearchShows": [
        "Human studies have examined Semax-related imaging changes and Selank-related symptom ratings independently.",
        "The study whose title names both peptides allocated participants to separate Semax, Selank or placebo groups. It cannot demonstrate synergy or combined-product effectiveness."
      ],
      "limitations": [
        "Effects observed for one ingredient cannot be added together to predict a mixture's effects.",
        "The cited studies do not establish blend interactions, a combined safety profile or equivalence of a nasal product to another preparation.",
        "A combined name does not resolve independent identity, content, impurity, formulation or shelf-life questions for a supplied batch."
      ],
      "openQuestions": [
        "Has a precisely characterized combined formulation been tested against its individual components and placebo?",
        "Does combining the peptides change exposure, stability, interactions or measured outcomes?"
      ],
      "studies": [
        {
          "id": "pmid-32342318",
          "title": "Functional Connectomic Approach to Studying Selank and Semax Effects",
          "authors": "Panikratova YR et al.",
          "year": 2020,
          "journal": "Dokl Biol Sci",
          "url": "https://pubmed.ncbi.nlm.nih.gov/32342318/",
          "doi": "10.1134/S001249662001007X",
          "pmid": "32342318",
          "evidenceType": "human",
          "design": "Acute resting-state fMRI study in 52 healthy participants receiving Semax, Selank or placebo separately.",
          "findings": "The authors reported amygdala-to-temporal-cortex connectivity differences.",
          "limitations": "Surrogate imaging endpoints; neither clinical effectiveness nor combined-blend effects established.",
          "appliesTo": "components-only",
          "verification": "abstract"
        },
        {
          "id": "pmid-30225715",
          "title": "Effects of Semax on the Default Mode Network of the Brain",
          "authors": "Lebedeva IS et al.",
          "year": 2018,
          "journal": "Bull Exp Biol Med",
          "url": "https://pubmed.ncbi.nlm.nih.gov/30225715/",
          "doi": "10.1007/s10517-018-4234-3",
          "pmid": "30225715",
          "evidenceType": "human",
          "design": "Resting-state fMRI experiment in 24 healthy adults, with Semax and placebo groups.",
          "findings": "The Semax group showed a larger rostral default-mode-network subcomponent.",
          "limitations": "Small, acute imaging study; no established improvement in practical cognition.",
          "appliesTo": "components-only",
          "verification": "abstract"
        },
        {
          "id": "pmid-18454096",
          "title": "Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia",
          "authors": "Zozulia AA et al.",
          "year": 2008,
          "journal": "Zh Nevrol Psikhiatr Im S S Korsakova",
          "url": "https://pubmed.ncbi.nlm.nih.gov/18454096/",
          "pmid": "18454096",
          "evidenceType": "human",
          "design": "Clinical comparison of Selank and medazepam in 62 patients; PubMed indexes a randomized trial.",
          "findings": "The abstract reports similar anxiety-related effects between groups.",
          "limitations": "Small active-comparator study; Russian full text not reviewed and no placebo arm described in the abstract.",
          "appliesTo": "components-only",
          "verification": "abstract"
        },
        {
          "id": "pmid-31667971",
          "title": "The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind",
          "authors": "Vanhee C et al.",
          "year": 2020,
          "journal": "Drug Test Anal",
          "url": "https://pubmed.ncbi.nlm.nih.gov/31667971/",
          "pmid": "31667971",
          "evidenceType": "analytical",
          "design": "Analytical investigation of suspicious preparations and development of a mass-spectrometric screening method for research peptides.",
          "findings": "The investigators identified preparations containing the named peptides and developed analytical screening methods.",
          "limitations": "These were other preparations, not HeartPep batches. Identification does not establish a combined formulation's effects, safety or stability.",
          "appliesTo": "identity-only",
          "verification": "abstract",
          "doi": "10.1002/dta.2717"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Searched for combination/blend trials and checked whether original reports administered the components together or separately. Initial selection on 8 November was substantively extended on 9 November, with clinical searches, accessible full-text consultation and bounded publication-notice checks.",
        "queries": [
          "site:pubmed.ncbi.nlm.nih.gov \"Semax\" \"Selank\" combination blend trial",
          "site:pubmed.ncbi.nlm.nih.gov/32342318/",
          "site:pubmed.ncbi.nlm.nih.gov/30225715/",
          "site:pubmed.ncbi.nlm.nih.gov/18454096/",
          "site:pubmed.ncbi.nlm.nih.gov/31667971/"
        ],
        "scope": "Direct blend evidence sought; individually administered component studies retained for background.",
        "limitations": "A bounded search cannot prove that no combination research exists. The complete retrieved PubMed record for PMID32342318 showed no linked retraction/erratum section; some other record fetches were incomplete. No paper here establishes the supplied blend."
      },
      "discussion": [
        {
          "heading": "A two-name title is not a combination trial",
          "body": "A paper mentioning both peptides can still test them in separate groups. Such a design cannot establish an interaction between them. The relevant next experiment would compare a characterized mixture with each component and a suitable control, using the same predefined outcome.",
          "citations": [
            "pmid-32342318"
          ]
        },
        {
          "heading": "Identity evidence answers a separate question",
          "body": "Analytical identification is essential background, but even a correctly identified ingredient does not demonstrate a useful mixture. The forensic paper illustrates laboratory identification in other preparations; it neither certifies this catalogue blend nor supplies a combined-product trial. Ratio, stability and interactions remain separate open questions.",
          "citations": [
            "pmid-31667971"
          ]
        }
      ]
    },
    {
      "slug": "sermorelin",
      "names": [
        "Sermorelin"
      ],
      "title": "Sermorelin",
      "kind": "compound",
      "summary": "Human research includes route-specific GH-response experiments and a small uncontrolled functional study in older men. Limited positive strength measures did not establish a reliable performance benefit.",
      "identity": "The paper identifies GHRH(1-29)-NH2, the peptide commonly called sermorelin. Matching that molecular description still does not authenticate a commercial batch.",
      "evidenceOverview": "Selected evidence includes human route-specific pharmacokinetics and a small uncontrolled study that measured strength, muscle bioenergetics and body composition in older men.",
      "whatResearchShows": [
        "The same compound had route-dependent exposure in the research preparation. Total labelled milligrams cannot establish equivalent systemic exposure across formats."
      ],
      "limitations": [
        "The functional study was small, uncontrolled and assessed multiple outcomes; it cannot provide a robust causal strength estimate.",
        "The route study involved a specific formulation. Neither paper authenticates a catalogue material or establishes equivalent delivery."
      ],
      "openQuestions": [
        "Does the material documentation specify GHRH(1-29)-NH2 and the complete formulation?",
        "Has exposure been measured for the actual formulation under investigation?"
      ],
      "studies": [
        {
          "id": "pmid-8329825",
          "title": "Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration",
          "authors": "Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R.",
          "year": 1993,
          "journal": "Acta Paediatrica Supplement",
          "url": "https://pubmed.ncbi.nlm.nih.gov/8329825/",
          "doi": "10.1111/j.1651-2227.1993.tb12827.x",
          "pmid": "8329825",
          "evidenceType": "human",
          "design": "Intravenous and intranasal GHRH(1-29)-NH2 pharmacology experiments in 30 healthy men.",
          "findings": "GH responses were observed with both studied routes, while measured nasal bioavailability was low in that formulation.",
          "limitations": "The study measured pharmacokinetics and endocrine responses. It did not establish performance benefits or equivalence to a current supplier spray.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-9005976",
          "title": "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men",
          "authors": "Vittone J, Blackman MR, Busby-Whitehead J, et al.",
          "year": 1997,
          "journal": "Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/9005976/",
          "doi": "10.1016/s0026-0495(97)90174-8",
          "pmid": "9005976",
          "evidenceType": "human",
          "design": "Six-week before-and-after study in 11 healthy older men with low baseline IGF-I, measuring hormones, several strength tests, muscle bioenergetics and body composition.",
          "findings": "Two of six strength measures and one endurance measure improved. Body composition, muscle histology and the measured muscle-energy responses did not change; IGF-I did not increase.",
          "limitations": "Small uncontrolled study with multiple outcomes. Practice effects, variation and changes unrelated to treatment cannot be separated confidently from a treatment effect.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.",
        "queries": [
          "8329825 GHRH pharmacokinetics",
          "site.pubmed.ncbi.nlm.nih.gov sermorelin GHRH 1-29 elderly physical performance randomized",
          "\"9005976\" authors DOI"
        ],
        "scope": "Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research."
      },
      "discussion": [
        {
          "heading": "One of the selected studies did measure function",
          "body": "The older-men study is relevant because it measured strength and muscle-related outcomes rather than hormones alone. Two of six strength measures and an endurance test improved, while body composition, muscle histology and several other measures did not. The small before-and-after design has no parallel placebo comparison in the reported experiment. Familiarity with testing, ordinary variation and multiple outcome testing therefore limit attribution of the positive measures to GHRH itself. The findings are hypothesis-generating, not a robust estimate of a strength benefit.",
          "citations": [
            "pmid-9005976"
          ]
        },
        {
          "heading": "The delivery comparison does not validate a present-day spray",
          "body": "The healthy-men pharmacokinetic study directly compared intravenous and intranasal GHRH(1-29)-NH2 and found low nasal bioavailability for its formulation. That establishes why molecular identity and route must be considered together. It does not mean every nasal preparation has that same exposure, or that matching the peptide name establishes equivalent delivery. A clinically useful conclusion would require both an exposure link for the actual formulation and an outcome study suited to the proposed application.",
          "citations": [
            "pmid-8329825"
          ]
        }
      ]
    },
    {
      "slug": "snap8",
      "names": [
        "Snap8"
      ],
      "title": "Snap8 / acetyl octapeptide-3",
      "kind": "compound",
      "summary": "The checked human evidence concerns multi-ingredient microneedle patches. It does not isolate acetyl octapeptide-3 or establish an effect of catalogue vials or nasal sprays.",
      "identity": "SNAP-8 is associated with acetyl octapeptide-3 in the identity record used by the existing catalogue references. A supplier name alone is not analytical confirmation of material identity.",
      "evidenceOverview": "Two formulation studies provide human skin-measurement data. Each changes several ingredients and a delivery system together, preventing attribution to one peptide.",
      "whatResearchShows": [
        "The 2024 patch comparison reported improvements in selected wrinkle and skin measurements versus a hyaluronic-acid-only patch.",
        "An earlier single-centre study reported changes after a multi-active patch regimen."
      ],
      "limitations": [
        "Neither study isolates this ingredient's contribution, and the earlier study's abstract does not establish a randomised ingredient-specific comparison.",
        "Short-term cosmetic measurements cannot establish systemic safety, nasal bioavailability or comparable effects of another formulation."
      ],
      "openQuestions": [
        "Would an independently run trial isolate the peptide's effect from the other ingredients and delivery device?"
      ],
      "studies": [
        {
          "id": "pmid-39082657",
          "title": "Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities",
          "authors": "Shin JY, Han D, Yoon KY, Jeong DH, Park YI",
          "year": 2024,
          "journal": "Annals of Dermatology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39082657/",
          "doi": "10.5021/ad.23.136",
          "pmid": "39082657",
          "evidenceType": "human",
          "design": "Opposite-eye comparison of combination versus hyaluronic-acid-only microneedle patches over 28 days; 24 adults enrolled and 21 completed.",
          "findings": "Several skin and wrinkle endpoints favoured the combination; no adverse effects were reported during the short study.",
          "limitations": "Multiple active ingredients, small sample and device-specific delivery. Several authors were affiliated with the patch company.",
          "appliesTo": "components-only",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11291098/"
        },
        {
          "id": "pmid-31134751",
          "title": "Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study",
          "authors": "Avcil M, Akman G, Klokkers J, Jeong D, Çelik A",
          "year": 2020,
          "journal": "Journal of Cosmetic Dermatology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/31134751/",
          "doi": "10.1111/jocd.13009",
          "pmid": "31134751",
          "evidenceType": "human",
          "design": "Twelve-week single-centre study of a patch containing several peptides, adenosine and seaweed extracts.",
          "findings": "Authors reported improved wrinkle, hydration, density and thickness measurements and no reported skin reactions.",
          "limitations": "A formulation result, not proof of isolated acetyl octapeptide-3 efficacy. Manufacturer-funded, with commercial affiliations.",
          "appliesTo": "components-only",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted searches of the catalogue's primary reference and related acetyl-octapeptide microneedle studies.",
        "queries": [
          "39082657 acetyl octapeptide microneedle",
          "Acetyl Octapeptide 31134751 authors",
          "Clinical Safety and Efficacy Evaluation Microneedle retracted",
          "Clinical Safety and Efficacy Evaluation 21 subjects Shin",
          "Clinical Safety and Efficacy Evaluation random 24 microneedle"
        ],
        "scope": "Two human multi-ingredient formulation reports. Full-text 2024 methods, participant flow, results and discussion were checked at the journal; the earlier report remains abstract-reviewed.",
        "limitations": "Not a complete ingredient dossier or systematic search. Ingredient-containing trials do not validate supplier material; a comprehensive publication-status audit was not performed."
      },
      "discussion": [
        {
          "heading": "The comparator determines what can be attributed",
          "body": "The 2024 experiment compares a formulation containing several actives with a hyaluronic-acid patch. It can test the package of ingredients and device together, but it has no arm removing only acetyl octapeptide-3. Attribution to that peptide or a claimed interaction therefore remains a hypothesis. The earlier multi-active study has the same ingredient-attribution problem. Two positive formulation reports do not become two independent demonstrations of isolated-peptide efficacy.",
          "citations": [
            "pmid-39082657",
            "pmid-31134751"
          ]
        },
        {
          "heading": "A delivery device is part of the tested intervention",
          "body": "A dissolving microneedle is designed to alter delivery through the skin barrier. Its results cannot establish what reaches tissue from a plain solution, conventional cosmetic, vial or nasal preparation. Instrumental skin measurements and short tolerability observation also answer narrower questions than lasting cosmetic benefit or long-term safety. Further research would need ingredient-specific comparisons, independently characterised formulations and follow-up beyond the short observation periods before a broad peptide claim could be justified.",
          "citations": [
            "pmid-39082657",
            "pmid-31134751"
          ]
        },
        {
          "heading": "Read participant flow alongside the headline",
          "body": "The later paper enrolled 24 people and analysed 21 completers. That is a small observation window with some attrition, not a broad assurance about everyone who might encounter the ingredient. A useful replication would preserve participant flow, prespecified endpoints and ingredient-specific comparisons alongside its headline result.",
          "citations": [
            "pmid-39082657"
          ]
        }
      ]
    },
    {
      "slug": "ss-31",
      "names": [
        "SS-31"
      ],
      "title": "SS-31 (elamipretide)",
      "kind": "compound",
      "summary": "SS-31 has both animal research and human clinical trials under the name elamipretide. Positive ageing-related mouse findings sit alongside a sizeable human myopathy trial that missed its primary endpoints.",
      "identity": "Elamipretide is the mitochondria-targeting peptide also called SS-31 in the cited research. A shared compound name does not establish equivalence between clinical-trial material and a supplier vial or nasal formulation.",
      "evidenceOverview": "Selected evidence now includes ageing mice, the negative MMPOWER-3 human myopathy trial, and controlled and open-label Barth syndrome studies. Disease biology, endpoints and study designs differ; longer uncontrolled improvement cannot be interpreted as if it came from the randomised comparison.",
      "whatResearchShows": [
        "Nickel and colleagues found sex-dependent functional changes in ageing mice, including different physical and cognitive findings.",
        "MMPOWER-3 did not improve its primary walking-distance or fatigue outcomes in people with genetically confirmed primary mitochondrial myopathy."
      ],
      "limitations": [
        "A mouse functional outcome is not evidence of longer human lifespan.",
        "A disease-specific pharmaceutical trial cannot be treated as proof for general wellness, muscle growth or a different supplied format.",
        "This review does not assess regulatory approval or authenticate HeartPep batches."
      ],
      "openQuestions": [
        "Which clinical populations and prespecified outcomes can show a reproducible benefit?",
        "How do actual formulation, identity and exposure compare with the study material?"
      ],
      "studies": [
        {
          "id": "pmid-36250163",
          "title": "Long-term treatment with Elamipretide enhances healthy aging phenotypes in mice",
          "authors": "Nickel K, Zhu L, Mangalindan R, et al.",
          "year": 2022,
          "journal": "Aging Pathobiology and Therapeutics",
          "url": "https://pubmed.ncbi.nlm.nih.gov/36250163/",
          "doi": "10.31491/apt.2022.09.089",
          "pmid": "36250163",
          "evidenceType": "animal",
          "design": "Long-term treatment of male and female C57BL/6 mice starting at 18 months, with physiological assessment at 28 months.",
          "findings": "Physical performance improved in males but not females; cognitive and body-composition findings differed by sex. Diastolic function improved in both sexes.",
          "limitations": "Specific mouse functional endpoints, not a human longevity study. Effects varied by sex and context.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9562127/"
        },
        {
          "id": "pmid-37268435",
          "title": "Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial",
          "authors": "Karaa A, Bertini E, Carelli V, et al.; MMPOWER-3 Trial Investigators",
          "year": 2023,
          "journal": "Neurology",
          "url": "https://pubmed.ncbi.nlm.nih.gov/37268435/",
          "doi": "10.1212/WNL.0000000000207402",
          "pmid": "37268435",
          "evidenceType": "human",
          "design": "Phase 3 double-blind placebo-controlled trial in 218 people with genetically confirmed primary mitochondrial myopathy over 24 weeks.",
          "findings": "Neither primary endpoint, six-minute walking distance nor total fatigue score, improved significantly versus placebo.",
          "limitations": "Clinical formulation and disease-specific setting. The null primary results should not be replaced with selected exploratory subgroup findings.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10382259/"
        },
        {
          "id": "pmid-33077895",
          "title": "A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism",
          "authors": "Thompson WR, Hornby B, Manuel R, et al.",
          "year": 2021,
          "journal": "Genetics in Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/33077895/",
          "doi": "10.1038/s41436-020-01006-8",
          "pmid": "33077895",
          "evidenceType": "human",
          "design": "Single-site double-blind placebo-controlled crossover trial in 12 males with genetically confirmed Barth syndrome, followed by an open-label extension.",
          "findings": "Neither primary endpoint improved significantly in the controlled phase. Improvements were reported during the subsequent open-label phase.",
          "limitations": "Very small rare-disease sample. Open-label within-person changes have no concurrent placebo control; sponsor participated in analysis and publication.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7935714/"
        },
        {
          "id": "pmid-38602181",
          "title": "Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER",
          "authors": "Thompson WR, Manuel R, Abbruscato A, et al.",
          "year": 2024,
          "journal": "Genetics in Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38602181/",
          "doi": "10.1016/j.gim.2024.101138",
          "pmid": "38602181",
          "evidenceType": "human",
          "design": "Long-term open-label follow-up of TAZPOWER; ten participants entered and eight reached week 168.",
          "findings": "Reported sustained within-person functional and selected cardiac improvements, with injection-site reactions the most common adverse events.",
          "limitations": "Same underlying cohort rather than independent replication. No randomised long-term comparator; attrition and expectation effects complicate causal attribution.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.",
        "queries": [
          "36250163 elamipretide long term aging mice",
          "elamipretide MMPOWER-3 randomized trial primary mitochondrial myopathy 2023",
          "\"MMPOWER-3\" \"Karaa\" \"10.\" 2023",
          "elamipretide Barth syndrome TAZPOWER trial randomized crossover 2021 PubMed",
          "elamipretide Barth syndrome 168 weeks open label 2025 primary trial",
          "\"10.1212/WNL.0000000000207402\" correction"
        ],
        "scope": "Mouse ageing, phase 3 myopathy, and small Barth syndrome controlled/open-label evidence. Full-text trial methods were consulted where accessible. Regulatory status and catalogue-product approval were not assessed.",
        "limitations": "Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates."
      },
      "discussion": [
        {
          "heading": "Keep the controlled and extension phases separate",
          "body": "The most informative comparison for a causal treatment effect is the prespecified contrast between randomised groups or periods. The Barth study illustrates why an encouraging extension should not be retrospectively substituted for that comparison. Longer follow-up can reveal durability or delayed signals, but all participants then know they receive treatment and the original control structure has gone. The extension is also the same cohort, so citing both reports is not evidence from two independent populations.",
          "citations": [
            "pmid-33077895",
            "pmid-38602181"
          ]
        },
        {
          "heading": "A null endpoint has a defined scope",
          "body": "MMPOWER-3 constrains claims about the walking and fatigue outcomes it actually tested. It does not prove that every mitochondrial mechanism is inactive, and it does not license selecting a favourable exploratory subgroup as a confirmed success. A credible next study would specify the subgroup and endpoint prospectively, define a meaningful effect size and replicate it. For researchers, trial duration, molecular diagnosis and formulation are therefore central study characteristics rather than footnotes.",
          "citations": [
            "pmid-37268435"
          ]
        },
        {
          "heading": "Translation is not chemical identity",
          "body": "The mouse findings motivate questions about function and sex-specific responses. They cannot bridge the separate analytical question of whether a marketed vial or nasal preparation matches clinical study material. Procurement and biological evidence need their own documentation.",
          "citations": [
            "pmid-36250163",
            "pmid-33077895"
          ]
        }
      ]
    },
    {
      "slug": "syringes",
      "names": [
        "1ml syringes",
        "1 mL Insulin Syringe 29G",
        "3 mL Syringe 23G 1 inch"
      ],
      "title": "Syringes: specification guide",
      "kind": "supply",
      "summary": "These are catalogue supplies rather than peptide interventions. Compare the exact capacity, dimensions, materials and pack specification required by the laboratory method.",
      "identity": "The listings cover different syringe descriptions and regional specifications. The UK/EU pack specification remains pending in the source catalogue.",
      "evidenceOverview": "Specification review, with a technical laboratory-quality reference. No biological benefit is assigned to this supply.",
      "whatResearchShows": [
        "Capacity, needle description and pack count are separate product attributes.",
        "Compatibility and performance need verification against the intended laboratory procedure."
      ],
      "limitations": [
        "Published quality guidance is not an assay or certification of a HeartPep product.",
        "The listing is not a substitute for the manufacturer’s complete specification or lot documentation."
      ],
      "openQuestions": [
        "Confirm the manufacturer, model, materials, graduation accuracy and connection type.",
        "Check the exact pack count, needle configuration and any claimed sterility documentation."
      ],
      "studies": [
        {
          "id": "who-trs-1052-annex-4",
          "title": "WHO good practices for pharmaceutical quality control laboratories",
          "authors": "World Health Organization",
          "year": 2024,
          "journal": "WHO Technical Report Series 1052, Annex 4",
          "url": "https://www.who.int/publications/m/item/who-good-practices-for-pharmaceutical-quality-control-laboratories",
          "evidenceType": "reference",
          "design": "Technical guidance, sections 4.1, 5.3 and 5.4 consulted.",
          "findings": "Laboratory supplies require appropriate specifications and documented suitability checks.",
          "limitations": "General guidance does not test or certify these catalogue items.",
          "appliesTo": "identity-only",
          "verification": "full-text",
          "fullTextUrl": "https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/trs1052_annex4.pdf"
        }
      ],
      "search": {
        "date": "2026-11-08",
        "method": "Catalogue specification review and official technical-reference check",
        "queries": [
          "site.who.int \"TRS 1052\" \"Annex 4\" \"quality control laboratories\""
        ],
        "scope": "Regional catalogue labels and WHO 2024 guidance on laboratory supplies, equipment and reagents.",
        "limitations": "No independent performance testing of the supplied items was undertaken. This is a specification guide, not a biological literature review."
      }
    },
    {
      "slug": "tb-500",
      "names": [
        "TB500",
        "TB-500"
      ],
      "title": "TB-500",
      "kind": "compound",
      "summary": "TB-500 naming requires particular care. Analytical fragment research and related thymosin-beta-4 experiments are informative, but a supplier label does not establish which sequence is present.",
      "identity": "A 2012 analysis identified acetylated thymosin-beta-4 residues 17-23, Ac-LKKTETQ, in the preparation examined. This is distinct from full-length thymosin beta-4 and from the unacetylated seven-residue fragment.",
      "evidenceOverview": "The selected record combines identity analysis, metabolism and fibroblast experiments, plus related-fragment work in mice. These are not clinical evaluations of HeartPep products.",
      "whatResearchShows": [
        "The 2024 study found significant wound-assay activity for one metabolite, rather than the parent peptide.",
        "Older mouse findings concern a related unacetylated fragment and full-length thymosin beta-4."
      ],
      "limitations": [
        "A positive result for a metabolite or related sequence cannot be transferred automatically to TB-500 material.",
        "No human recovery trial of the supplied preparation is established by these references."
      ],
      "openQuestions": [
        "What exact sequence, terminal modifications and independent identity measurements accompany each supplied lot?"
      ],
      "studies": [
        {
          "id": "pmid-22962027",
          "title": "Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500…",
          "authors": "Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P",
          "year": 2012,
          "journal": "Drug Testing and Analysis",
          "url": "https://pubmed.ncbi.nlm.nih.gov/22962027/",
          "doi": "10.1002/dta.1402",
          "pmid": "22962027",
          "evidenceType": "analytical",
          "design": "Chemical analysis of a TB-500-labelled preparation, with synthesis of a reference fragment.",
          "findings": "Identified Ac-LKKTETQ and developed an analytical detection approach.",
          "limitations": "Identity work on that sample, not evidence of healing or authentication of another supplier's product.",
          "appliesTo": "identity-only",
          "verification": "abstract"
        },
        {
          "id": "pmid-38382158",
          "title": "Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats…",
          "authors": "Rahaman KA, Muresan AR, Min H, et al.",
          "year": 2024,
          "journal": "Journal of Chromatography B",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38382158/",
          "doi": "10.1016/j.jchromb.2024.124033",
          "pmid": "38382158",
          "evidenceType": "laboratory",
          "design": "Human serum, enzyme systems, rat urine and fibroblast assays with parent peptide and metabolites.",
          "findings": "Only Ac-LKKTE showed significant wound-assay activity versus control. Parent and tested metabolites were not cytotoxic under the assay conditions.",
          "limitations": "An in-vitro wound assay and lack of assay cytotoxicity do not establish human recovery or systemic safety.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-12581423",
          "title": "Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice",
          "authors": "Philp D, Badamchian M, Scheremeta B, et al.",
          "year": 2003,
          "journal": "Wound Repair and Regeneration",
          "url": "https://pubmed.ncbi.nlm.nih.gov/12581423/",
          "doi": "10.1046/j.1524-475x.2003.11105.x",
          "pmid": "12581423",
          "evidenceType": "animal",
          "design": "Dermal-wound experiments in diabetic and aged mice, including full-length thymosin beta-4 and LKKTETQ.",
          "findings": "Repair-related measures improved in selected models; the unacetylated fragment promoted repair in aged mice.",
          "limitations": "The tested sequences and models do not establish equivalence to an acetylated catalogue preparation.",
          "appliesTo": "related-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record searches for TB-500 identity, metabolism and related wound experiments.",
        "queries": [
          "TB-500 22962027 Esposito 2012",
          "22962027 Abstract peptide",
          "38382158 TB-500 metabolism"
        ],
        "scope": "Selected sequence-identification and preclinical studies, with exact-versus-related material distinguished.",
        "limitations": "Selected primary records only, with abstracts checked. Exact identity and a full clinical or retraction-status audit remain outside this bounded review; no absence-of-evidence claim is made."
      },
      "discussion": [
        {
          "heading": "Why the sequence must come before the claim",
          "body": "TB-500 is a commercial label, while a research paper tests a particular chemical entity. The identity paper is valuable precisely because it measured that entity instead of trusting the label. Acetylation and peptide length distinguish the analysed fragment from both full-length thymosin beta-4 and the unacetylated sequence used in older experiments. For a literature comparison, a supplier sequence and terminal modifications should be checked against the paper before interpreting any biological result. A matching name is insufficient.",
          "citations": [
            "pmid-22962027",
            "pmid-12581423"
          ]
        },
        {
          "heading": "The parent peptide and a metabolite are different exposures",
          "body": "The metabolism study provides a reason to resist a simple wound-healing narrative. A significant response for Ac-LKKTE, alongside a nonsignificant parent-peptide result under those assay conditions, leaves open whether metabolism changes activity. It does not prove that the parent is universally inactive, nor that the metabolite will work in an organism. Conversely, absence of cell toxicity within one assay cannot establish systemic safety. Useful follow-up would connect chemically measured exposure with replicated functional outcomes and appropriate controls.",
          "citations": [
            "pmid-38382158"
          ]
        },
        {
          "heading": "What a transferable experiment would report",
          "body": "Sequence, terminal chemistry, analytical identity, exposure and the tested comparator should travel with every result. Without those details, apparently conflicting findings may concern different molecules or assay conditions. Keeping them visible is more informative than assigning every thymosin-related paper to a single product name.",
          "citations": [
            "pmid-22962027",
            "pmid-38382158",
            "pmid-12581423"
          ]
        }
      ]
    },
    {
      "slug": "tesamorelin",
      "names": [
        "Tesamorelin"
      ],
      "title": "Tesamorelin",
      "kind": "compound",
      "summary": "Controlled clinical studies found changes in visceral fat in specific populations. These findings should not be turned into a general weight-loss, muscle or strength promise.",
      "identity": "Tesamorelin is the defined GHRH analogue studied in the trials below. Clinical products and research-catalogue formats are separate specifications.",
      "evidenceOverview": "Selected controlled studies examine visceral fat in defined populations and liver fat in people with HIV and steatosis. Imaging and biopsy findings add clinical depth but do not establish a general weight-loss or strength benefit.",
      "whatResearchShows": [
        "The studies distinguish visceral from subcutaneous fat, rather than treating all weight-related outcomes as equivalent.",
        "The extension phase shows why persistence after stopping is a separate question from a response during treatment."
      ],
      "limitations": [
        "No general athletic-performance benefit is established here.",
        "Trial-product results do not validate nasal products or establish the identity, purity or effectiveness of catalogue materials."
      ],
      "openQuestions": [
        "Which population and fat compartment does a cited result concern?",
        "Are outcomes sustained after the intervention ends, and were clinically important outcomes directly measured?"
      ],
      "studies": [
        {
          "id": "pmid-23015655",
          "title": "Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial",
          "authors": "Makimura H, Feldpausch MN, Rope AM, et al.",
          "year": 2012,
          "journal": "Journal of Clinical Endocrinology & Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/23015655/",
          "doi": "10.1210/jc.2012-2794",
          "pmid": "23015655",
          "evidenceType": "human",
          "design": "Randomized double-blind placebo-controlled 12-month study in 60 adults with abdominal obesity and reduced GH secretion.",
          "findings": "Tesamorelin reduced visceral abdominal fat relative to placebo. Subcutaneous abdominal fat did not change significantly; IGF-I increased.",
          "limitations": "Selected participants with reduced GH secretion and surrogate metabolic endpoints. The trial does not establish general weight-loss, strength or cardiovascular-event benefits.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3513535/"
        },
        {
          "id": "pmid-20101189",
          "title": "Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension",
          "authors": "Falutz J, Potvin D, Mamputu JC, et al.",
          "year": 2010,
          "journal": "Journal of Acquired Immune Deficiency Syndromes",
          "url": "https://pubmed.ncbi.nlm.nih.gov/20101189/",
          "doi": "10.1097/QAI.0b013e3181cbdaff",
          "pmid": "20101189",
          "evidenceType": "human",
          "design": "Randomized placebo-controlled trial in 404 people with HIV, antiretroviral treatment and excess abdominal fat, followed by a blinded extension.",
          "findings": "Visceral fat decreased during treatment. Initial improvement was rapidly lost in participants switched to placebo during the extension.",
          "limitations": "Findings concern a specific clinical population and trial product. They do not demonstrate lasting effects after stopping or validate research-catalogue formats.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-31611038",
          "title": "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial",
          "authors": "Stanley TL, Fourman LT, Feldpausch MN, et al.",
          "year": 2019,
          "journal": "The Lancet HIV",
          "url": "https://pubmed.ncbi.nlm.nih.gov/31611038/",
          "doi": "10.1016/S2352-3018(19)30338-8",
          "pmid": "31611038",
          "evidenceType": "human",
          "design": "Twelve-month randomized placebo-controlled trial in people with HIV and defined liver steatosis. Liver fat was the primary endpoint; imaging, liver biopsies and safety assessments were used.",
          "findings": "Liver fat decreased more with tesamorelin. Fewer participants had fibrosis progression, but existing fibrosis did not significantly improve.",
          "limitations": "The study was designed for liver-fat change, not definitive treatment of steatohepatitis or long-term clinical events. Two treated participants stopped for worsening hyperglycaemia despite neutral mean glucose results.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6981288/"
        },
        {
          "id": "pmid-43013893",
          "title": "Detecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS",
          "authors": "Colpaert T, Miller G, Goodrum J, et al.",
          "year": 2026,
          "journal": "Drug Testing and Analysis",
          "url": "https://pubmed.ncbi.nlm.nih.gov/43013893/",
          "doi": "10.1002/dta.70189",
          "pmid": "43013893",
          "evidenceType": "analytical",
          "design": "Mass spectrometry method study using urine and serum from six volunteers given a defined clinical preparation, plus a separate serum metabolism experiment.",
          "findings": "The authors identified five previously unreported metabolites. They reported different detection performance across the urine and serum samples.",
          "limitations": "Small method study using one preparation. PubMed and university repository abstracts consulted. The findings do not measure treatment benefit or verify a commercial batch.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-16",
        "method": "Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions. Added a targeted November 2026 analytical source check.",
        "queries": [
          "23015655 tesamorelin",
          "\"Metabolic effects of a growth hormone-releasing factor in obese subjects\"",
          "site.pubmed.ncbi.nlm.nih.gov tesamorelin HIV abdominal fat 18057338",
          "site.pubmed.ncbi.nlm.nih.gov tesamorelin nonalcoholic fatty liver randomized 2019",
          "\"31611038\" tesamorelin authors DOI",
          "PMID 43013893 / DOI 10.1002/dta.70189"
        ],
        "scope": "Selected primary research relevant to the named compound, its molecular specification and the endpoints described below. Checked the PubMed abstract and Ghent University record for the new analytical method.",
        "limitations": "Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research. The new analytical source was reviewed at abstract level."
      },
      "discussion": [
        {
          "heading": "Fat compartments and durability matter",
          "body": "The abdominal-fat studies distinguish visceral adipose tissue from subcutaneous fat. A reduction in one compartment is a more precise result than a general statement about weight loss. The blinded extension also shows that a response maintained during treatment is different from a lasting response after discontinuation: initial visceral-fat improvement was rapidly lost after switching to placebo. Neither observation establishes improved strength or prevention of cardiovascular events.",
          "citations": [
            "pmid-23015655",
            "pmid-20101189"
          ]
        },
        {
          "heading": "Liver-fat research adds clinical depth, with a defined boundary",
          "body": "The HIV/liver-steatosis trial used blinded imaging and paired biopsies, giving a stronger basis for its liver-fat endpoint than hormone measurements alone. The fibrosis-progression signal is informative, but existing fibrosis did not significantly improve and the trial was not designed to establish definitive treatment of steatohepatitis. Mean glucose measures also cannot capture every participant’s experience: two treated participants discontinued for hyperglycaemia. This supports a population- and endpoint-specific interpretation, rather than a broad claim of liver protection or metabolic safety.",
          "citations": [
            "pmid-31611038"
          ]
        },
        {
          "heading": "Measuring metabolites is an analytical outcome",
          "body": "This study adds evidence about detecting the peptide and its degradation products in biological matrices. The endpoint concerns assay performance, so it should be read separately from randomized clinical studies of body composition or liver fat.",
          "citations": [
            "pmid-43013893"
          ]
        }
      ]
    },
    {
      "slug": "tesofensine",
      "names": [
        "Tesofensine"
      ],
      "title": "Tesofensine",
      "kind": "compound",
      "summary": "The frequently cited obesity trial has a published expression of concern. Its reported weight changes must be read with that notice, and its adverse-event reporting should not be treated as settled.",
      "identity": "Tesofensine is a small-molecule monoamine reuptake inhibitor, not a peptide. The selected trial studied an oral investigational medicine, not a catalogue vial or nasal product.",
      "evidenceOverview": "This entry retains the original phase 2 trial alongside the journal's expression of concern and the authors' later correspondence about adverse-effect under-reporting.",
      "whatResearchShows": [
        "The 2008 trial reported weight reductions with tesofensine plus dietary intervention, but subsequently received an expression of concern [1,2].",
        "The bibliographic record links the notice to correspondence titled Under-reporting of adverse effects of tesofensine [3]. The notice must travel with any citation of the original result."
      ],
      "limitations": [
        "The notice and response have no PubMed abstracts; only their bibliographic records and linkage were verified here. Their full text requires further appraisal.",
        "A contested safety record, short follow-up and limited replication prevent a confident general safety conclusion. No catalogue-formulation equivalence was established."
      ],
      "openQuestions": [
        "How do the complete inspection findings, corrected adverse-event data and subsequent independent trials affect the interpretation?",
        "Can longer-term cardiovascular and psychiatric outcomes be assessed with adequately reported controlled data?"
      ],
      "studies": [
        {
          "id": "pmid-18950853",
          "title": "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial",
          "authors": "Astrup A, Madsbad S, Breum L, et al.",
          "year": 2008,
          "journal": "The Lancet",
          "url": "https://pubmed.ncbi.nlm.nih.gov/18950853/",
          "doi": "10.1016/S0140-6736(08)61525-1",
          "pmid": "18950853",
          "evidenceType": "human",
          "design": "24-week phase 2 randomized placebo-controlled trial in 203 adults receiving an energy-restricted diet.",
          "findings": "The paper reported additional weight reduction and increased heart rate in one active group. These results must be read with the subsequent expression of concern.",
          "limitations": "Published expression of concern, PMID23561987. Do not treat the original adverse-event profile as complete or infer efficacy of a catalogue preparation.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-23561987",
          "title": "Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial",
          "authors": "The Lancet, no named author listed in PubMed",
          "year": 2013,
          "journal": "The Lancet",
          "url": "https://pubmed.ncbi.nlm.nih.gov/23561987/",
          "doi": "10.1016/S0140-6736(13)60778-3",
          "pmid": "23561987",
          "evidenceType": "reference",
          "design": "Journal expression of concern linked to the 2008 obesity trial.",
          "findings": "PubMed explicitly classifies this notice as an Expression of Concern for PMID18950853.",
          "limitations": "Bibliographic record verified, no abstract available. An expression of concern is not itself a retraction; the full notice was not reviewed here.",
          "appliesTo": "exact-compound",
          "verification": "record"
        },
        {
          "id": "pmid-23849924",
          "title": "Under-reporting of adverse effects of tesofensine",
          "authors": "Astrup A, Madsbad S, Breum L, et al.",
          "year": 2013,
          "journal": "The Lancet",
          "url": "https://pubmed.ncbi.nlm.nih.gov/23849924/",
          "doi": "10.1016/S0140-6736(13)61563-9",
          "pmid": "23849924",
          "evidenceType": "reference",
          "design": "Authors' correspondence linked to the expression of concern.",
          "findings": "The primary record identifies a response specifically concerning adverse-effect under-reporting.",
          "limitations": "No abstract available and full letter not reviewed. This bibliographic notice is not a new independent efficacy or safety trial.",
          "appliesTo": "exact-compound",
          "verification": "record"
        },
        {
          "id": "umin-000054277",
          "title": "Efficacy and safety of tesofensine for the treatment of obesity in adults: a phase 3 randomized controlled study",
          "authors": "Investigator-submitted UMIN-CTR record; principal investigator Reyes-Garcia JG",
          "year": 2024,
          "journal": "UMIN Clinical Trials Registry",
          "url": "https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061771",
          "evidenceType": "human",
          "design": "Registry results for a 24-week placebo-controlled Mexican study reporting 372 randomized participants.",
          "findings": "The registry reports larger average weight reductions in active groups than placebo and provides participant-flow and adverse-event summaries.",
          "limitations": "Investigator-entered registry result, not a full peer-reviewed report appraised here. Disclosure in 2024 postdates the listed 2017-2018 study period. This does not resolve the separate 2008 trial notice.",
          "appliesTo": "exact-compound",
          "verification": "record"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record verification, with explicit follow-up of journal-integrity notices.",
        "queries": [
          "site.pubmed.ncbi.nlm.nih.gov/18950853 Tesofensine",
          "site.pubmed.ncbi.nlm.nih.gov tesofensine phase 3",
          "site.pubmed.ncbi.nlm.nih.gov/23561987 Expression of concern",
          "site.pubmed.ncbi.nlm.nih.gov/23849924 Under-reporting",
          "https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061771",
          "site.thelancet.com 23561987 OR 60778-3"
        ],
        "scope": "Original obesity trial, linked journal notices and an investigator-submitted Mexican phase 3 registry result, kept distinct from a peer-reviewed trial report.",
        "limitations": "Not a systematic review. Original trial abstract, notice metadata/linkage and public registry fields checked. The full integrity notices, any corrected dataset and a full publication of the registry study were not appraised."
      },
      "discussion": [
        {
          "heading": "Preserve the integrity notice with the efficacy citation",
          "body": "A trial can report an efficacy signal while its conduct or safety reporting remains in question. The journal expression of concern is therefore not a footnote to drop when reproducing a weight-loss headline. It is also not automatically a retraction: those publication statuses have different meanings. The linked correspondence specifically concerns adverse-effect under-reporting, but its full text was not retrieved here. Consequently this review does not reconstruct the inspection or assert that a particular corrected adverse-event count is known. Its interpretation stays within the verified publication trail.",
          "citations": [
            "pmid-18950853",
            "pmid-23561987",
            "pmid-23849924"
          ]
        },
        {
          "heading": "A later registry result adds context without resolving the earlier notice",
          "body": "The UMIN record prevents the mistaken impression that no later phase 3 study is documented anywhere. It lists a Mexican study, outcomes and participant flow, but the public disclosure occurred years after its stated study period. That timing limits the use of this registration to verify prospective outcome specification. Registry-entered results are useful primary evidence, yet they are not equivalent to independently appraising a complete journal report, protocol and dataset. They neither repair the separate historical trial nor establish long-term cardiovascular or psychiatric safety, and they do not validate catalogue nasal or vial preparations.",
          "citations": [
            "umin-000054277",
            "pmid-23561987"
          ]
        }
      ]
    },
    {
      "slug": "thymosin-alpha-1",
      "names": [
        "Thymosin Alpha-1"
      ],
      "title": "Thymosin Alpha-1",
      "kind": "compound",
      "summary": "Thymosin alpha-1 has been investigated as an immunomodulatory drug. A large placebo-controlled sepsis trial found no clear mortality benefit, and its corrected publication should be used rather than an outdated cached abstract.",
      "identity": "The cited research concerns the defined thymosin alpha-1 study drug. A research-category label such as immune signalling describes the topic, not proof that a supplied peptide improves immunity.",
      "evidenceOverview": "The TESTS phase 3 trial provides a substantial disease-specific test. A May 2025 correction updated survival and immunological data without changing the overall interpretation that a mortality reduction was not demonstrated.",
      "whatResearchShows": [
        "The corrected TESTS analysis did not show a significant reduction in 28-day all-cause mortality.",
        "The corrected hazard ratio was 0.97, with a 95% confidence interval of 0.76 to 1.24."
      ],
      "limitations": [
        "A null sepsis result does not answer every possible indication, but cannot support a general immune-benefit claim.",
        "Subgroup suggestions do not override the overall primary result.",
        "The trial does not establish equivalence or safety of a commercial research vial."
      ],
      "openQuestions": [
        "Which prespecified patient populations, if any, show a reproducible benefit in independent trials?",
        "Are future analyses based on the corrected dataset and clearly registered outcomes?"
      ],
      "studies": [
        {
          "id": "pmid-39814420",
          "title": "The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial",
          "authors": "Wu J, Pei F, Zhou L, et al.; TESTS study collaborator group",
          "year": 2025,
          "journal": "BMJ",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39814420/",
          "doi": "10.1136/bmj-2024-082583",
          "pmid": "39814420",
          "evidenceType": "human",
          "design": "Multicentre phase 3 double-blind placebo-controlled study, with 1106 adults randomised and 1089 in the modified intention-to-treat analysis.",
          "findings": "Corrected results show no significant 28-day mortality reduction: hazard ratio 0.97 (95% CI 0.76 to 1.24), P=0.82.",
          "limitations": "Use the corrected publisher version. The overall result does not support an immune-enhancement or sepsis-survival claim.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://www.bmj.com/content/388/bmj-2024-082583"
        },
        {
          "id": "pmid-40447307",
          "title": "Correction: The efficacy and safety of thymosin α1 for sepsis (TESTS)",
          "authors": "BMJ",
          "year": 2025,
          "journal": "BMJ",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40447307/",
          "doi": "10.1136/bmj.r1098",
          "pmid": "40447307",
          "evidenceType": "reference",
          "design": "Publisher correction to the TESTS trial, published 30 May 2025; not an additional clinical study.",
          "findings": "Updated survival analyses after obtaining follow-up data for nine participants and corrected lymphocyte data for 35 participants.",
          "limitations": "The correction changes estimates, not the overall conclusion of no clear mortality benefit. Older cached abstracts can contain superseded statistics.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://www.bmj.com/content/389/bmj.r1098"
        },
        {
          "id": "pmid-23327199",
          "title": "The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial",
          "authors": "Wu J, Zhou L, Liu J, et al.",
          "year": 2013,
          "journal": "Critical Care",
          "url": "https://pubmed.ncbi.nlm.nih.gov/23327199/",
          "doi": "10.1186/cc11932",
          "pmid": "23327199",
          "evidenceType": "human",
          "design": "Six-centre single-blind randomised trial in 361 patients with severe sepsis.",
          "findings": "Reported lower 28-day mortality numerically; the unstratified comparison was not significant and the confidence interval for relative risk included no effect. A log-rank analysis was borderline significant.",
          "limitations": "Analysis-dependent result in an earlier, less fully blinded trial. It should not be presented as definitive mortality reduction.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4056079/"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.",
        "queries": [
          "39814420 thymosin alpha1 sepsis randomized placebo mortality",
          "\"TESTS\" \"e082583\" correction 2025",
          "\"The efficacy and safety of thymosin\" \"Wu\" 2025 e082583",
          "thymosin alpha1 ETASS trial 2013 severe sepsis randomized PubMed"
        ],
        "scope": "Earlier ETASS trial, larger TESTS trial and its publisher correction. Corrected publisher results retained where a cached PubMed abstract is outdated. Not an all-indication or pooled meta-analysis.",
        "limitations": "Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates."
      },
      "discussion": [
        {
          "heading": "Why a larger follow-up matters",
          "body": "The earlier ETASS result illustrates the fragility of a conclusion that changes with the statistical comparison. A numerical difference, a borderline survival test and an interval that includes no effect should not be compressed into an unqualified positive result. The larger, double-blind TESTS study then provides a more substantial test of the mortality hypothesis in its defined population.",
          "citations": [
            "pmid-23327199",
            "pmid-39814420"
          ]
        },
        {
          "heading": "Interpret uncertainty rather than reverse the null result",
          "body": "A confidence interval containing no effect does not prove the true effect is exactly zero. It constrains the effects compatible with the trial under its assumptions. Conversely, a favourable age or diabetes subgroup cannot establish a treatment indication merely because the overall result was negative. That would need a prespecified, independently replicated comparison with appropriate attention to interaction and multiplicity.",
          "citations": [
            "pmid-39814420"
          ]
        },
        {
          "heading": "Publication corrections belong in the evidence chain",
          "body": "The TESTS correction is an analysis update, not another trial or a retraction. It matters because a reader extracting an older abstract may enter superseded values into a review. Our interpretation is that version control is part of evidence quality: record which corrected publication supplied each estimate and retain its linked notice. A study count should exclude such notices from the number of independent clinical experiments.",
          "citations": [
            "pmid-39814420",
            "pmid-40447307"
          ]
        }
      ]
    },
    {
      "slug": "tirzepatide",
      "names": [
        "Tirzepatide"
      ],
      "title": "Tirzepatide",
      "kind": "compound",
      "summary": "Controlled human trials support weight outcomes for defined clinical tirzepatide preparations. These findings do not authenticate or validate a research-catalogue formulation.",
      "identity": "Tirzepatide is a dual GIP and GLP-1 receptor agonist. Clinical drug research and a supplier's use of the same name are separate kinds of evidence.",
      "evidenceOverview": "The selected evidence includes a large placebo-controlled obesity trial and a later comparison with semaglutide. The selected evidence also includes a randomized adolescent trial and an active-comparator study in early type 2 diabetes.",
      "whatResearchShows": [
        "SURMOUNT-1 found greater weight reduction than placebo in adults with obesity without diabetes [1].",
        "SURMOUNT-5 directly compared two clinical medicines rather than relying on comparisons between unrelated study populations [2].",
        "SURPASS-EARLY adds a two-year comparison with intensified conventional care in adults with early type 2 diabetes [4].",
        "The phase 3 adolescent trial reported greater BMI reduction than placebo, alongside more gastrointestinal adverse events [5]."
      ],
      "limitations": [
        "The trials do not test the identity, stability, exposure, sterility or clinical effectiveness of HeartPep catalogue products.",
        "Their selected populations, follow-up periods and adverse-event patterns limit generalization. These summaries are not treatment or administration instructions."
      ],
      "openQuestions": [
        "How durable are outcomes after withdrawal, and which outcomes depend on ongoing treatment?",
        "How should rare adverse events and population-specific effects be assessed beyond individual trials?"
      ],
      "studies": [
        {
          "id": "pmid-35658024",
          "title": "Tirzepatide Once Weekly for the Treatment of Obesity",
          "authors": "Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators",
          "year": 2022,
          "journal": "New England Journal of Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
          "doi": "10.1056/NEJMoa2206038",
          "pmid": "35658024",
          "evidenceType": "human",
          "design": "72-week double-blind randomized placebo-controlled trial in 2,539 adults without diabetes.",
          "findings": "Mean weight changes ranged from -15.0% to -20.9% across trial groups, compared with -3.1% with placebo. Gastrointestinal adverse events and discontinuations were reported.",
          "limitations": "Manufacturer-supported trial of a defined clinical preparation. It does not establish outcomes with other routes or commercial research products.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-40353578",
          "title": "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity",
          "authors": "Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators",
          "year": 2025,
          "journal": "New England Journal of Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40353578/",
          "doi": "10.1056/NEJMoa2416394",
          "pmid": "40353578",
          "evidenceType": "human",
          "design": "72-week open-label randomized comparison in 751 adults with obesity without diabetes.",
          "findings": "Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide; gastrointestinal events were common.",
          "limitations": "Open-label, manufacturer-funded comparison of defined clinical preparations, without a placebo arm. It did not test commercial research-catalogue products.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-38078870",
          "title": "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial",
          "authors": "Aronne LJ, Sattar N, Horn DB, et al.; SURMOUNT-4 Investigators",
          "year": 2024,
          "journal": "JAMA",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38078870/",
          "evidenceType": "human",
          "design": "After a 36-week open-label lead-in, 670 participants were randomized to continue tirzepatide or switch to placebo for 52 weeks.",
          "findings": "From randomization, average weight changed by -5.5% with continued treatment and +14.0% after switching to placebo. Gastrointestinal events remained relevant.",
          "limitations": "Randomization occurred after the lead-in, selecting participants who completed that phase. This maintenance estimate is not an initiation effect in an untreated population.",
          "appliesTo": "exact-compound",
          "verification": "abstract",
          "doi": "10.1001/jama.2023.24945",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/",
          "pmid": "38078870"
        },
        {
          "id": "pmid-42184419",
          "title": "Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes: A Randomized Clinical Trial",
          "authors": "Del Prato S, Heine RJ, Pérez Manghi FC, et al.",
          "year": 2026,
          "journal": "Annals of Internal Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/42184419/",
          "doi": "10.7326/ANNALS-25-05602",
          "pmid": "42184419",
          "evidenceType": "human",
          "design": "Open-label randomized phase 4 SURPASS-EARLY trial in 794 adults with early type 2 diabetes and inadequate glycaemic control on metformin. Published online 26 May 2026. Results for the same trial were first posted in ClinicalTrials.gov on 12 November 2026.",
          "findings": "At two years the journal abstract reports a treatment-regimen difference in HbA1c of −0.68 percentage points (95% CI −0.84 to −0.51). Gastrointestinal events were the most common adverse events in both groups.",
          "limitations": "Sponsor-funded and open-label. The comparator was clinician-selected care that could include a GLP-1 receptor agonist. The publisher full text was inaccessible; PubMed abstract and registry tables were consulted.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-43035096",
          "title": "Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial",
          "authors": "Kelly AS, Pamidipati KC, Rachmiel M, et al.",
          "year": 2026,
          "journal": "JAMA",
          "url": "https://jamanetwork.com/journals/jama/fullarticle/2856796",
          "doi": "10.1001/jama.2026.23420",
          "pmid": "43035096",
          "evidenceType": "human",
          "design": "Double-blind phase 3 SURMOUNT-ADOLESCENTS study (NCT06075667). Randomized 160 adolescents to subcutaneous tirzepatide or placebo alongside lifestyle intervention for 72 weeks. Published 15 November 2026.",
          "findings": "Mean BMI fell by 18.5% versus a 0.5% increase with placebo in the treatment-regimen analysis. Gastrointestinal events occurred in 81.5% versus 54.9%, and 9.3% versus 0% discontinued treatment because of an adverse event.",
          "limitations": "Sponsor-funded. Most participants had obesity, many had reached sexual maturity, and longer follow-up is needed to assess growth and uncommon harms.",
          "appliesTo": "exact-compound",
          "verification": "full-text"
        },
        {
          "id": "pmid-42997917",
          "title": "Erratum: Tirzepatide attenuates doxorubicin-induced cardiotoxicity via mitochondrial function improvement",
          "authors": "Editorial Office",
          "journal": "Translational Cancer Research",
          "year": 2026,
          "url": "https://tcr.amegroups.org/article/view/127274/html",
          "doi": "10.21037/tcr-20262-11",
          "pmid": "42997917",
          "evidenceType": "reference",
          "design": "Publisher erratum dated 20 October 2026 and indexed by PubMed on 8 November. It applies to mouse study PMID 42180982.",
          "findings": "The notice corrects the units and distinguishes the four-week treatment period from the later observation period in the figure legend.",
          "limitations": "Full publisher notice consulted. A correction to an animal experiment does not add a clinical efficacy result.",
          "appliesTo": "exact-compound",
          "verification": "full-text"
        },
        {
          "id": "pmid-43010688",
          "title": "Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation",
          "authors": "Aubrac G et al.",
          "year": 2026,
          "journal": "Diabetes, Obesity and Metabolism",
          "url": "https://pubmed.ncbi.nlm.nih.gov/43010688/",
          "doi": "10.1111/dom.71550",
          "pmid": "43010688",
          "evidenceType": "human",
          "design": "Claims-based observational comparison of adults with overweight or obesity and atherosclerotic cardiovascular disease, without diabetes.",
          "findings": "The adjusted primary comparison did not detect a statistically significant difference in major adverse cardiovascular events between the two groups.",
          "limitations": "This is not a randomized or equivalence trial. Residual confounding is possible, and the study does not establish interchangeability or the performance of a catalogue product.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-43022342",
          "title": "Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes",
          "authors": "Doma M et al.",
          "year": 2026,
          "journal": "American Heart Journal Plus: Cardiology Research and Practice",
          "url": "https://www.sciencedirect.com/science/article/pii/S2666602226002934",
          "doi": "10.1016/j.ahjo.2026.101003",
          "pmid": "43022342",
          "evidenceType": "human",
          "design": "Propensity-matched retrospective TriNetX cohort of people with atherosclerotic cardiovascular disease and without diabetes.",
          "findings": "The analysis did not detect a statistically significant difference between the groups for the reported cardiovascular composite outcomes.",
          "limitations": "Matching does not exclude residual confounding, and a null difference does not establish equivalence. Cohort overlap with other US database studies was not assessed. This is not evidence about any catalogue product.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        }
      ],
      "search": {
        "date": "2026-11-20",
        "method": "Targeted PubMed and ClinicalTrials.gov results check with DOI and trial registration deduplication. Also checked newly indexed or previously omitted original abstracts and identifiers.",
        "queries": [
          "PubMed: tirzepatide, 6–16 November 2026 entry or publication dates",
          "ClinicalTrials.gov NCT05433584 results",
          "PMID 42184419 / DOI 10.7326/ANNALS-25-05602",
          "PMID 43035096 / DOI 10.1001/jama.2026.23420",
          "PMID 42997917 / DOI 10.21037/tcr-20262-11",
          "PMID 43010688 / DOI 10.1111/dom.71550",
          "PMID 43022342 / DOI 10.1016/j.ahjo.2026.101003"
        ],
        "scope": "Compared the registry’s two-year primary outcome and four-year fields with the linked journal abstract. Reviewed the JAMA full-text primary results, safety table and study limitations for SURMOUNT-ADOLESCENTS. Read the full publisher erratum for the separate mouse paper. Added selected human study records dated 2026, with study-specific limitations.",
        "limitations": "The journal abstract and sponsor-submitted registry tables use differently presented analyses. The journal full text was inaccessible during this review. The adolescent JAMA report was available in full. Long-term adolescent safety and comparisons across distinct trials remain uncertain."
      },
      "discussion": [
        {
          "heading": "Initiation, direct comparison and maintenance answer different questions",
          "body": "SURMOUNT-1 asks about starting treatment relative to placebo; SURMOUNT-5 compares two active medicines; SURMOUNT-4 asks what happens after an initial response and continued exposure. Pooling their headline percentages without the relevant baseline obscures those differences. In SURMOUNT-4, the reported increase after switching to placebo starts from the lower weight reached at randomization, not from the original pretreatment weight. The participants selected for that randomized period also differ from everyone who first entered the lead-in. Such distinctions are central to interpreting durability.",
          "citations": [
            "pmid-35658024",
            "pmid-40353578",
            "pmid-38078870"
          ]
        },
        {
          "heading": "A strong trial result still has a defined scope",
          "body": "Randomization supports causal interpretation within the comparison studied; it does not erase selection criteria, treatment discontinuation or formulation differences. The maintenance trial provides stronger withdrawal evidence than an uncontrolled follow-up, but participants had already completed an active-treatment period, so it cannot fully represent early tolerability among new users. Manufacturer-supported development trials also benefit from independent replication and complete safety appraisal. These findings support research on clinical tirzepatide preparations while leaving the identity, exposure and quality of any separately supplied catalogue material to be established on its own evidence.",
          "citations": [
            "pmid-38078870",
            "pmid-35658024"
          ]
        },
        {
          "heading": "The registry and journal report describe one trial",
          "body": "The newly posted registry tables for NCT05433584 report the two-year HbA1c comparison from the same study already published in May. The registry’s mixed-model estimate differs from the treatment-regimen estimate in the journal abstract. The two numbers belong to their respective analyses and must not be combined as independent results. The registry lists four-year outcomes without numerical results in this posting.",
          "citations": [
            "pmid-42184419"
          ]
        },
        {
          "heading": "Adolescent outcomes require their own assessment",
          "body": "The adolescent trial extends the placebo-controlled evidence beyond adult groups. Serious-event estimates were imprecise, and the study gives limited information about participants with overweight or early stages of puberty. Its BMI effect cannot be used to rank treatments against the differently designed adolescent semaglutide registry trial.",
          "citations": [
            "pmid-43035096"
          ]
        },
        {
          "heading": "Check the corrected animal study legend",
          "body": "The publisher corrected a discrepancy between a figure legend and the methods for a doxorubicin injury model. The correction is relevant to interpreting the animal experiment. The human data above address different questions.",
          "citations": [
            "pmid-42997917"
          ]
        }
      ]
    },
    {
      "slug": "vip",
      "names": [
        "VIP"
      ],
      "title": "VIP (vasoactive intestinal peptide)",
      "kind": "compound",
      "summary": "VIP research spans immune mechanisms and clinical trials of synthetic VIP, aviptadil. A positive experimental arthritis study does not outweigh the absence of benefit in a sizeable COVID-19 respiratory-failure trial.",
      "identity": "VIP denotes vasoactive intestinal peptide. The cited human trial used a specified intravenous aviptadil study formulation; its results cannot establish the properties of a supplier vial or nasal product.",
      "evidenceOverview": "Animal inflammation research and a human respiratory-disease trial answer different questions. The selected human trial was stopped for futility and did not demonstrate improved clinical outcomes, so mechanistic plausibility alone is insufficient.",
      "whatResearchShows": [
        "Delgado and colleagues reported reduced inflammatory and joint outcomes in experimental mouse arthritis.",
        "The TESICO trial found no significant improvement in its 90-day clinical outcome with aviptadil versus placebo."
      ],
      "limitations": [
        "Mouse arthritis is not a clinical test in people with rheumatoid arthritis.",
        "TESICO concerns a specific severe infection context and studied formulation, not all possible VIP applications.",
        "Neither source supports general immune enhancement, self-administration, or equivalence of catalogue nasal and vial products."
      ],
      "openQuestions": [
        "Which mechanistic findings reproduce independently and translate into prespecified human benefits?",
        "How do formulation and exposure affect the interpretation of future studies?"
      ],
      "studies": [
        {
          "id": "pmid-11329057",
          "title": "Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease",
          "authors": "Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP",
          "year": 2001,
          "journal": "Nature Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/11329057/",
          "doi": "10.1038/87887",
          "pmid": "11329057",
          "evidenceType": "animal",
          "design": "Experimental mouse arthritis study examining disease severity, joint damage and inflammatory/autoimmune pathways.",
          "findings": "Reported lower arthritis severity and changes in inflammatory and autoimmune components in the model.",
          "limitations": "Preclinical disease model, not evidence of an effective rheumatoid-arthritis treatment in humans.",
          "appliesTo": "exact-compound",
          "verification": "abstract"
        },
        {
          "id": "pmid-37348524",
          "title": "Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial",
          "authors": "Brown SM, Barkauskas CE, Grund B, et al.",
          "year": 2023,
          "journal": "The Lancet Respiratory Medicine",
          "url": "https://pubmed.ncbi.nlm.nih.gov/37348524/",
          "doi": "10.1016/S2213-2600(23)00147-9",
          "pmid": "37348524",
          "evidenceType": "human",
          "design": "Multicentre randomised placebo-controlled trial; 461 participants received at least part of aviptadil or its matched placebo.",
          "findings": "No significant improvement in the primary 90-day ordinal clinical outcome or mortality; the aviptadil trial was stopped for futility.",
          "limitations": "Disease-specific clinical study. It does not validate a catalogue formulation or establish benefits in other conditions.",
          "appliesTo": "exact-compound",
          "verification": "full-text",
          "fullTextUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10527239/"
        }
      ],
      "search": {
        "date": "2026-11-09",
        "method": "Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.",
        "queries": [
          "site:pubmed.ncbi.nlm.nih.gov vasoactive intestinal peptide aviptadil randomized trial COVID 2023 TESICO",
          "\"37348524\" aviptadil \"10.\" Brown",
          "\"10.1038/87887\" correction retraction",
          "\"10.1016/S2213-2600(23)00147-9\" correction retraction"
        ],
        "scope": "Mouse arthritis and TESICO human aviptadil trial. Full-text stopping rules and statistical analysis sections of TESICO consulted. No comprehensive indication-level search.",
        "limitations": "Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates."
      },
      "discussion": [
        {
          "heading": "Mechanism and clinical outcome can diverge",
          "body": "A candidate can alter inflammatory pathways in a model without producing a detectable benefit in a particular human disease. The mouse arthritis experiment and the aviptadil respiratory trial should therefore not be pooled as though they measured the same effect. Our interpretation is that the mechanistic study motivates a hypothesis, while the clinical trial tests a specified intervention in a specified setting.",
          "citations": [
            "pmid-11329057",
            "pmid-37348524"
          ]
        },
        {
          "heading": "Futility is not a universal biological verdict",
          "body": "TESICO stopped the aviptadil comparison because continued enrolment was unlikely to establish the planned benefit. That does not answer every conceivable VIP question. It does mean the trial should remain visible when discussing clinical translation, rather than citing pathway rationale as if no substantive human test existed. The estimated effect and uncertainty are more informative than a simple success or failure label.",
          "citations": [
            "pmid-37348524"
          ]
        },
        {
          "heading": "Track the actual randomised comparison",
          "body": "The master protocol allowed participants to enter more than one treatment comparison. A researcher should extract the relevant comparator, analysis population and prespecified outcome for aviptadil itself, not transfer results from the separate remdesivir comparison. Further translational work would need an explicit disease rationale and formulation match, followed by independently reproduced patient-important outcomes.",
          "citations": [
            "pmid-37348524"
          ]
        }
      ]
    }
  ]
}